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Prostate cancer is the second most common cancer in men.  Studies now indicate a strong 
association of the disease with chronic bacterial infection, which may ultimately induce 
oncogenesis. It has been shown that P. acnes is the predominant organism isolated from 
prostatectomy samples and is significantly associated with organ inflammation. Further 
evidence suggests that P. acnes is able to chronically infect the prostate gland and in vitro 
experiments clearly indicate its potential to drive oncogenic changes. This thesis investigates 
the oncogenic potential of specific prostate-derived P. acnes phylogenetic types, with the 
ultimate aim of developing risk stratification approaches for the development of the 
disease.   
In vitro infection models were used to compare the effects of different phylogenetic 
types of P. acnes on prostate epithelial cells. Soft agar assays and quantitative PCR 
(qPCR) were used to investigate the molecular expression profiles associated with 
endothelial-mesenchymal transition (EMT) and inflammation during bacterial infection. 
Cells infected with phylotype IA1 were able to form colonies in soft agar assays, 
indicating cellular transformation. Additionally, qPCR results showed a decrease in the 
expression of the EMT marker E-cadherin. These findings were supported by 
immunostaining experiments. Furthermore, qPCR expression analysis revealed that 
phylotype IA1 infection induces changes suggestive of apoptosis resistance, increased 
proliferation and androgen-independent growth, all characteristics of advanced 
treatment-resistant cancer. In contrast, cells infected with type III strain exhibited 
expression changes consistent with anti-cancer behaviour, including increased 
apoptosis and androgen-dependent signalling.  
These findings highlight the strain-specific response to infection and suggest the 
attractive possibility that infection with P. acnes may be a modifiable risk factor for 
prostate cancer. Since some phylotypes of P. acnes may be oncogenic, while others are 
cancer-protective, the development of a screening test to identify the presence of 
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HRP Horseradish peroxidase 
HS High sensitivity 
IF Immunofluorescence 
IFNγ Interferon gamma 
IGF-1/IGF1 Insulin-like growth factor 1 (somatomedin C) 
IGFBP5 Insulin-like growth factor binding protein 5 





IL1R Interleukin 1 receptor 
IL-1β/IL1B Interleukin 1 beta (protein/gene) 
IL-6/IL6 Interleukin 6 (protein/gene) 
IL6R Interleukin 6 receptor 
IL-8/IL8 Interleukin 8 (protein/gene) 
IntDen Integrated density 
IκB Inhibitor of κB 
JAK Janus kinase 
JNK c-Jun N-terminal kinase 
KLHL13 Kelch-like 13 (Drosophila) 
KLK Kallikrein 
KLK3 Kallikrein-related peptidase 3 (PSA) 
KSFM Keratinocyte serum-free medium 
LDH Lactate dehydrogenase 
lepA GTP-binding protein 
LGALS4 Lectin, galactoside-binding, soluble, 4 
LH Luteinizing hormone 
LnCAP Prostate cancer cell line 
LOXL1 Lysyl oxidase-like 1 
LRP lipoprotein receptor-related protein 
LSGS Low serum growth supplements 
MAD Mothers against decapentaplegia in Drosophila 




MAPKAPK Mitogen-activated protein kinase-activated protein kinase 
MAPKK Mitogen-activated protein kinase 
MAPKKK Mitogen-activated protein kinase kinase kinase (also called MAP3K) 
MAX MYC associated factor X 
Mcl-1 Myeloid cell leukaemia 1, BCL2 family apoptosis regulator 
MCP-1 Monocyte chemoattractant protein-1 (CCL2) 
M-CSF Macrophage colony-stimulating factor 
MDM2 Mouse double minute 2 homolog 
MEK MAPK/ERK Kinase, aka MAP2K 
MET Mesenchymal-epithelial transition 
MGMT O-6-methylguanine-DNA methyltransferase 
MKI67 Marker of proliferation Ki-67 
MLH1 mutL homolog 1, mutated in Lynch syndrome 
MLST Multilocus sequence typing 
MMP Matrix metalloproteinase 
MNK Menkes' protein, also known as ATP7A 
MOI Multiplicity of infection 
M-PER Mammalian protein extraction reagent 
M-phase Mitotic phase 
MPS Massive parallel sequencing 
MSH2 mutS homolog 2, mutated in Lynch syndrome 
MSH6 mutS homolog 6, mutated in Lynch syndrome 
MSK Mitogen and stress-activated protein kinase 




MSX1 Msh homeobox 1 
MTO1 Mitochondrial translation optimization 1 homolog 
mTOR Mechanistic target of rapamycin 
mTORC Mechanistic target of rapamycin complex 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NAD+ Nicotinamide adenine dinucleotide (oxidized) 
NADH Nicotinamide adenine dinucleotide (reduced) 
NCTC National Collection of Type Cultures  
NDRG3 NDRG family member 3 
NEMO Nuclear factor-kappa B Essential Modulator 
NF-κB Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
NF-κB1 NF-κB family member class I, p105, becomes p50 when processed 
NF-κB2 NF-κB family member class I, p100, becomes p52 when processed 
NIK NF-κB inducing kinase 
NK Nature killer cells 
NKX3-1 NK3 homeobox 1 
NLRP3 Cryopyrin, inflammasome component 
NormIntDen Normalised integrated density 
NRIP1 Nuclear receptor interacting protein 1 
NSAID Non-steroidal anti-inflammatory drug 
OD Optical density 
p16INK4a Cyclin-dependent kinase inhibitor 2A, also known as CDKN2A 
P2 QIAGEN Primer and External Control Mix  




P53AIP1 p-53-regulated apoptosis-inducing protein 1 
PAmce  Putative cell invasion-associated protein 
Pap60 Putative cell invasion-associated protein 
PB QIAGEN QIAquick PCR Purification Kit binding buffer 
PBS Phosphate buffered saline 
PBST PBS-Tween 
PC Positive control 
PC-3 Metastatic (bone) human prostate carcinoma cell line 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PDGFR Platelet-derived growth factor receptor 
PDK1 3-phosphoinositide-dependent protein kinase-1 
PDLIM4 PDZ and LIM domain 4 
PDPK1 3-phosphoinositide dependent protein kinase-1 
PE QIAGEN QIAquick PCR Purification Kit wash buffer 
PES1 Pescadillo homolog 1, containing BRCT domain (zebrafish) 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 
PH Prolyl hydroxylases 
PhIP 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PIA Proliferative inflammatory atrophy 
PIN Prostatic intraepithelial neoplasia, mutated in Lynch syndrome 
PIP3 Phosphatidylinositol (3,4,5)-trisphosphate 




PMH Progressive macular hypomelanosis 
PMS2 PMS1 homolog 2, mutated in Lynch syndrome 
PPP2R1B Protein phosphatase 2, regulatory subunit A, beta 
PRKAB1 Protein kinase, AMP-activated, beta 1 non-catalytic subunit 
PSA Prostate specific antigen 
PTEN Phosphatase and tensin homolog 
PTGS Prostaglandin-endoperoxide synthase, also known as COX-2 
PTGS1 Prostaglandin-endoperoxide synthase 1, also called COX-1 
PTGS2 Prostaglandin-endoperoxide synthase 2, also called COX-2 
qPCR Quantitative/real-time polymerase chain reaction 
RAF Rapidly accelerated fibrosarcoma proto-oncogene 
RARB Retinoic acid receptor, beta 
RAS Rat sarcoma gene 
RASSF1 Ras association (RalGDS/AF-6) domain family member 1 
Rb Retinoblastoma 
RBM39 RNA binding motif protein 39 
RE3 QIAGEN Reverse Transcriptase Enzyme Mix 3          
recA Recombinase A protein 
RelA NF-κB family member class II, p65 
RelB NF-κB family member class II 
RLT QIAGEN RNeasy Plus Mini-Kit lysis buffer 
RNA Ribonucleic acid 
RNase Ribonuclease 




RNAseq RNA sequencing 
ROS Reactive oxygen species 
RPE QIAGEN RNeasy Plus Mini-Kit wash buffer 
RPLP0 Ribosomal protein, large, P0 
RPMI-1640 Roswell Park Memorial Institute - 1640 medium 
rRNA Ribosomal RNA 
RSK Ribosomal s6 kinase 
RT Reverse transcription 
RTK Receptor tyrosine kinase 
RT-PCR Reverse-transcription polymerase chain reaction 
RW1 QIAGEN RNeasy Plus Mini-Kit wash buffer 
RWPE-1 Non-cancerous human prostate epithelial cell line 
SCAF11 SR-related CTD-associated factor 11 
SEM Standard error of the mean 
SEPT7 Septin 7 
SFRP1 Secreted frizzled-related protein 1 
SHBG Sex hormone-binding globulin 
SHP SH2 domain-containing phosphatase 
S-HRP Streptavidin-horseradish peroxidase conjugate 
SLC5A8 Solute carrier family 5 (iodide transporter), member 8 
sma Small body gene in C. elegans 
SMAD Portmanteau of sma (in C. elegans) and MAD (in Drosophila) 
SNAI1 Snail family zing finger 1 (Snail) 




SOCS3 Suppressor of cytokine signalling 3 
sodA Superoxide dismutase 
SOX4 SRY (sex determining region Y)-box 4 
S-phase Synthesis phase 
SREBF1 Sterol regulatory element binding transcription factor 1 
ST Sequence type 
STAT Signal transducer and activator of transcription 
STI Sexually transmitted infection 
STK11 Serine/threonine kinase 11 
SUPT7L Suppressor of Ty 7 
TACE Tumour necrosis factor-α conversing enzyme (also called ADAM17) 
TBP TATA-binding protein 
TCA Tricarboxylic acid cycle, also called Krebs cycle or Citric acid cycle 
TFPI2 Tissue factor pathway inhibitor 2 
TGFB1I1 Transforming growth factor beta 1 induced transcript 1 
TGFBR Transforming growth factor beta receptor 
TGF-β/TGFB Transforming growth factor beta (protein/gene) 
Th1 Type 1 helper T cells 
THP-1 Acute monocytic leukaemia cell line 
TIMP Tissue inhibitor of metalloproteinases 
TLR Toll-like receptor 
tly Putative haemolysin gene 
TMB 3,3',5,5'-Tetramethylbenzidine 




TNFR Tumour necrosis factor receptor 
TNFRSF10D TNF superfamily, member 10d, decoy with truncated death domain 
TNF-α/TNF Tumour necrosis factor (protein/gene) 
TNM Tumour/node/metastasis staging system 
TP53 Tumour protein p53 
TRADD Tumour necrosis factor receptor type 1-associated DEATH domain 
TRAF TNF receptor associated factor 
TRUS Transrectal ultrasound  
TSP-1 Thrombospondin-1 
TUNEL Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling 
TWIST1 Twist-related protein 1 
U Unit 
UPEC Uropathogenic Escherichia coli 
USP5 Ubiquitin specific peptidase 5 (isopeptidase T) 
VacA H. pylori vacuolating cytotoxin A 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
VIM Vimentin 
ZIP1 Zinc transporter protein 1 
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The main topic of this thesis is the role of Propionibacterium acnes infection in prostate 
oncogenesis. This chapter provides a comprehensive introduction to prostate anatomy 
and pathophysiology, the bacterium of interest P. acnes, and concludes with a summary 
of studies investigating the relationship between P. acnes and prostate cancer. The 
potential for this knowledge to be applied in the field of stratified medicine is also 
highlighted. 
1.1. Prostate cancer 
 Prostate anatomy and physiology 
The human prostate is a walnut-shaped accessory gland of the male reproductive tract. 
It is located in the pelvis, below the bladder and anterior to the rectum. The gland is 
composed of luminal secretory epithelial cells, basal cells, and neuroendocrine cells 
(Figure 1.1.A) (McNeal, 1981; di Sant'Agnese, 1998). The stroma of the prostate includes 
smooth muscle cells, myofibroblasts, lymphatic cells and nerves, as well as inflammatory 
cells (Bartsch et al., 1979). 
McNeal (1981) proposed the currently accepted prostate zonal anatomy concept with 
four anatomical zones – peripheral zone, central zone, transition zone, and anterior 
fibromuscular stroma, as seen in Figure 1.1.B. (McNeal, 1981). The peripheral zone is 
the largest zone of the prostate, comprising roughly 70% of the gland, and is the origin 
of 68% of prostate adenocarcinomas (McNeal et al., 1988). The central zone, located 
around the ejaculatory ducts, expanding upwards towards the base of the bladder, 
represents 20-25% of the prostate volume. It is associated with a densely packed stroma 
and large and irregular glands. Finally, the transition zone forms 5-10% of the gland, and 
it has two pear-shaped lobes that surround the urethra; the transition zone is associated 
with 26% of adenocarcinomas (McNeal et al., 1988). 
The production of semen by the testes, epididymis, and male accessory glands (including 
the prostate gland) is vital for human reproduction. Semen is composed of 2-5% 
spermatozoa, 65-75% seminal vesicle fluid (e.g. prostaglandins, fructose), 20-30% 
prostatic fluid (including zinc ions (Zn2+), citrate, kallikreins) and about 1% bulbourethral 
fluid (mucins, galactose, sialic acid) (Verze et al., 2016). The role of the prostate is key to 









Figure 1.1. Zonal anatomy and histology of the prostate gland. 
A. Histology of the healthy (1-3) and cancerous (4-6) prostate gland (Gleason score 6). The healthy prostate has a large number of glands (G) 
surrounded by stroma (S) (A1) and those structures are lost in cancer (A4). Under higher magnification the secretory epithelial cells (SC) forming the 
glands (G) can be clearly seen (A2), while the differentiation is lost in cancer (A5). At the highest magnification, basal cells (BC) and secretory epithelial 
cells can be seen surrounded by stroma (A3), including smooth muscle cells (SMC); this contrasts with cancerous cells (A6) where the tumour cells 
(TC) and the tumour stroma (TS) can be seen. Image credit: Human Protein Atlas available from www.proteinatlas.org, version 17, 
https://goo.gl/HHUsWM and https://goo.gl/H5Dmgv, accessed 03-10-2017 (Uhlen et al., 2017) 
B. Zonal anatomy of the prostate. The prostate is located below the bladder. The central zone (CZ) surrounds the ejaculatory ducts (E). The transition 
zone (TZ) surrounds the urethra (U) and presents 5-10% of the gland. The peripheral zone (PZ) comprises 70%, the central zone (CZ) is 20%-25%. The 





molecular processes involved in ejaculation, sperm activation and capacitation (Gilany 
et al., 2015). 
Human prostate epithelial cells, which form the glandular structures within the prostate, 
accumulate large amounts of Zn2+ ions (roughly 4% of the total zinc in the body) (Verze 
et al., 2016). The zinc ions inhibit the first step of the Krebs cycle: the conversion of citric 
acid to isocitrate by the enzyme aconitase (Franklin et al., 2005). Due to their truncated 
Krebs cycle, healthy prostate epithelial cells are energy inefficient, have low levels of 
respiration, and lower levels of reactive oxygen species (ROS) than most other cells in 
the body; it has been suggested that the normally lower level of ROS in prostate 
epithelial means they are less tolerable to elevation in ROS levels (Dakubo et al., 2006). 
It is worth noting, that while in most cases cells go from energy efficient healthy cells to 
energy inefficient malignant cells, the opposite is true for prostate epithelial cells: they 
normally have poor energy efficiency but become energy efficient when cancerous 
(Costello and Franklin, 2000). An early sign of this transformation is the decreased 
expression or loss of ZIP1, a Zn2+ transporter protein (Costello and Franklin, 2006; 
Johnson et al., 2010). 
The kallikreins (KLKs) secreted by the prostate are a subgroup of 15 serine proteases, 
with the most notable example being the prostate specific antigen (PSA), encoded by 
the KLK3 gene), which play a role in sperm motility and liquefy sperm by directly 
targeting the gel proteins semenogelin-1 and semenogelin-2 (Lilja, 1985; Lilja et al., 
1987; Lilja et al., 2008). Zn2+ ions have an inhibitory role on kallikreins while within the 
prostatic tissue. After ejaculation, semenogelin-rich seminal vesicle fluid is mixed with 
prostatic secretions; semenogelins and fibronectin form a gelatinous mass that is 
liquefied within a few minutes by the activated kallikreins, and it allows the movement 
of sperm towards the fallopian tube (Verze et al., 2016) 
 Prostate disease 
As the prostate plays a key role in the male reproductive system, it is important to study 
any issues within the organ which may interfere with its function. The focus of this thesis 
is prostate cancer and, more specifically, the role of chronic infection in prostate 
oncogenesis; however, a brief introduction to other prostate-related diseases is 
necessary to highlight the impact they have on the function of the gland and how they 





Prostatitis, or inflammation of the prostate gland, according to the current National 
Institute of Health definition can be divided into four categories: acute bacterial 
prostatitis, chronic bacterial prostatitis, chronic prostatitis/chronic pelvic pain 
syndrome, or asymptomatic inflammatory prostatitis (Krieger et al., 1999). 
1.1.2.1.1. Acute bacterial prostatitis 
Acute bacterial prostatitis is rare, and occurs as a result of ascending urinary tract 
infections, or as a direct intervention to the prostate gland, for example following a 
prostate biopsy (Millan-Rodriguez et al., 2006; Wagenlehner et al., 2013). The bacteria 
most commonly associated with acute prostatitis include Escherichia coli (including 
uropathogenic E. coli, also known as UPEC), Pseudomonas aeruginosa, Klebsiella spp.; if 
the condition is intervention-related, there is a higher number of mixed cultures (Krieger 
et al., 2008; Yoon et al., 2012). 
1.1.2.1.2. Chronic prostatitis/chronic pelvic pain syndrome 
The aetiology of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is unknown. 
Symptoms of the syndrome include pelvic discomfort, erectile dysfunction and issues 
with urination (Khan et al., 2017). 
1.1.2.1.3. Chronic prostatitis 
E. coli has also been implicated in causing chronic prostate infections, while other 
studies suggest that Gram-positive cocci, such as Enterococcus faecalis, Staphylococcus 
spp., Streptococcus agalactiae, predominate (Weidner et al., 1991; Bundrick et al., 
2003). Chronic prostatitis is commonly found in both benign prostatic hyperplasia (BPH) 
and prostate cancer (Gerstenbluth et al., 2002). 
1.1.2.1.4. Asymptomatic inflammatory prostatitis 
Asymptomatic inflammatory prostatitis differs from the previously described categories 
of prostatitis, as patients have no symptoms of infection. The two signs that a patient 
has an asymptomatic infection are elevated PSA and the presence of leukocytes if the 
prostate is examined histologically. This type of prostatitis is commonly seen in men with 
benign prostatic hyperplasia and prostate cancer (Nickel et al., 1999). Chronic 




role in P. acnes in chronic inflammation leading to prostate oncogenesis will be further 
discussed in Section 1.3. 
1.1.2.2. Benign prostatic hyperplasia 
BPH is a non-cancerous hyperplasia of epithelial and stromal cells of the prostate’s 
transition zone (McNeal, 1968; McNeal, 1988). The condition is not thought to be a 
precursor of prostate cancer (Kristal et al., 2010). While the number of cells increases, 
they retain their morphology. BPH is seen in 25% of 50-year olds and 90% of 80-year-
olds; however, symptoms are only seen in 10% of cases (Bushman, 2009). The 
hyperplasia of epithelial cells causes an enlargement of the prostate which can lead to 
a number of lower urinary tract symptoms, including difficulty urinating and increased 
frequency (Barry et al., 1992). Increased cardiovascular risk, chronic infection of the 
prostate gland, and changes in androgen levels have been suggested as possible causes, 
although the aetiology is currently unknown (Kim et al., 2016). 
1.1.2.3. Proliferative inflammatory atrophy 
Proliferative intraepithelial atrophy (PIA) (illustrated in Figure 1.2.B) is a rare condition 
represented by inflammation-associated atrophy and post-atrophic hyperplasia, and has 
been shown to merge with adenocarcinoma lesions (Wang et al., 2009). It has been 
suggested that PIA is a possible prostate cancer precursor via prostatic intraepithelial 
neoplasia (PIN), as PIA lesions are commonly merged with PIN (Putzi and De Marzo, 
2000). 
1.1.2.4. Prostatic intraepithelial neoplasia 
Prostatic intraepithelial neoplasia (PIN) is presented by clusters of luminal epithelial cells 
with the appearance of cancerous cells (e.g. enlarged nuclei with prominent nucleoli) 
but a preserved basal layer, see Figure 1.2.C (Presti, 2007). It has been reported that the 
incidence of PIN increases with age and is seen in 7-8% of men in their 20s and 63-86% 
(dependent on race, with rates being higher in African-Americans) of 70-year-olds 
(Merrimen et al., 2013). It has been suggested that high-grade PIN is a precursor of 
prostate adenocarcinoma (Haussler, 1999). While PIN and invasive cancers display 
frequent multifocal co-occurrence, previous studies disagree on whether PIN predates 
cancer, as would be expected if it was in fact a precursor of oncogenesis (Sanchez-













Figure 1.2. Changes seen in prostate disease. 
A. The normal prostate is composed of columnar secretory epithelial cells forming the 
glands and is outlined by basal cells. 
B. Proliferative inflammatory atrophy is associated with proliferating epithelial cells 
which fail to differentiate into columnar secretory cells. The PIA areas are also 
associated with chronic inflammation. 
C. In prostatic intraepithelial neoplasia, the cells possess some morphological 
similarities to cancerous cells, including enlarged nuclei, however, they have a 
preserved basal layer. 
D. With prostate cancer, in addition to changes in morphology, the cells infiltrate the 
surrounding stroma and this migration can progress to metastasis, if not identified 





1.1.2.5. Prostate cancer 
This thesis is primarily focused on investigating the role of chronic infection, specifically 
infection with Propionibacterium acnes, in the development of prostate cancer. Before 
considering the role of infection in oncogenesis, however, it is important to present the 
risk factors for the disease, as well as diagnosis and treatment options available. 
1.1.2.5.1. Incidence of prostate cancer 
In the UK in 1993, prostate cancer accounted for 16% of cancer diagnoses; by 2014 the 
number had increased to 26%, making prostate cancer the most commonly diagnosed 
cancer in men with the projection that the percentage would rise further (Smittenaar et 
al., 2016). Prostate cancer is the most common cancer diagnosed in European men 
(Arnold et al., 2015). It is estimated that in US men prostate cancer will have accounted 
for 19% of cancer diagnoses in 2017, and will be responsible for 8% of deaths (Siegel et 
al., 2017). Over the last decade in the US, especially early 2010s, there was a rapid 
decrease of the number of prostate cancer diagnoses (more than 10% annually between 
2010 and 2013), which was mainly due to changes of screening recommendations by 
the US Preventive Services Task Force (Siegel et al., 2017). The changes were suggested 
mainly due to concerns of over-diagnosis and unnecessary treatment (Moyer, 2012). 
Newly developed prostate cancer usually displays symptoms that do not differ from 
BPH, including difficulties in urination, increased frequency or decreased urine flow. As 
the cancer progresses, it may become metastatic which is the main cause of death; the 
most common metastasis sites include bone (90%, associated with severe pain), lung 
(46%) and liver (25%) (Bubendorf et al., 2000). Another complication of advanced 
prostate cancer is cachexia, also called wasting syndrome; it is associated with weight 
loss, loss of appetite, loss of muscle mass, and fatigue. It has been suggested that 
inflammatory cytokines (e.g. interleukin-6 (IL-6) and tumour necrosis factor α (TNF-α)) 
are involved in promoting cachexia in cancer patients. In animal models, IL-6 can drive 
cachexia via Signal transducer and activator of transcription 3 (STAT3) activation 
(Bonetto et al., 2011). In prostate cancer patients, increased IL-6 levels are associated 
with poor prognosis, with the cytokine being produced by both immune and cancer cells 




1.1.2.5.2. Risk factors 
Risk factors for the development of prostate cancer include age, family history, race, 
diet and other environmental factors. 
Age is the most important risk factor for prostate cancer, and post-mortem studies have 
shown that 30% of men over the age of 50 have prostate cancer, with the percentage 
rising to 70% in men over the age of 70 (Hoffman, 2011). 
Family history is a major risk factor for the development of prostate cancer. Twin studies 
have revealed that prostate tumours have a stronger hereditary link than any other 
malignancy (Gronberg et al., 1994; Ahlbom et al., 1997). If a first-degree relative has 
been diagnosed the calculated risk ratio is 2.1 (Hemminki, 2012). Furthermore, if one, 
two or three first-degree relatives are diagnosed with prostate cancer, a man’s risk of 
developing the disease increases 2-fold, 5-fold and 11-fold, respectively (Steinberg et 
al., 1990). Familial prostate cancers are more likely to be diagnosed earlier than sporadic 
cancers, and have a significantly better 10-year cancer specific survival (92% for familial 
cancers compared to 69% for sporadic cancers) (Plonis et al., 2015; Raheem et al., 2015; 
Randazzo et al., 2016). 
It has been shown that men with the Lynch syndrome (a cancer disorder associated with 
germline mutations of mismatch repair genes EPCAM, MLH1, MSH2, MSH6, or PMS2) 
are five times more likely to develop prostate cancer that non-carriers and those cancers 
are not more likely to be of the aggressive variety (Haraldsdottir et al., 2014). Another 
example of familial prostate cancer, carriers of BRCA2 mutations, are at increased risk 
of developing early onset prostate cancer (up to 7 years earlier onset than non-
hereditary cancer of the prostate) and those cancers are more likely to be aggressive 
and have poor survival rates (4-year median survival post-diagnosis) (Narod et al., 2008; 
Castro et al., 2013). 
Incidence of prostate cancer is lower in Asia, compared with the US and Western Europe 
(Hsing et al., 2000). If men of Asian origin immigrate to the west, their risk of developing 
cancer of the prostate increases, strongly suggesting than lifestyle and environment play 
and important role in the disease (Haenszel and Kurihara, 1968; Shimizu et al., 1991; 
Whittemore et al., 1995). In the US, African Americans are at a doubled risk of prostate 




(Howlader et al., 2011). African American men are usually diagnosed on average 1.2 
years earlier than white men and are twice as likely to be diagnosed before the age of 
45, yet they have a higher mortality rate (Karami et al., 2007; Robbins et al., 2015). 
Animal fats and red meats heave been implicated as a potential driver of prostate 
oncogenesis (Giovannucci et al., 1993; Gann et al., 1994; Lemarchand et al., 1994). 
Notably, meats cooked at high temperature form a number of carcinogens, one of which 
(2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine or PhIP) has been shown to cause 
prostate cancer in rats (Gross et al., 1993; Stuart et al., 2000). 
On the other hand, it has been suggested that some vegetables might have a cancer 
protective role (Chan and Giovannucci, 2001). A notable example is that high plasma 
levels of lycopene (an antioxidant associated with increased intake of tomatoes) has 
been linked with a reduced risk of prostate cancer (Rowles et al., 2017). Other 
antioxidants connected with decreased prostate cancer risk include vitamin E and 
selenium; however, a recent randomised controlled trial showed that vitamin E, 
selenium, or both used in a combination did not prevent prostate cancer in the cohorts 
examined (Nelson et al., 2003; Lippman et al., 2009). 
A meta-analysis on alcohol use and relative risk of prostate cancer showed that there is 
a statistically significant link between consumption of small amounts of alcohol 
(between 1.3 and 24 g per day) and increased prostate cancer morbidity and mortality 
(Zhao et al., 2016). 
Metabolic syndrome is not significantly associated with prostate cancer risk, but two of 
its components (high waist circumference and hypertension) have shown a significant 
link (Esposito et al., 2013). 
Epidemiological studies suggest that a prior history of prostatitis related to sexually 
transmitted infections (STIs), such as human papilloma virus, syphilis and gonorrhoea, 
leads to an increased risk of prostate cancer development, although they highlight the 





1.1.2.5.3.1. Prostate specific antigen 
PSA is a serine protease encoded by the KLK3 gene, and is produced by prostate 
epithelial cells. Together with other KLKs it plays a role in sperm liquification and 
motility. 
Increased PSA levels in the blood are not a consequence of increased production of PSA 
by the prostate, but are thought to be a result of physical changes in the gland that lead 
to the PSA leaking into the bloodstream, as during prostate cancer development there 
is actually a significant decrease in KLK3 expression (Qiu et al., 1990; Lilja et al., 2008). 
The use of PSA as a sole biomarker for prostate cancer in not considered to be ideal. 
While a serum PSA value above 4 ng/ml is regarded as elevated, results between 4 and 
10 ng/ml are considered to be within the test’s “grey zone” and are associated with low 
levels of sensitivity (at 23%) and specificity (93%) (Thompson et al., 2005). As many 
prostate cancers are not life threatening and clinically significant, it is thought that PSA 
testing leads to over-diagnosis of clinically non-significant disease (Gilgunn et al., 2013). 
Furthermore, increased levels of PSA are not specific to prostate cancer but can also be 
due to BPH or prostatitis (Pinsky et al., 2006; Azab et al., 2012). Despite this, a recent 
study highlighted that PSA-screening decreases the risk of prostate cancer related death 
by 25 to 32% (Tsodikov et al., 2017). There is, however, a need for a more reliable 
diagnostic test than the current PSA analysis.  
Novel diagnostic tests aimed at increased specificity and sensitivity are currently under 
development. Both tests (one using the prostate health index mathematical formula and 
the other using a panel four KLKs) are hoped to decrease the number of unnecessary 
biopsies currently performed due to inadequate performance of the PSA test (Loeb and 
Catalona, 2014; Bryant et al., 2015). 
The current EU guidelines recommend testing of all men above the age of 50 (45 if family 
history is present or the man is of African origin); while optimal testing intervals have 
not been studied the current recommendation for follow-up is 2 years for men who are 




1.1.2.5.3.2. Digital rectal examination 
Digital rectal examination (DRE) is a routinely used procedure, where the prostate is felt 
for any asymmetry or nodule formation, as well as enlargement or hardening of the 
prostate gland as a whole; however, cancers detected via DRE are usually at an advanced 
stage (Stewart et al., 2017). 
1.1.2.5.3.3. Transrectal ultrasound guided prostate biopsy 
Transrectal ultrasound (TRUS) guided biopsy is a technique used for cancer diagnosis. 
The decision whether biopsy is required is based on either elevated PSA levels, an 
abnormal DRE, or the presence of both. The ultrasound probe is inserted into the rectum 
while a biopsy sample is taken from the prostate transrectally or transperineally. The 
currently employed biopsy method is called the “extended method”, as it includes 10 or 
12 core biopsies taken along the length of the gland, bilaterally and far from the 
periphery (Mottet et al., 2017). There is no significant difference between detection 
rates of transrectal and transperineal biopsies, but transperineal biopsies have a mild 
detection advantage if the patient’s PSA levels were in the “grey zone”. 
The risks associated with TRUS and a prostate biopsy include haematuria (66% of the 
cases), haematospermia (38%), rectal bleeding (<28%) (Efesoy et al., 2013). 
1.1.2.5.3.4. Gleason scoring and tumour staging 
While prostate cancer is suspected after DRE and/or elevated PSA, the diagnosis is based 
on histopathological analysis of the biopsy (Mottet et al., 2017). 
The Gleason grading system is used for assessing the aggressiveness of the tumour 
(Gleason and Mellinger, 1974). The glandular histology of the biopsy is studied and 
graded based on five different growth and differentiation patterns. A score of 1 is given 
for differentiated patterns, and a score of 5 for the least differentiated. For cancer 
biopsies, the European Association of Urology guidelines advise that the Gleason score 
consists of the sum of the grade of the most prevalent pattern and the grade of the 
highest scored pattern (Mottet et al., 2017). For radical prostatectomy samples the 
Gleason score is calculated by summing the lowest and the highest scoring patterns that 
take up at least 5% of the sample (Heidenreich et al., 2011; Mottet et al., 2017). The 




Gleason score 6 can be seen in Figure 1.1.A, and a general illustration comparing 
prostate cancer to pre-malignant prostate conditions can be seen in Figure 1.2.D. 
TNM (tumour, node, metastasis) staging assesses the tumour (whether it is palpable, 
visible, organ confined), whether adjacent lymph nodes have been affected and whether 
metastasis is present (either to non-adjacent lymph nodes, bone or other organs). A 
tumour at stage T1N0M0 would be clinically insignificant, while a tumour staged 
T4N1M1b (non-organ confined, spread to regional lymph nodes with proof of bone 
metastasis) would be associated with a poor prognosis (Cheng et al., 2012). 
1.1.2.5.4. Treatment 
1.1.2.5.4.1. Monitoring 
There are two types of monitoring approaches currently in use. 
Active surveillance is employed in younger patients with life expectancy of over 10 years. 
It is used in patients who have low-risk prostate cancer and aims to decrease toxicity 
due to treatment without endangering the patient’s life (Mottet et al., 2017). Regular 
assessments, such as DRE, PSA and biopsies, follow the disease progression, and a switch 
to active treatment is usually based on changes in the tumour staging after a biopsy 
(Klotz et al., 2010). 
“Watchful waiting” is recommended for frail patients, who have a life expectancy of less 
than ten years due to age or co-morbidities. It aims to reduce treatment related toxicity 
and side effects. Studies have shown that if a patient has a Charlson comorbidity index 
of 2 or more, tumour aggressiveness does not have a significant impact on overall 
survival (Albertsen et al., 2011). 
1.1.2.5.4.2. Radical prostatectomy 
Radical prostatectomy (the surgical removal of the prostate and surrounding lymph 
nodes) is used for the eradication of organ-contained disease. The surgery can be 
performed as an open surgery, laparoscopy (performed via small incisions, using a 
laparoscope) or as a robot-assisted prostatectomy. While there is no evidence that one 
procedure is superior to the others, robotic surgery has been shown to carry a lower risk 
of complications during the procedure (Ramsay et al., 2012). Common side effect of 




1.1.2.5.4.3. Radiation therapy 
Brachytherapy is used as a common treatment for localised prostate cancer. Initially 
developed in the 1970s, a radioactive isotope of iodine (125I) was inserted into the 
prostate (Whitmore et al., 1972). At this stage, however, the delivery method did not 
guarantee consistent dosage and lead to serious complications. When TRUS was 
developed, the guided implantation of the radioactive isotope was made possible, which 
lead to accurate delivery and allowed for the identification of patient subgroups that 
would benefit most from the treatment (Ragde et al., 2000). 
With the development of higher energy accelerators and advancement in tomography 
methods, external beam radiotherapy (the delivery of high doses of radiation to deep-
seated cancers from outside the body) became a possibility (Denmeade and Isaacs, 
2002). Several randomised trials have demonstrated the benefits of combining 
androgen deprivation therapy with radiation therapy (as both lead to the death of 
prostate epithelial cells, including cancerous cells), such as improvement of overall 
survival and increased relapse-free time (Pilepich et al., 1995; Bolla et al., 1997; Pilepich 
et al., 1997).  
1.1.2.5.4.4. Hormonal therapy 
While the treatments above are chosen for organ confined tumours, hormonal therapy 
is recommended for advanced metastatic cancers. 
1.1.2.5.4.4.1. Hypothalamic-pituitary-gonadal axis and the androgen receptor 
To understand the action of androgen-deprivation therapy, a brief introduction to the 
hypothalamic–pituitary–gonadal (HPG) axis and the role of androgens in the male 
physiology is necessary. The hypothalamus produces the gonadotropin-releasing 
hormone (GnRH) which has a direct effect on the pituitary gland, activating the release 
of luteinizing hormone (LH) and follicle stimulating hormone (FSH). FSH acts on the 
Sertoli cells of the testis and drives the production androgen-binding protein necessary 
for testosterone transport in the blood; also via the Sertoli cells, FSH has a direct effect 
on germ cells by stimulating spermatogenesis. LH stimulates testosterone production in 
the Leydig cells of the testis. Elevated levels of testosterone can lead to the inhibition of 







Figure 1.3. HPG axis. 
Gonadotropin-releasing hormone (GnRH) is produced by the hypothalamus and acts 
on the pituitary gland, leading to the production of luteinizing hormone (LH) and 
follicle stimulating hormone (FSH). LH acts on the Leydig cells in the testis to produce 
testosterone, while FSH stimulate androgen binding globulin and inhibin production 
from the Sertoli cells. The produced inhibin and testosterone can act as negative 





The androgen receptor (AR) is a nuclear receptor of 3C subclass, and it functions as a 
ligand-dependent transcription factor (Lu et al., 2006). AR, inactivated by chaperone 
proteins, is present in the cytoplasm diffusely (Figure 1.4) (Centenera et al., 2008). When 
bound to an androgen ligand, such as testosterone or the higher affinity 5α-
dihydrotestosterone (DHT), the AR is released from its chaperone proteins (Edwards and 
Bartlett, 2005). Once freed, the AR changes conformation, forms a homodimer and is 
translocated to the nucleus where it undergoes post-translational modification 
(Centenera et al., 2008). The activated dimer AR then binds to DNA at sequences called 
androgen-responsive elements. Following, transcriptional co-factors and activators are 
summoned to the site, and initiate the process (Shang et al., 2002; Centenera et al., 
2008). The AR mediates a number of basic prostate cell functions such as zinc levels and 
KLK3 expression, thus PSA can be used to monitor disease progression, and response to 
treatment, especially androgen deprivation therapy (Ryan et al., 2006; Verze et al., 
2016). 
1.1.2.5.4.4.2. Castration sensitive cancers 
The standard treatment for metastatic prostate cancer in the last few decades has been 
androgen deprivation therapy, either by surgical castration via bilateral orchiectomy 
(removal of both testes) or chemical castration via GnRH analogue treatment. (Yamaoka 
et al., 2010) 
The most common goal of hormonal therapy is to deprive the androgen receptor of its 
ligand. To achieve this, drugs target GnRH and release of LH from the pituitary, which in 
turn prevents testosterone production (Wong et al., 2014). This is followed by a brief 
surge in testosterone levels (called testosterone flare), but testosterone production in 
the testes is inhibited and testosterone concentration in the serum of chemically 
castrated men reaches levels comparable to those of men who have undergone surgical 
castration (van Poppel and Nilsson, 2008). 
Animal studies have shown that when androgen deprivation therapy is used, the loss of 
ligand leads to a loss of signalling which causes death in most secretory epithelial cells, 
as androgen is required for their survival; when androgen signalling is restored, a rapid 







Figure 1.4. Androgen receptor activation. 
Once testosterone enters the cells, it is converted to a more active form DHT by 5α-
reductase. The androgen receptor (AR) is found in the cytoplasm bound to inhibiting 
chaperone proteins (C). Once DHT binds AR, C are removed, leading to active AR 
which forms dimers and translocates to the nucleus, where it binds DNA and 
summons activators (A) which help it initiate transcription of molecules involved in a 





AR antagonists are sometimes used in combination with drugs targeting GnRH; these 
antagonists actively target the AR by recruiting co-repressors (rather than co-activators) 
that lead to conformational changes in the receptor, preventing transcriptional 
activation (Knudsen and Penning, 2010). 
A recent study has shown that abiraterone plus prednisone added to androgen 
deprivation therapy in newly diagnosed, castration-sensitive, metastatic prostate 
cancer, leads to prolonged overall survival and prolonged progression-free survival 
(Fizazi et al., 2017). 
1.1.2.5.4.4.3. Castration-resistant cancer 
Despite the initial positive response to androgen deprivation therapy, most metastatic 
prostate cancers progress to androgen-independent growth, also known as castration 
resistant prostate cancer (CRPC) (Tucci et al., 2015). Once resistance to androgen 
deprivation therapy is developed, the CRPC is associated with poor prognosis, with 
docetaxel being the standard of care, demonstrating prolonged survival in CRPC 
patients. It has, however, been associated with severe side effects, e.g. anaemia, 
diarrhoea, sensory neuropathy (Tannock et al., 2004). A more recently discovered drug, 
abiraterone (androgen biosynthesis inhibitor) has demonstrated promising results both 
as a treatment in naïve CRPC patients, and in patients previously treated with docetaxel 
(Huggins et al., 1941; de Bono et al., 2011). 
Multiple factors have been suggested as facilitators of androgen deprivation therapy 
resistance, including androgen receptor signalling through androgens produced in the 
adrenal glands, increased androgen production within the tumour, mutations in the 
androgen receptor and within the androgen signalling pathway, reviewed in detail by 
Knudsen and Penning (2010) (Stanbrough et al., 2006; Montgomery et al., 2008). 
Nuclear-factor kappa B (NF-κB) is a potent activator of inflammatory response and has 
been implicated in oncogenesis, as it can promote proliferation, metastasis and 
angiogenesis, while inhibiting apoptosis (Karin et al., 2002). In the context of prostate 
cancer, NF-κB and the AR show a direct correlation, with in vitro data suggesting that 
AR-expression is modulated by NF-κB, highlighting a possible pathway for inflammation 




1.1.2.5.5. Prostate microflora 
Using ultra-deep pyro sequencing, a study evaluated the prevalent bacterial species in 
radical prostatectomy samples, showing no significant difference between tumour and 
non-tumour sites analysed (Cavarretta et al., 2017). The study did, however, give insight 
into the bacterial taxa present in the prostate, with the most prevalent genus being 
Propionibacteria. Multiple explanations are possible for the presence of P. acnes in the 
prostate, including ascension via the urethra, as studies have shown that the bacterium 
is present in the genitourinary tract; an alternative explanation could be that the 
bacterium is sexually transmitted, as it has also been cultured from both healthy women 
and women with vaginosis (Thomason et al., 1984; Shannon et al., 2006a; Cavarretta et 
al., 2017). 
Two studies, using massive parallel sequencing (MPS) and RNA sequencing, analysed 
prostate cancer samples for the presence of microorganisms. The MPS study 
demonstrated the presence of different bacterial species with P. acnes being isolated 
from 95% of samples (Yow et al., 2017). The second study showed that P. acnes is 
present in both cancerous and benign adjacent tissue, and is not seen in healthy 
controls; it also demonstrated the differences between the organisms present in 
prostate samples from Chinese and Western patients (Chen and Wei, 2015). A change 
in the prostate microflora could explain why prostate cancer incidence in Asian men 
increases if they relocate to the West. 
1.2. Propionibacterium acnes 
P. acnes has been associated with a number of chronic diseases over the years and most 
recently it has been suggested that it could be a key factor in oncogenesis in a subgroup 
of prostate cancers. Before exploring the evidence for its role in prostate cancer, we will 
highlight some aspects of P. acnes biology and its role in disease. 
P. acnes is a pleomorphic rod-shaped Gram-positive anaerobic-to-microaerophilic 
microorganism. It is a part of the normal human skin microflora, with about half of the 
bacteria normally found on the skin being anaerobes, including P. acnes (Tancrede, 
1992). Other Propionibacteria species found on the skin include P. granulosum and P. 
avidum. In addition to the skin, P. acnes can also be isolated from the gastrointestinal 




is found in the pilosebaceous units of sebaceous glands and produces lipases that 
degrade the triglycerides from sebum (the lipid-rich product of the glands) to free fatty 
acids (Marples et al., 1971). The free fatty acids then contribute to the acidity of the skin, 
thus discouraging the growth of common pathogens such as Staphylococcus aureus and 
Streptococcus pyogenes and promoting the growth of coagulase-negative bacteria and 
Corynebacterium spp. (Grice and Segre, 2011). 
 Genetic Divisions 
In recent years, the investigation of P. acnes has shifted focus from researching the 
involvement of the organism in the development of acne to investigating the possibility 
that some phylogenetic types may be associated with a specific disease, while others 
may be associated with health. Using a combination of 16S rRNA sequencing and 
multilocus sequence typing (MLST) there are now six confirmed phylogroups of P. acnes: 
IA1, IA2, IB, IC, II and III. The initial split of P. acnes into two distinct phenotypes I and II 
was based on agglutination differences and the pattern of sugars in the cell walls: type I 
contains galactose, glucose and mannose, while type II only has glucose and mannose 
(Johnson and Cummins, 1972). More recently McDowell et al. (2005) confirmed that the 
two phenotypes are phylogenetically distinct groups using the non-ribosomal 
housekeeping gene recA (encoding a DNA-dependent ATPase) and a putative 
haemolysin/FtsJ-like methyltransferase gene tly, with type I later divided into subtypes 
IA and IB (Valanne et al., 2005). Subtype IA was then further split into IA1 and IA2, based 
on high resolution MLST and whole genome sequencing analysis (Vörös et al., 2012). 
Additionally, subtype IC was proposed following phylogenetic and whole genome 
analysis with isolates from this group displaying antibiotic resistance to erythromycin 
and tetracycline (McDowell et al., 2012b). Finally, type III P. acnes was identified based 
on cell morphology, antibody reactivity and phylogenetic analysis of recA (McDowell et 
al., 2008). More recently, a reclassification of the Propionibacterium family and 
renaming of P. acnes to Cutibacterium acnes was proposed (Scholz and Kilian, 2016). 
 Virulence factors 
Several whole genome sequences of different types of P. acnes have been published, 
giving insight not only in the phylogenetic relationships between the different types of 




al., 2004; Hunyadkurti et al., 2011; Horvath et al., 2012; McDowell et al., 2012b; Vörös 
et al., 2012). 
1.2.2.1. Christie-Atkins-Munch-Petersen factors 
Christin-Atkins-Munch-Petersen (CAMP) reaction is a synergistic reaction first observed 
with Group B Streptococci (GBS, e.g. Streptococcus agalactiae) producing complete 
haemolysis only in the presence of β-toxin/sphingomyelinase C-producing 
Staphylococcus aureus (Christie et al., 1944). Five similar homologues were discovered 
in P. acnes, and it has been suggested that during an acne infection, when phagocytosed 
by the macrophage, P. acnes uses the host lysosomal acid sphingomyelinase, thus 
enhancing the activity of CAMP factor and escaping phagocytosis (Nakatsuji et al., 2011). 
All five CAMP factors are present in different types but they show differences in 
expression, e.g. CAMP factor 1 production was seen in types IB and II, but not in type IA, 
and CAMP factor 2 production was higher in IA, compared to IB and II (Valanne et al., 
2005). The proposed mechanisms of action for the action of CAMP factors in GBS is the 
formation of 1.6 to 2.7 nm pores in the cell membrane, leading to increased osmotic 
pressure and eventually to cell lysis (Lang and Palmer, 2003). 
1.2.2.2. Lipase 
P. acnes has been shown to release extracellular lipases that hydrolyse triglycerides from 
sebum to release free fatty acids which are then thought to aid colonization by assisting 
adherence, and may also reduce the invasion of other, more pathogenic bacteria, by 
altering pH. Additionally, it has been proposed that free glycerol is also released from 
the hydrolysis of triglycerides, and that it is utilized as a carbon source by P. acnes. 
(Ingham et al., 1981; Miskin et al., 1997). An example of a lipase produced by P. acnes is 
the product of gehA, which encodes a 339 amino acid CG rich signalling peptide (Miskin 
et al., 1997).  
1.2.2.3. Biofilm formation 
Biofilm formation is the irreversible attachment of microorganisms to a surface and the 
formation of an extracellular matrix, resulting in phenotype alteration and increased 
antimicrobial resistance, most commonly associated with medical device infections, e.g. 
prosthetic joints. P. acnes is shown to have three separate clusters encoding genes 
involved in extracellular polysaccharide synthesis, indicating that it has the ability to 




hour incubation and that lipase activity is higher in P. acnes biofilm, compared to 
planktonic cells (Bruggemann et al., 2004; Coenye et al., 2007a). Electron microscope 
study of the P. acnes biofilm showed that it forms a layer 10 µm thick with a filamentous 
structure, and unlike other bacterial species, biofilm formation was inhibited by plasma, 
which could be a possible explanation why P. acnes infection is more often seen in 
prosthetic join infection and cerebrospinal fluid shunts, compared to heart valves 
(Holmberg et al., 2009a). 
1.2.2.4. Other virulence factors 
The production of porphyrins has also been suggested as a means for P. acnes to cause 
skin damage as a result of increased oxygen tension; molecular oxygen reacts with the 
released porphyrins and causes cell damage via free oxygen radicals (Bruggemann et al., 
2004). 
Hoeffler (1977) reported the presence of chondroitin sulphatase, hyaluronidase and 
DNase in some P. acnes strains, with a widely-reported gelatinase activity. The presence 
of a bacteriocin-like substance with bacteriostatic activity, called acnecin, has also been 
reported (Fujimura and Nakamura, 1978). In addition to the different virulence factors, 
P. acnes has alterations in the peptidoglycan layer structure, namely unsubstituted 
glucosamine residues, which are responsible for lysozyme resistance (Kamisango et al., 
1982). 
 Stimulation of the immune system 
P. acnes has been proven to be a strong driver of immune response and its ability to do 
so has previously been used as an anti-cancer treatment. Multiple animal experiments 
have shown that when murine cancer models (including melanoma, mastocytoma, 
mammary carcinoma, sarcoma) were injected with P. acnes of an unknown phylotype, 
there was evidence of delayed growth and even protection from cancer progression 
(Woodruff and Boak, 1966; Millman et al., 1977; Tsuda et al., 2011). A suggested 
explanation is that P. acnes activates a Th1 immune response which in turn summons 
cytotoxic T cells and natural killer (NK) cells to the site, thus exhibiting anti-tumour 




 Antibiotic resistance 
Due to the widespread use of antimicrobials as treatment for acne, P. acnes, which used 
to be susceptible to antibiotic treatment, has developed resistance mechanisms (Wang 
et al., 1977). The main resistance mechanism adopted by P. acnes are point mutations 
and the antimicrobials that it is most commonly resistant to are erythromycin and 
tetracycline, which used to be the two main treatments for acne. Tetracycline resistance 
is often due to nucleotide substitution of guanine with cytosine at base 1058 of the 16S 
rRNA, and resistance to erythromycin is a result of point mutation at bases 2057, 2058 
or 2059 in the 23S rRNA, or the mobile gene element transposon Tn5432 carrying erm(X) 
resistance gene (Ross et al., 1997; Ross et al., 1998; El-Mahdy et al., 2010). P. acnes also 
shows intrinsic resistance to metronidazole, which is usually used to treat anaerobic 
infections (Denys et al., 1983). 
 P. acnes and disease 
In addition to being associated with the normal microflora, P. acnes has been linked to 
a number of diseases, e.g. acne vulgaris, prosthetic joint infections, sarcoidosis, 
endophthalmitis, prostate cancer, etc. (Homma et al., 1978; Somani et al., 1997; Cohen 
et al., 2005; Zeller et al., 2007). 
1.2.5.1. Acne 
P. acnes is known as the causative agent of acne, although the exact mechanism of its 
involvement in the development of acne is unclear. Circumstantial evidence supports 
this idea, as antibiotic treatment of acne improves the condition, and if resistance to 
antibiotics is generated, the condition then recurs. Studies have shown an association 
of phylogenetic type IA1 with acne (McDowell et al., 2013). As reviewed by Dessinioti 
and Katsambas (2010), there are numerous mechanisms in which P. acnes may be 
involved in epidermal colonization and subsequent inflammation associated with acne, 
for example, it may activate toll-like-receptors which in turn initiate NF-κB-response, 
regulating the expression of immune response genes. 
1.2.5.2. Medical implant infections 
P. acnes, previously disregarded as a contaminant if isolated from implants, is associated 
with chronic low-grade infection related to implants as often as Staphylococcus aureus 
(Tunney et al., 1998). P. acnes forms a firm biofilm on the biomaterial and isolates from 




healthy skin (Soderquist et al., 2010). Infection with type I was seen in 63% of cases and 
37% were linked to type II, with the percentages being similar in the case of aseptic 
failure, 67% and 33% respectively (Sampedro et al., 2009). A more recent study shows 
that the association of types IB, II and III with prosthetic hip infections is higher 
compared to type IA (McDowell et al., 2011). The main symptom of a P. acnes infection 
of the orthopaedic implant is pain which makes the condition difficult to diagnose 
accurately (Sampedro et al., 2009). The treatment of P. acnes infection related to 
implants presents a challenge, as the bacteria grow in a biofilm, and as a result the 
resistance to some antibiotics (e.g. cefamandole, vancomycin, and ciprofloxacin) 
increases. An additional challenge for the treatment of orthopaedic implant infections 
is that there is no single antibiotic that is effective against both P. acnes and S. aureus, 
which are the two most common isolates. Furthermore, the slow growth of P. acnes and 
long incubation period of at least 7 days, means that it is possible for cultures to be 
discarded before growth is visible (Ramage et al., 2003; Dodson et al., 2010). In the case 
of shoulder arthroplasty, Dodson et al. (2010) suggest that the axillary region should be 
isolated with an antimicrobial drape, to avoid contamination, and that the usual blood 
tests (erythrocyte sedimentation rate, white blood cell count, C-reactive protein) are not 
good indicators of P. acnes infection. Zeller et al. (2007) point out that macrophage and 
lymphocyte infiltrations would reflect the immune response in slow-developing 
prosthetic joint infections, and not neutrophilic infiltration. 
P. acnes has been related to both native and prosthetic heart valves. The cases of 
endocarditis linked to Propionibacterium spp., are usually associated with a long history 
and lack clinical signs of infection. The mortality rates of Propionibacteria-related 
endocarditis vary between 9.1% and 46%, which highlights the importance of evaluating 
the presence of bacteria in patient blood and the importance of not dismissing positive 
culture results (Mohsen et al., 2001; Clayton et al., 2006). 
1.2.5.3. Sarcoidosis 
Sarcoidosis is a systemic granulomatous disease, with the organs most commonly 
affected being the lungs and lymph nodes. The aetiology of the disease is unknown but 
it is suggested that it results from an antigen-driven response to an exogenous agent in 
genetically predisposed patients (Hunninghake et al., 1999). P. acnes was the first 




thus been implicated as having a role in the development of the disease (Abe et al., 
1984). In following studies, both P. acnes and P. granulosum were isolated from 
sarcoidosis samples from different countries, averaging at 89% and 60%, respectively 
(Eishi et al., 2002). It was later shown that there is no difference between the 
phenotypes and genotypes of sarcoid and non-sarcoid isolates, however, a correlation 
between the amino acid profiles of genes PAmce and Pap60 and invasiveness was found, 
indicating that the two genes may be involved in cell invasion, although the study did 
not prove the direct involvement of P. acnes in sarcoidosis (Furukawa et al., 2009) 
P. acnes can exist as dormant and cell wall-deficient forms in macrophages, in the form 
of Hamazaki-Wesenberg bodies, which can be activated and proliferate in cells at the 
site of latent infection. The newly formed small round bodies are infective P. acnes and 
when released from the macrophages they can still lead to infection (Eishi, 2013). 
1.2.5.4. Sciatica 
Sciatica is the term used for any pain related to compression or irritation of the sciatic 
nerve, including lower back pain. It has been proposed that P. acnes plays a role in 
sciatica. The bacterium was isolated from 84% (16/19) of culture positive samples (53% 
culture positive, 19/56) from patients who had undergone microdiscectomy (Stirling et 
al., 2001). Further studies used antibiotic therapy in an uncontrolled trial with patients 
diagnosed with Type 1 Modic changes (bone oedema), and the results at follow-up 
showed significant improvement, strongly suggesting bacterial involvement; these 
findings were confirmed in a controlled double-blind study (Albert et al., 2008; Albert et 
al., 2013). 
1.2.5.5. Progressive macular hypomelanosis 
Progressive macular hypomelanosis (PMH) is a condition associated with skin 
discolouration, mainly on the front and the back of the trunk. It has been suggested that 
P. acnes plays a role in the disease, and it was recently shown that phylogenetic type III 
P. acnes is significantly associated with the hypomelanotic lesions (Westerhof et al., 
2004; Barnard et al., 2016) 
1.2.5.6. Endophthalmitis 
P. acnes is also involved in certain eye infections. Endophthalmitis as a result of a P. 




infections include chronic postoperative endophthalmitis with the inflammation 
producing a white plaque in the capsular bag of the eye, typically inducing recurrent 
infections, or endophthalmitis following cataract extraction and posterior chamber 
intraocular lens, with symptoms including decreased vision, anterior chamber reaction, 
a white intracapsular plaque and pain, and is once again associated with reoccurrence 
(Aldave et al., 1999; Csukas et al., 2004).  
1.2.5.7. Primary biliary cirrhosis 
Using P. acnes-specific polymerase chain reaction (PCR), it was suggested that the 
bacterium is involved in granuloma formation and 56% of periportal hepatocytes in 
primary biliary cirrhosis (Harada et al., 2001). It is not clear what the exact mechanism 
of granuloma formation is but it is suggested that immunomodulation by P. acnes may 
be involved (Harada et al., 2001). 
1.3. P. acnes and prostate cancer 
 Chronic inflammation and cancer 
The prostate is an immunocompetent organ, meaning that small numbers of immune 
cells are present at all times (90% CD8+ T-lymphocytes, as well as B-lymphocytes, mast 
cells, macrophages) (Di Carlo et al., 2007; De Nunzio et al., 2011). In contrast, 
inflammatory infiltrate, consisting of CD3+ T cells and macrophages is often seen in both 
the epithelial and stromal cells of radical prostatectomy samples and prostate biopsies 
(Wagenlehner et al., 2007). 
It has been observed that both acute and chronic multifocal inflammation can be seen 
in prostatectomy samples. This inflammation is not just confined to the area of the 
tumour, and can also be seen in malignancy-free tissue, indicating that it is not simply 
an immune response to the cancer cells (Blumenfeld et al., 1992). Chronic inflammation 
plays an important role in oncogenesis by causing cellular damage via the products of 
inflammatory cells, e.g. reactive nitrogen and oxygen species which lead to DNA 
damage.  
The involvement of infection in prostate oncogenesis has long been suggested and is 
supported by circumstantial evidence. In addition to the potential role of acute 
prostatitis related to STIs, single nucleotide polymorphisms in genes involved in the 




ribonuclease L (RNASEL), macrophage scavenger receptor-1 (MSR-1) and toll-like 
receptors, are also suggested as risk factors for prostate oncogenesis. RNASEL is one of 
the best studied prostate-associated loci and encodes a ribonuclease involved in 
interferon signalling in viral infections; MSR-1 encodes a homotrimeric “scavenger” 
receptor class A, expressed mainly in the macrophages, and has the ability to bind a 
variety of ligands, including Gram-positive and Gram-negative bacteria, apoptotic cells, 
and oxidised high and low density lipoproteins (Gonzalgo and Isaacs, 2003; De Marzo et 
al., 2007). 
Examples of chronic inflammation being linked to oncogenesis include hepatitis C 
infection of the liver, leading to hepatocellular carcinoma, Helicobacter pylori infection 
and the development of gastric cancer and Fusobacterium spp. and colorectal and 
pancreatic cancer (Ernst and Gold, 2000; Coussens and Werb, 2002; Keku et al., 2013; 
Mitsuhashi et al., 2015). 
1.3.1.1. Gastric carcinoma and Helicobacter pylori 
H. pylori is a Gram-negative microaerophilic bacterium which colonizes the human 
stomach and gastrointestinal tract. The link between H. pylori and gastric carcinoma was 
first highlighted by a number of large epidemiological studies which showed the 
organism was more frequently present in patients with gastric cancer compared to 
control groups (Parsonnet et al., 1991; Talley et al., 1991). The bacterium has a number 
of virulence factors which are linked to an increased risk of developing stomach cancer, 
e.g. cytotoxin-associated gene A (CagA) is a bacterial protein that activates numerous 
oncogenesis promoting pathways in epithelial cells, including β-catenin signalling and 
phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt) signalling 
(Franco et al., 2005; Nagy et al., 2009). Another example is vacuolating cytotoxin A 
(VacA), which is a toxin capable of suppressing T cell development (Gebert et al., 2003). 
The role of H. pylori in gastric carcinoma has been reviewed in detail by Amieva and Peek 
(2016). The development of a vaccine against H. pylori aimed at prevention of gastric 
carcinoma has been proposed (Chui et al., 2005).  
1.3.1.2. Bacteria and colorectal cancer 
The genus Fusobacteria is represented by Gram-negative, anaerobic, non-spore forming 
bacilli and is found as a part of the normal microflora of the oropharynx. Studies have 




spp. were shown to be present at increased levels in colorectal adenoma (benign 
precursor to adenocarcinoma) tissue, as well as in stool samples for patients with 
adenomas and cancer diagnoses, compared to healthy controls (Kostic et al., 2013). 
Further animal studies demonstrated that F. nucleatum leads to an increased number 
of tumours in colorectal cancer mouse models and that the inflammation resulting from 
infection drives oncogenesis (Kostic et al., 2013). A molecular mechanism suggested for 
the role of Fusobacteria in oncogenesis is via the Fusobacterium adhesin A (FadA) 
adhesion molecule; FadA has been shown to bind to E-cadherin in order to invade 
epithelial cells, which in turn leads to the activation of a number of oncogenic pathways, 
including β-catenin signalling (Rubinstein et al., 2013). It has also been suggested that 
Fusobacterium spp. play a role in the development and progression of pancreatic and 
oesophageal cancer (Mitsuhashi et al., 2015; Yamamura et al., 2016).  
Streptococcus gallolyticus has been also implicated in colorectal cancer for a long time 
and a recent study, using both cell culture and animal experiments, demonstrated that 
the bacterium promotes cell proliferation and tumour growth (Kumar et al., 2017). 
1.3.1.3. Viral infections and cancer 
1.3.1.3.1. Human papilloma virus (HPV) and cervical cancer 
HPV is a sexually transmitted virus which has been associated with a number of 
conditions, including genital warts and cervical cancer. As reviewed by Schiffman et al. 
(2016), there are 13 HPV genotypes that have been linked to causing a large number of 
cervical cancers, as well as some oropharyngeal malignancies. Extensive care is taken for 
the prevention of cervical cancer caused by HPV, including regular screening and 
commercially available vaccines targeting the types of HPV most commonly associated 
with oncogenesis, most notably HPV16 and HPV18 (De Vincenzo et al., 2014). 
1.3.1.3.2. Hepatitis C and hepatocellular carcinoma 
Another example of a cancer driven by viral disease is hepatocellular carcinoma caused 
by hepatitis C infection. Unlike HPV, there are currently no vaccines developed against 
hepatitis C, but there is ongoing work for the development of antiviral agents which can 
prevent the damage caused by this viral infection. An extensive review on the topic by 




 P. acnes and prostatectomy samples 
In 2005 it was reported that the predominant organism isolated from radical 
prostatectomy samples (at 35%) was P. acnes, and it was shown to be positively 
associated with the inflammation present in the tissue (Cohen et al., 2005). Possible 
reasons why the bacterium had not been isolated from the prostate earlier include P. 
acnes’ resistance to lysozyme and the low number of bacteria present (Kamisango et al., 
1982). Due to lysozyme resistance, the conventional methods for bacterial DNA 
extraction cannot be used in this case. The low bacterial numbers mean that Gram-
staining of the tissue would be an inappropriate and non-specific method of detection. 
Furthermore, the specific requirements for P. acnes culture such as anaerobic 
environment and long incubation time (up to a week), are not routinely used. Finally, 
even if present, the organism is frequently dismissed as a contaminant. 
Subsequent studies have focused on confirming the presence of the bacterium in 
prostate specimens. Using 16S rRNA, Alexeyev et al. (2006) demonstrated that P. acnes 
is the predominant microorganism isolated from BPH, and also showed that there is an 
association between the presence of P. acnes and subsequent prostate cancer diagnosis. 
The authors also concluded that the relative risk of prostate cancer for patients who 
tested positive for P. acnes is at levels similar to those with history of STIs or BPH 
(Lightfoot et al., 2004; Patel et al., 2005). A separate PCR-based study investigated the 
prevalence of different types of P. acnes in the male genitourinary tract in different age 
groups of healthy patients and in patients with prostate cancer: they identified P. acnes 
types IA, IB and II but found no association between the presence of different types of 
the bacterium in urine samples and the prostate biopsy results of patients (Shannon et 
al., 2006a). The presence of the bacterium was also demonstrated using fluorescent in 
situ hybridization, and P. acnes was seen both intracellularly and as extracellular biofilm-
like aggregates, with the two forms differing in shape, size and organization (Alexeyev 
et al., 2007). 
It is possible that the immune system may aid colonisation with P. acnes as the 
bacterium can use phagocytes as transport vectors (Drott et al., 2010). P. acnes can 
survive in macrophages, though the mechanism is not clear, and it differs from typical 




within the host cells, and it does not escape the host cells (Fischer et al., 2013; Nakamura 
et al., 2016). 
 In vitro investigation of P. acnes infection of the prostate 
In vitro studies, using the human HPV-immortalised prostate epithelium cell line RWPE-
1, demonstrated that P. acnes infection drives RWPE-1 cells to secrete vascular 
endothelial growth factor (VEGF), a number of cytokines (including IL-6, IL-8, TNF-α, etc.) 
and cyclcooxygenase-2 (COX-2, also known as prostaglandin-endoperoxide synthase 2 
or PTGS2), all of which have been associated with prostate cancer progression (Drott et 
al., 2010; Fassi Fehri et al., 2011; Mak et al., 2012). VEGF is a signal protein which plays 
a role in angio- and vasculogenesis, and angiogenesis is one of the hallmarks of cancer 
as it enables the tumour to progress further and to become metastatic (Hanahan and 
Weinberg, 2011b). Both IL-6 and IL-8 affect the activity of VEGF. Via its influence on the 
production of VEGF, IL-6 may act as a driver of metastasis, and IL-8 has been shown to 
play a role in angiogenesis and prostate tumour progression (Cohen et al., 1996; 
McCarron et al., 2002). COX-2 is an enzyme involved in the synthesis of prostaglandins. 
It has been confirmed that the use of COX-2 inhibitors decreases the risk of a number of 
cancers, including skin and colorectal (Thun et al., 2002). It has been demonstrated that 
non-steroidal anti-inflammatory drugs (NSAIDs) may play a role in the prevention and 
treatment of cancer as in vitro studies have shown that on the cellular level NSAIDs 
inhibit proliferation and angiogenesis, and stimulate apoptosis and the immune system 
(Dannenberg et al., 2001). Additionally, in vitro studies have demonstrated that infection 
of prostate epithelial cells with P. acnes can also cause anchorage-independent growth 
(as demonstrated by soft-agar assays) and cell migration (Fassi Fehri et al., 2011). 
 Animal models 
To date, there are two animal models of chronic infection of the prostate with P. acnes. 
A rat model of infection, where the animals were inoculated with live bacteria via an 
abdominal incision and sacrificed at day 5, week 3 or month 3 and 6. At 3 months viable 
P. acnes was still present in the dorso-lateral lobe of the prostate, together with clear 
signs of active inflammation (Olsson et al., 2012). However, the ventral lobes were clear 
of any sign of infection and live bacteria by the month 3 time point (Olsson et al., 2012). 
A mouse model of chronic infection with a prostate-derived P. acnes strain has also been 




killed P. acnes via transurethral catherization, and were sacrificed at day 2, week 1, 2 or 
8. The resulting infection of the dorsal lobe of the prostate persisted for the duration of 
the experiment and was only seen if live bacteria were used (Shinohara et al., 2013). 
Both animal models of infection can be used to study the effect of chronic inflammation 
and its relationship to prostate disease, including BPH and prostate cancer. 
It is worth noting that the murine prostate differs significantly from the human gland 
both histologically (e.g. rodent prostates have a higher epithelial-to-stroma ratio 
compared to human glands), and anatomically, as well as in that mice and rats do not 
develop spontaneous prostate cancers, unlike humans (Ittmann et al., 2013). Thus, 
rodent models of prostate P. acnes infection would not be an accurate representation 
of human prostate infection. 
1.4. Stratified Medicine 
With the development of high-throughput genome sequencing, other “-omic” 
technologies, completion of the human genome and the 1000 genome project, scientists 
have gained insight into predisposing factors or biomarkers for some diseases, as well 
as trends in response and lack of response to treatment in different subpopulations 
(Venter et al., 2001; Consortium, 2012). This approach, called stratified, personalized or 
precision medicine is now widely used in the treatment of a number of diseases, with 
the goal of stratifying patients into subgroups and finding the best possible treatment. 
An example of stratification used in the field of oncology is breast cancer patients 
harbouring an overexpression of the HER2/neu receptor tyrosine kinase where 
treatment with trastuzumab (Herceptin® Genentech, US) proves a superior alternative 
to conventional treatment (Burstein, 2005). Another example of successful stratification 
has been seen in cystic fibrosis patients and depending on the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene mutation present different 
treatment approaches are appropriate: in patients with the G551D mutation (about 5%) 
there is inadequate CFTR channel regulation, treatment which leads to dramatic 
improvement as it increases channel opening times (Ramsey et al., 2011; Brodlie et al., 
2015). If the patients harbour a deletion leading to misfolding of the protein and 
decreased trafficking to the cell surface (F508del, seen in 85% of cases) a combination 




2016). Contemporary approaches to antimicrobial therapy, based on identification and 
analysis of the resistance of the infecting organism, which in turn greatly increases 
chances of eradicating the infection, are also an example of stratified medicine. 
There is a clinical need for development of better screening tests for prostate cancer 
that would lead to better diagnosis and the ability to predict outcome. There are 
currently three key issues which restrict the management of prostate cancer. 
1. The widely used PSA test does not provide the necessary specificity and 
sensitivity, and leads to over-diagnosis and an increased number of unnecessary 
biopsies. 
2. The only way to definitively diagnose and monitor prostate cancer progression 
is thorough biopsies. 
3. The only way to analyse infection present in the prostate is once again via a 
biopsy or prostatectomy. However, if infection does play a role in oncogenesis, 
identification of the patients harbouring infection would offer a chance for 
antibiotic or other antimicrobial therapy as a preventative measure. 
The idea of P. acnes infection as a modifiable risk factor for the development of prostate 
cancer presents it as an attractive target for the development of novel diagnostic tests 
which can identify the presence of the bacterium and could lead to the eradication of 
infection prior to oncogenesis. 
1.5. Hypothesis 
The involvement of P. acnes in prostate oncogenesis is strain-specific, with members of 
some phylogenetic types inducing a cancer-promoting immune response, while other 




1.6. Aims and objectives 
Aim 1 Genotypic analysis of prostate cancer-associated phylogenetic types of P. 
acnes (Chapter 3) 
To perform MLST analysis on a number of available P. acnes prostate isolates. 
Aim 2 Optimisation of in vitro infection model (Chapter 3) 
To optimise the conditions for short and long-term in vitro infection models and to 
develop proof of concept experiments with cancer cell-lines, which will then be used in 
follow-up long-term experiments. 
Aim 3 Investigation of the potential of P. acnes phylogenetic types to drive 
oncogenesis (Chapter 4) 
To compare the molecular dysregulation of inflammatory and epithelial-mesenchymal 
transition genes caused by infection with different phylogenetic types of P. acnes in 
acute and chronic infections of human prostate epithelial cells. Additionally, to contrast 
bacterial and eukaryotic behaviour and select infection models to be used in follow-up 
experiments. Finally, to study the ability of P. acnes infection to induce anchorage-
independent growth, migration and its potential to stimulate angiogenesis. 
Aim 4 Analysis of prostate cancer-related genes following infection (Chapter 5) 
Using a qPCR array to investigate the dysregulation in prostate cancer-related genes as 
a result of infection with different phylogenetic types of P. acnes, and to contrast the 
differences in expression patterns between the different infections studied. 
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2.1. Cell culture 
 Cell culture and subculture 
RWPE-1 (ATCC® CRL-11609™), a non-cancerous HPV-immortalised human prostate 
epithelium cell line, was cultured in keratinocyte serum-free medium (KSFM), 
supplemented with 0.05 mg/ml bovine pituitary extract and 5 ng/ml epidermal growth 
factor (EGF; Gibco, Life Technologies, UK) at 37°C in a 5% CO2 humid environment. The 
cells were subcultured at a 1:5 ratio every 3 days. Upon reaching 80-90% confluence, 
the cells were washed with phosphate-buffered saline (PBS, 0.14M sodium chloride, 2.7 
mM potassium chloride, 8.1 mM sodium phosphate dibasic, 1.5 mM potassium 
phosphate monobasic; Oxoid, UK) and then detached by treatment with 0.25% trypsin-
EDTA (Gibco, Life Technologies, UK) and incubation at 37°C for 5 min. The trypsin was 
then neutralised with 10% (v/v) foetal bovine serum (FBS; Gibco, Life Technologies, UK) 
and the cell suspension was centrifuged for 5 min at 200 x g. The supernatant was 
removed, and the cell pellet was resuspended in PBS and centrifuged again for 5 min at 
1000 rpm to remove any remaining trypsin and FBS. Finally, the PBS was aspirated, and 
the cells were resuspended in complete KSFM. 
The prostate cancer cell lines PC-3 (ATCC® CRL-1435™) and 22Rv1 (ATCC® CRL-2505™) 
were cultured in RPMI-1640 medium (Gibco, Life Technologies, UK), supplemented with 
10% (v/v) FBS (Gibco, Life Technologies, UK) at 37°C in a 5% CO2 humid atmosphere. The 
PC-3 and 22Rv1 cell lines were subcultured every 3 days as follows: the medium was 
removed, and the cells were washed with PBS. They were then detached using 0.25% 
trypsin-EDTA (Gibco, Life Technologies, UK) and incubated at 37°C for 5 min. The trypsin 
was then neutralised with complete RPMI-1640 medium and the cell suspension was 
centrifuged at 200 x g for 5 min. The supernatant was aspirated, the cell pellet was 
resuspended in complete medium at ratio 1:3 for PC-3 and 1:5 for 22Rv1. 
Human dermal microvascular endothelial cells (HDMEC, cell line HMEC-1, ATCC® CRL-
3243™) were cultured in phenol red-free Medium 200 (Gibco, Life Technologies, UK), 
supplemented with 50x low growth serum supplements (LSGS; Gibco, Life Technologies, 
UK), with final concentrations after supplementation: 2% (v/v) FBS, 1 μg/ml 
hydrocortisone, 10 ng/ml human EGF, 3 ng/ml basic fibroblast growth factor, 10 μg/ml 
heparin. The flasks used for HDMEC culture were coated with 1% (w/v) gelatine (Sigma-




was the same as described above for PC-3 and 22Rv1 cell lines with the medium used 
being complete Medium 200.  
The different cell lines were kindly provided by: RWPE-1 – Prof Lorraine Martin (Queen’s 
University Belfast); PC-3 and 22Rv1 – Dr Caroline Conway and Philip Egan (Ulster 
University); HMEC-1 – Prof Christopher Mitchell and Naomi Todd (Ulster University). A 
summary of information relevant to the cell lines used in this thesis can be found in 
Table 2.1. The cell lines were validated by short tandem repeat (STR) analysis. STR typing 
was performed as follows: for 22Rv1, PC-3 and HDMEC-1 – prior to acquiring the cell 
lines; RWPE-1 was STR-typed before experiments were initiated. Mycoplasma screening 
was also performed at different stages during the project to confirm there was no 
contamination present. 
 Cell cryopreservation 
For cryopreservation, the cells were detached as described in Section 2.1.1, and the 
resulting pellet was resuspended in freezing medium. The RWPE-1 cells were frozen in 
complete KSFM supplemented with 15% (v/v) FBS and 10% (v/v) dimethyl sulfoxide 
(DMSO; Sigma-Aldrich, UK). Complete RPMI-1640 with 10% (v/v) DMSO was used to 
freeze the PC-3 and 22Rv1 cell lines. FBS supplemented with 10% (v/v) DMSO was used 
for the HMEC-1 cell line. The cell suspensions for 22Rv1, PC-3 and RWPE-1 were 
prepared at 1.5 x 106 cells/ml, and 1 ml aliquots were stored at -80°C. For the HMEC-1 
cell line, one third of an 80% confluent T75 flask was used. 
 Cell resuscitation 
An aliquot of cells was thawed rapidly in a water bath for 2 mins and the contents of the 
cryovials were added to 4 ml of complete medium (KSFM for the RWPE-1 cell line; RPMI-
1640 for PC-3 and 22Rv1; Medium 200 for HDMEC). The suspension was then 
centrifuged for 5 min at 200 x g to wash the cells. The supernatant was removed, and 
the cells were resuspended in fresh complete medium and seeded into a T25 flask. After 
an overnight incubation, the medium of the resuscitated cells was replaced with fresh 
complete medium to wash off any debris and remaining DMSO. The cells were then 





Table 2.1. List of cell lines used 
Cell line Derivation Medium (Supplier) Supplements (Supplier) Source 
22Rv1 
(ATCC® CRL-2505™) 




(Life Technologies, UK) 
10% Foetal bovine serum 
(Life Technologies, UK) 




Endothelial cells from 
human foreskin 
Medium 200, phenol red-free 
(Life Technologies, UK) 
Low serum growth supplements 
(Life Technologies, UK) 







(Life Technologies, UK) 
10% Foetal bovine serum 
(Life Technologies, UK) 




Human prostate epithelial 
cells from a histologically 
normal peripheral zone, 
immortalized with HPV-18 
Keratinocyte serum-free 
medium 
(Life Technologies, UK) 
0.05 mg/ml bovine pituitary extract 
5 ng/ml epidermal growth factor 
(Life Technologies, UK) 
Prof L. Martin+ 
 





 Cell viability counting 
The trypan blue exclusion viability assay utilises the ability of live cells to not absorb the 
trypan blue dye, while it penetrates dead cells with damaged cell membranes. Trypan 
blue (Sigma-Aldrich, UK) viability counts were performed to calculate cell density. Equal 
volumes of trypan blue and cell suspension were added together and incubated at room 
temperature for 5 min. The suspension was then added to a haemocytometer (Immune 
Systems Ltd., UK) and cell counts were performed in 4 squares, with clear cells counted 
as viable and blue cells considered dead. The number of cells per ml was calculated by 
taking the average of the number of cells across all squares, which was then multiplied 
by the dilution factor 2 and the volume of the haemocytometer 104 with the result 
indicating the number of cells per ml of suspension. 
cells
ml� =  average number of cells ×  2 ×  10
4 
Percentage viability was calculated by dividing the number of viable cells by the total 
number of cells, and then multiplying by 100. 
% viability =  
number of viable cells
total number of cells
×  100 
2.2. Bacterial culture methods 
 Routine bacterial culture 
Different strains of Propionibacterium acnes, Propionibacterium avidum and 
Propionibacterium granulosum were used for the in vitro infection models and for 
multilocus sequence typing (MLST). A complete list of all strains used can be found in 
Table 2.2). The bacterial strains were routinely cultured on brain heart infusion (BHI) 
agar plates in boxes with anaerobic atmosphere generators (GenBox Anaerob, 
bioMerieux, France) for 5-7 days at 37°C. Additionally, for use in experiments, bacterial 
strains were cultured in BHI broth for 16-20 hours under anaerobic conditions at 37°C 
with mild agitation. 
For optimization experiments a strain of Staphylococcus epidermidis (as described in 
Table 2.2) was used. S. epidermidis was cultured routinely on BHI agar overnight at 37°C. 
For experiments, BHI broth was inoculated and incubated at 37°C for 6 hours with mild 





Table 2.2. Bacterial strains used 
Species Strain Referred to in this thesis as: 
Phylogenetic 
type Source Comments on usage 
P. acnes 
00035 prostate 00035 
IA1 
Prostate Chapters 3, 4, 5 
00060R 00060R Prostate Chapter 3 
B2, 700-2010-0512 B2 Prostate Chapter 3 
NCTC 737, also known as 
ATCC® 6919™ NCTC737 
Acne, National Collection of 
Type Cultures 
Chapters 3, 4, 5 
Multiplex PCR control 
24.1.A1 ST27* Normal skin Chapters 4, 5 
Pacn17 Pacn17 IA2 Corneal scrape Multiplex PCR control 
03E3900R 03R3900R 
IB 
Prostate Chapter 3 
B3, 700-2010-0512 B3 Prostate Chapters 3, 4, 5 
P6 P6 Prostate - 
W1392 W1392 Dental Multiplex PCR control 
PV66 PV66 IC Acne Multiplex PCR control 
NCTC 10390, also known 
as ACTC® 12930 ™ NCTC10390 II 
National Collection of Type 
Cultures 
Chapters 3, 4, 5 
Multiplex PCR control 
Asn14 Asn14 III Human disc material Multiplex PCR control CFU2, L0076D CFU2 Prostate Chapters 3, 4, 5 
P. avidum pf771 P. avidum - Skin Chapter 4 
P. granulosum PRP-18 P. granulosum - Skin Chapters 4, 5 
Staphylococcus 
epidermidis 
NCTC 11047, also known 
as ATCC® 14990™ S. epidermidis - Nose Chapter 6 
 
* Identified as ST27 using the “Aarhus” MLST9 scheme. The strain belongs to ST4 using the “Belfast” MLST8 method. 






 Bacterial counts 
For bacterial counts the Miles Misra method was used (Miles et al., 1938). In brief, a 
1:10 dilution series of broth cultures were prepared and 20 μl of each dilution were 
pipetted on the surface of an agar plate in triplicate. The plates were allowed to dry and 
were then incubated as described in Section 2.2.1. Following incubation, the colonies 
were counted at the dilution factor which showed clear, well defined colonies, and the 
mean of the three replicates was calculated. The average value of the triplicates was 
then multiplied by 50 (to give numbers per ml of broth) and by the dilution factor, 
resulting in colony-forming units (CFU)/ml. 
CFU
ml� = average number of colonies ×  50 ×  dilution factor 
 Gram staining 
Gram staining (Gram Staining kit, Sigma-Aldrich, UK) was utilised to visualise bacteria 
under the microscope. Briefly, bacterial cells were heat-fixed on a glass microscope slide. 
The slide was subsequently flooded with Gram’s crystal violet for 60 seconds, washed 
with water, and flooded again with Gram’s iodine solution for 60 seconds. The slide was 
washed briefly with Gram’s Decolourizer Solution, and was then washed with water and 
counterstained with Gram’s safranin solution for a minute. Finally, the slide was briefly 
washed with water, air dried and examined under the microscope using Axio Imager.A2 
with Zeiss EC Plan-NEUFLUAR 100x/1,30 oil immersion objective and AxioCam MRm with 
1.0x magnification (Carl Zeiss Microscopy, GmbH, Germany). 
2.3. Co-culture methods 
 Co-culture set-up 
The RWPE-1 cell line was used for host response studies and was infected with different 
strains of P. acnes or P. granulosum. The RWPE-1 cells were counted as described in 
Section 2.1.1, and seeded at density of 100,000 cells/ml, and left overnight to attach. 
BHI broths were inoculated with strains of P. acnes or P. granulosum. 
The following day, selected cell culture dishes were sacrificed to perform viability counts 
of the RWPE-1 cells. These counts were then used to calculate the number of bacteria 
needed to infect the prostate cells at a multiplicity of infection (MOI) 15:1, i.e. 15 




et al. (2010). The bacterial broths were incubated until they reached an optical density 
at 600 nm (OD600) of 0.3. 
The number of bacterial cells needed was determined by multiplying the total number 
of RWPE-1 cells in a cell culture dish by 15. Following, the volume of the bacterial 
suspension needed in μl per cell culture dish was calculated by dividing 1000 by the 
bacterial counts at OD600, and then multiplying the result by the number of bacterial 
cells needed. The resulting volume was then taken from the broth culture, centrifuged 
at 10,000 rpm for 5 min and the BHI medium was removed. The bacteria were washed 
in PBS, centrifuged again at 10,000 rpm for 5 min, and the PBS was removed before 
resuspension of the bacteria in complete KSFM, prior to infecting the cells. The same 
amount of sterile complete KSFM was used for non-infected “mock” control RWPE-1 
cells. Non-infected controls were used every time an experiment was set up. 
 Acute infections 
Short-term or acute infection models were set up as described above (Section 2.3.1) and 
were defined as 24 to 72 hours in duration. In short term infections the cells were left 
undisturbed with no media changes, and at each time point (0h, 24h, 48h and 72h) 
epithelial cell counts and viability (Section 2.1.1), bacterial counts (Section 2.2.2), and 
RNA extraction (Section 2.4.2.1) were performed. In addition, a lactate dehydrogenase 
(LDH) assay (as described in Section 2.3.5) was used at each time point to determine the 
cytotoxic effect different strains have on the RWPE-1 cells. Intracellular bacteria were 
also counted at each time point (as outlined in Section 2.3.6). The conditioned medium 
from all acute experiments was stored at -80°C (Section 2.3.4). 
 Chronic infections 
Long-term or chronic infection models were defined as 15 or 30 days in duration. The 
long-term infections were set up as described above (Section 2.3.1), and were split to 
100,000 cells/ml every 5th day. Their medium was replaced every 3rd day post-split. 
Viability counts (Section 2.1.1) of the RWPE-1 cells were performed at every passage. At 
day 15 and day 30, conditioned medium was processed (Section 2.3.4) and, along with 
extracted RNA (Section 2.4.2.1), frozen at -80°C. DNA was also extracted at day 30 and 
stored at -20°C (outlined in Section 2.4.2.2). Finally, a soft agar assay to investigate 




migration (see Section 2.3.9) were set up, and immunostaining slides were also prepared 
(see Section 2.3.8). 
 Conditioned medium storage 
The conditioned medium from the infection models was preserved for future 
downstream experiments. The medium was removed from the cells and three 1 ml 
aliquots were prepared. The aliquots were then centrifuged for 5 min at 10,000 rpm to 
pellet cells and bacteria. The supernatant was moved to a fresh tube and frozen at -80°C 
until further use. 
 Lactate dehydrogenase assay 
The Pierce LDH Cytotoxicity assay (ThermoScientific, UK) was used to determine the 
cytotoxic effect of different P. acnes and P. granulosum strains on RWPE-1 cells. The 
colorimetric assay uses coupled enzymatic reactions to measure the amount of lactate 
dehydrogenase (LDH) released by damaged cells. The first reaction, the conversion of 
lactate to pyruvate, is catalysed by LDH via the reduction of NAD+ to NADH. The NADH 
is then used in a second reaction, resulting in formazan formation, which produces 
colour that can be measured. 
𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿𝐿 + 𝑁𝑁𝑁𝑁𝑁𝑁+
𝑳𝑳𝑳𝑳𝑳𝑳
�⎯�  𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝐿𝐿𝐿𝐿𝐿𝐿 + 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 + 𝐿𝐿𝐿𝐿𝐿𝐿𝑃𝑃𝐿𝐿𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑃𝑃𝑡𝑡 𝑠𝑠𝐿𝐿𝑡𝑡𝐿𝐿
𝑳𝑳𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫
�⎯⎯⎯⎯⎯⎯⎯�𝑁𝑁𝑁𝑁𝑁𝑁+ + 𝑓𝑓𝑡𝑡𝑃𝑃𝑡𝑡𝐿𝐿𝑡𝑡𝐿𝐿𝑓𝑓 
The assay was performed following the manufacturer’s instructions. Briefly, 50 μl of 
reaction mixture was added to 50 μl of supernatant from different acute infection 
models. The samples were then incubated at room temperature for 30 min, and 50 μl of 
stop solution was added. The optical density was measured at 490 nm and 680 nm. Non-
infected samples were used as spontaneous LDH release controls, and lysed cells were 
used as maximum LDH release controls. Percentage cytotoxicity was calculated using 
the formulas below: 
LDH activity = LDH at 490nm − LDH at 680nm 
% cytotoxicity =
infected cells LDH activity− spontaneous LDH activity





 Intracellular bacterial counts 
The RWPE-1 cells were seeded and infected at an MOI 15:1 as described in Section 2.3.1. 
At 24h, 48h and 72h intracellular bacterial counts were performed using a modification 
of the method described by Fischer et al. (2013), based on the monocytic cell line THP-
1. The medium was removed from the cells, and they were washed twice with PBS. Fresh 
complete medium, supplemented with 0.4 mg/ml gentamycin (Gibco, Life Technologies, 
UK), 500 units/ml penicillin and 0.5 mg/ml streptomycin (Gibco, Life Technologies, UK), 
was added and the cells were incubated for 3 hours; following, the media was removed, 
and the cells were washed twice with PBS to remove any remaining antibiotics. Finally, 
a 20-minute treatment with 0.5% (w/v) saponin (Sigma-Aldrich, UK) solution was used 
to lyse the eukaryotic cells. Bacterial counts were performed as described in Section 
2.2.2. Non-infected cells were used as controls for contamination. Additionally, cells 
treated with antibiotics but not lysed were used to determine whether all extracellular 
bacteria were eradicated following antibiotic treatment. If any growth was observed in 
the antibiotic controls, this number was subtracted of the intracellular counts of the 
corresponding strain. 
 Soft Agar assay 
Soft agar assays were used to investigate anchorage independent growth and cellular 
transformation of the RWPE-1 cells following long-term infections. The two prostate 
cancer cell lines PC-3 and 22Rv1 were chosen as positive controls, and the non-infected 
RWPE-1 cell line as a negative control. 
The soft agar assay consisted of two layers of agar. The bottom layer was prepared by 
melting 3% (w/v) UltraPure agarose (Invitrogen, UK) and adding it to complete medium 
(RPMI-1640 or KSFM, as appropriate for the cell line used) to a final concentration of 
0.5% (w/v) agarose. The mixture was then aliquoted in 6-well plates, with 1.5 ml added 
per well, and left at room temperature to solidify. For the top layer, a cell suspension 
was prepared as described in Section 2.1, and the cells were counted as outlined in 
Section 2.1.1. A diluted suspension was then prepared at 7,500 cells/ml and molten 3% 
(w/v) agarose was added to a final concentration of 0.3% (w/v) agarose and a total of 
10,000 cells/well. Erythromycin (Sigma-Aldrich, UK), at a final concentration 20 μg/ml 
was added to the cell/agarose mixture, to ensure no bacterial colonies were formed in 




solidified layer of 0.5 % (w/v) agarose. The assays were briefly placed at 4°C to solidify 
and were then incubated at 37°C in a humid 5% CO2 atmosphere for 14 days. 
Appropriate medium (100 μl) was added to each well every 3 days to prevent desiccation 
of the agar. The assay was stained by adding 100 μl of 10 mg/ml nitrotetrazolium blue 
chloride (Sigma-Aldrich, UK) per well and incubated overnight. Images were then taken 
at no magnification (Canon EF 50 mm f/1.2 USM objective, ChemiDoc-It2 Imager, UVP, 
USA) and at x2 magnification using a PrimoVert inverted microscope (Primo Plan-
ACHROMAT 4x/0.10 objective and AxioCam 105 colour with 0.5x magnification; Carl 
Zeiss Microscopy GmbH, Germany). 
 Immunofluorescence methods 
2.3.8.1. Specimen preparation and immunostaining 
The PathScan® Duplex IF kit (Cell Signalling, USA) was used for immunofluorescence 
investigation of whether the cells were undergoing epithelial-mesenchymal transition 
(EMT) after a chronic exposure to different P. acnes strains and P. granulosum. The kit 
contained PathScan® EMT duplex IF Kit Primary Antibody Cocktail, targeting E-cadherin 
and vimentin, and PathScan® Duplex IF Kit Detection Cocktail I secondary antibody mix 
targeting the E-cadherin and vimentin primary antibodies, labelled with fluorescent dyes 
AlexaFluor® 488 and AlexaFluor® 555, respectively. 
At day 15 or day 30, the cells were harvested as described in Section 2.1 and a 
suspension was prepared at 100,000 cells/ml, 400 μl of which were added to a 35-mm 
Petri-dish (μ-Dish 35 mm, high, Ibidi, Germany). The cells were left to attach, and 1.6 ml 
of medium were added to the dishes. Alternatively, 700 μl of cell suspension were added 
if 4 well μ-slides (μ-Slide 4 Well, Ibidi, Germany) were used. The dishes were then 
incubated as described above until the cells reached confluence. 
Once the cells had reached confluence, the medium was aspirated, and the cells were 
fixed for 15 min with 4% (v/v) formaldehyde diluted in warm PBS. The fixative was then 
aspirated, and the cells were washed 3 times with PBS. The specimen was blocked with 
blocking buffer (20% (v/v) FBS (Gibco, Life Technologies, UK), 5% (w/v) bovine serum 
albumin (BSA) (Sigma-Aldrich, UK), 0.05% (v/v) Triton X (Sigma-Aldrich, UK), 0.01% (v/v) 
Tween-20 (Sigma-Aldrich, UK) in PBS) for 60 min. The blocking buffer was removed from 




to the sample and incubated at 4°C overnight. Post incubation, the cells were rinsed 
three times with PBS for 5 min, and PathScan Duplex IF Kit Detection Cocktail, diluted 
1:100 in blocking buffer, was added and incubated for 90 minutes at room temperature 
in the dark. After another cycle of 3 washes in PBS for 5 min, the slides were 
counterstained with a drop of ProLong® Diamond Antifade Mountant with 4',6-
diamidino-2-phenylindole, dihydrochloride (DAPI) (Life Technologies, UK), and 
incubated overnight at room temperature in the dark. The slides were then ready for 
imaging, and stored at 4°C in the dark until used. All experiments were performed in 
triplicate. 
2.3.8.2. Acquisition and analysis 
For each slide, 20 images were captured for each fluorescent dye and DAPI, using Axio 
Imager.A2 (Carl Zeiss Microscopy GmbH, Germany) with a Zeiss EC Plan-NEOFLUAR 
40x/0.75 objective and AxioCam MRm with 1.0x magnification. The filters used for 
AlexaFluor® 488 and AlexaFluor® 555 were EGFP (enhanced green fluorescent protein; 
Filter 38; excitation 450-490 nm; emission 500-550 nm, Carl Zeiss Microscopy GmbH, 
Germany) and Rhodamine (Filter 20; excitation 540-552 nm; emission 575-640 nm, Carl 
Zeiss Microscopy GmbH, Germany), respectively. The exposure settings for each colour 
were optimised, so there were no overexposed sections and all signals were within the 
colour histogram, and were constant between slides and treatments. 
The images were analysed using imageJ (Schneider et al., 2012). The DAPI staining was 
used to assess the number of nuclei in each slide. The orange and green channels were 
analysed separately following the same procedure. First, a threshold was selected to 
include all strong signal but remove any background fluorescence. The fluorescence was 
then quantified by measuring the integrated density (IntDen) on every image. Following, 
the IntDen was normalised by dividing by the number of nuclei in each image, resulting 
in the average signal per cell (NormIntDen). The NormIntDen was then averaged across 
all 20 images per biological replicate. The result for all three biological replicates was 
used for statistical analysis. 
 Scratch assay 
At the end of a long-term infection, the cells were harvested as described in Section 
2.1.1, and a 100,000 cells/ml suspension was prepared. The suspension was aliquoted 




100% confluence. The confluent monolayer was then scratched using a 200 μl pipette 
tip and a uniform wound was created. The medium was replaced in order to remove any 
debris, and the cells were incubated at 37°C in 5% CO2 atmosphere. Images were taken 
every 24 hours, until the wound had healed, at 2x magnification using a PrimoVert 
inverted microscope (Carl Zeiss Microscopy GmbH, Germany) with a Prime Plan-
ACHROMAT 4x/0,10 objective and AxioCam 105 colour with 0.5x magnification. The 
width of the wound at each time point was measured using ZEN 2.3 (Carl Zeiss 
Microscopy GmbH, Germany). An average for each biological replicate was calculated 
for every timepoint and the percentage closure was calculated by subtracting the 
distance measured at each time point from the initial T0 distance, and the number was 
then divided by the T0 measurement. 
% closure =  
measurement at T0 − measuremeant at time point
measurement at T0
 
  MTT assay 
The HDMEC cell line was seeded at 5x104 cells/ml in a 96 well plate (Thermo Scientific, 
UK). The cells were left for 24h to attach. The medium was then removed, and the cells 
were treated with a serial dilution of conditioned medium from chronic infection 
models. Following, the cells were incubated for 48h at 37°C. A stock solution of 12 mM 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, UK) 
was added to each well, to a final concentration of 1.2 mM. The cells were then 
incubated for a further 3 hours. Metabolically active cells reduce the tetrazolium MTT 
salt to formazan crystals which can then be solubilised, resulting in a colour change. 
After the incubation, 100 μl of DMSO (Sigma-Aldrich, UK) solubilising solution was added 
and the plate was incubated at room temperature with mild agitation for 20 min. The 
colour change was measured at 570 nm using a microplate spectrophotometer (Epoch, 
BioTek Instruments, US). 
𝑀𝑀𝑀𝑀𝑀𝑀 + 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁
𝑫𝑫𝑫𝑫𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝒓𝑫𝑫𝑫𝑫𝒓𝒓 𝑫𝑫𝒓𝒓 𝒎𝒎𝑫𝑫𝒓𝒓𝑫𝑫𝒓𝒓𝑫𝑫𝑫𝑫𝒓𝒓𝒓𝒓𝑫𝑫𝑫𝑫𝑫𝑫




2.4. Molecular methods 
 Nucleic acid quantification 
2.4.1.1. Nanodrop 
Extracted short-term infection model RNA was quantified using a Nanodrop 1000 
(Thermo Scientific, UK). Each sample was assessed in triplicate by adding 2 μl to the 
instrument. The elution buffer for each sample was used to calibrate the instrument 
prior to use. 
2.4.1.2. Qubit assays 
For chronic infection analysis, Qubit® RNA BR Assay kit (Thermo Scientific, UK) was used. 
Additionally, polymerase chain reaction (PCR) products for multilocus sequence typing 
(MLST) analysis were quantified using the Qubit® DNA HS assay kit. Briefly, 200 μl of 
working solution was prepared per reaction by diluting the Qubit® RNA/DNA reagent 
1:200 in Qubit® RNA/DNA buffer. The samples were briefly vortexed and incubated for 
2 mins. Two standards were used to calibrate the instrument by adding 10 μl of each 
standard to 190 μl of working solution (0 ng/μl low standard for both RNA and DNA kits; 
100 ng/μl high standard for Qubit® RNA BR Assay; 10 ng/μl high standard for Qubit® 
DNA HS assay). For sample analysis, 2 μl of RNA/PCR product was added to 198 μl of 
working solution. The Qubit 3.0 fluorometer was then used to measure and calculate 
the nucleic acid concentration in the initial sample. 
 Eukaryotic analysis 
2.4.2.1. RNA extraction 
RNA was extracted using the RNeasy Plus Mini-Kit (QIAGEN, Germany), according to the 
manufacturer’s instructions as follows: the cells were harvested as described in Section 
2.1.1, pelleted and resuspended in 350 μl of buffer RLT Plus with 1% (v/v) β-
mercaptoethanol (β-ME) (Sigma-Aldrich, UK). The cells were then homogenised by pulse 
vortexing for 30 seconds and were transferred to a genomic DNA eliminator tube and 
centrifuged for 30 s at 8000 x g. An equal volume of 70% (v/v) ethanol was added to the 
flowthrough and mixed. The sample was then transferred to an RNeasy column and 
centrifuged for 15s at 8000 x g. The membrane was then washed with 700 μl of Buffer 
RW1 and centrifuged for 15s at 8000 x g. The extraction was completed with two 




Finally, the RNA was eluted in 40 μl of RNase-free water by centrifuging for 1 min at 
8000 x g. The extracted RNA was stored at -80°C until further use. 
2.4.2.2. DNA extraction 
Cells were harvested as described above and the pellet was resuspended to a final 
volume of 200 μl in PBS. QIAGEN’s QIAamp DNA Mini Kit (QIAGEN, Germany) was used 
for DNA extraction following the manufacturer’s protocol. Briefly, 20 μl proteinase K and 
200 μl Buffer AL were added to the sample. The mixture was pulse-vortexed for 15 s and 
incubated for 10 min at 56°C before the addition of 200 μl of 100% ethanol with brief 
vortexing. The mixture was then applied to a QIAamp Mini Spin column and centrifuged 
at 6000 x g for 1 min. The filtrate was discarded, and the column was washed twice: first 
with 500 μl of buffer AW1 by centrifuging at 6000 x g for 1 min, and then with 500 μl of 
buffer AW2 and 3 min centrifugation at 20,000 x g. A drying step was used to remove 
any remaining ethanol from the column by an additional 1 min centrifugation at 20,000 
x g. Finally, 100 μl of buffer AE (10 mM Tris-Cl; 0.5 mM EDTA; pH 9.0) were added to the 
column, and after 1 min incubation at room temperature, the DNA was collected by 
centrifuging at 6000 x g for 1 min. The extracted DNA was stored at -20°C until further 
use. 
2.4.2.3. Complementary DNA synthesis 
The Transcriptor First Strand complementary DNA (cDNA) Synthesis Kit (Roche, 
Switzerland) was used to produce 1 μg of cDNA from RNA, with a final concentration of 
50 μg/ml. This would allow downstream analysis of gene expression using methods such 
as quantitative PCR (qPCR). The average of the three Nanodrop readings for each 
sample, or Qubit result, was used to calculate the amount of RNA in μl needed by 
dividing 1000 by the average RNA yield in ng/μl. The resulting volume of RNA was then 
topped up to 11 μl with UltraPure™ RNase free water (Invitrogen, Life Technologies, UK). 
cDNA synthesis was performed according to the manufacturer’s protocol for each 20 μl 
reaction as follows: 11 μl of RNA and water, 2 μl of Random Hexamer Primers (600 
pmol/μl), 4 μl of Transcriptor Reverse Transcriptase reaction buffer (5x conc.), 2 μl of 
Protector RNase Inhibitor (40 U/μl), deoxynucleotide (dNTP) mix (10 mM each), and 0.5 
μl of Transcriptor Reverse Transcriptase (20 U/μl) were added (final concentrations of 
60 μM, 1x 8 mM MgCl2, 20 U, 1 mM each and 10 U, respectively). The reactions were 




min at 50°C, and a final inactivation step at 85°C for 5 min. The reaction products were 
then stored at -20°C. Reactions with no reverse transcriptase (no-RT) reactions were 
used with every synthesis. 
2.4.2.4. Quantitative polymerase chain reaction 
2.4.2.4.1. Quantitative PCR protocol 
Quantitative PCR was used to assess the differences in the expression in a range of 
genes. Probes master and primer-probe mixes (Roche, Switzerland) were used to set up 
qPCR reactions with 12.5 ng of cDNA used for most reactions, except for IL6, TNF and 
CDH2 where 62.55 ng was used per reaction, as the second group of genes could not be 
detected at a lower concentration. Each reaction was prepared to a final volume of 10 
μl using 5 μl LightCycler® 480 Probes Master (2x concentrate) (Roche, Switzerland), 1.5 
μl of the primer-probe mix and 2.5 μl of cDNA. The reaction was run in a LightCycler® 
480 (Roche, Switzerland) following the manufacturer’s instructions. This consisted of a 
pre-incubation cycle of 10 min at 95°C, followed by 45 amplification cycles consisting of 
three steps, 95°C for 10 s, 60°C for 30 s, and 72°C for 1s; the program concluded with a 
cooling step of 30 s at 40°C. Cycle threshold (Ct values, also known as Cp values) were 
recorded and used to calculate fold-change in expression. If a Cp value was not detected, 
the value of 40 was used to calculate the ratio change. Each qPCR plate included 
negative (water) controls (to confirm there is no contaminating DNA in the reagents) 
and no-RT controls (to confirm that the cDNA reactions were successful and that there 
was no contaminating genomic DNA in the cDNA reactions). 
2.4.2.4.2. qPCR assay efficiencies 
To calculate the efficiency of each primer-TaqMan® probe mix (Roche, Switzerland), a 
serial dilution was prepared following the protocol described above (Section 2.4.2.4.1), 
and a standard curve was created for each gene. The efficiency was then calculated using 
𝐸𝐸% = (10
−1
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠� )  × 100. The full list of genes can be found in Table 2.3. 
2.4.2.4.3. Housekeeping gene selection 
For the selection of the optimal housekeeping gene(s), cDNA prepared from short term 
infection models of infected and non-infected cells was used at different timepoints: T0, 






Table 2.3. List of Real-Time ready assays used 
Gene Assay ID Full name Function 
ACTB 143636 Beta-actin Housekeeping 
CDH1 103920 E-cadherin EMT 
CDH2 137066 N-cadherin EMT 
GAPDH 141139 Glyceraldehyde 3-phosphate dehydrogenase Housekeeping 
HPRT1 145173 Hypoxanthine-guanine phosphoribosyltransferase Housekeeping 
IL1B 100950 Interleukin-1 beta Inflammatory 
IL6 144013 Interleukin-6 Inflammatory 
IL8 103136 Interleukin-8 Inflammatory 
SNAI1 144082 Snail family zing finger 1 (Snail) EMT 
SNAI2 147564 Snail family zing finger 2 (Slug) EMT 
TBP 101145 TATA-binding protein Housekeeping 
TGFB1 145593 Transforming growth factor beta Inflammatory 
TNF 103295 Tumour necrosis factor Inflammatory 
TWIST1 110770 Twist-related protein 1 EMT 






 cells, and for housekeeping gene selection three technical replicates for each biological 
replicate were used. The genes investigated were ACTB, GAPDH, HPRT, and TBP, which 
are housekeeping genes previously used in the literature with the RWPE-1 cell line. 
Normfinder (https://moma.dk/normfinder-software) (MOMA, Aarhus University 
Hospital, Denmark), a statistical package specialising in the selection of the most stable 
housekeeping gene or a combination of housekeeping genes, based on a mathematical 
model of estimation of expression of variation, was then used (Andersen et al., 2004). 
The expression data for the housekeeping genes tested was separated into two groups 
(infected and non-infected) and the software then ranked the genes by a stability value, 
a combination of intragroup and intergroup variation, to provide a realistic assessment 
of the potential systematic error introduced by the different housekeeping genes in the 
dataset. 
2.4.2.4.4. Ratio difference calculation 
The ratio of differences in expression was calculated based on Cp values for the 
housekeeping gene and the gene of interest. The gene efficiencies (E) were used to more 
accurately represent the fold-change dysregulation. The formulas below were used to 
calculate ΔCp for the target and housekeeping (reference) genes, and these two values 
were used to calculate the ratio change for each target gene. 
∆𝐶𝐶𝑠𝑠𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 𝐶𝐶𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑐𝑐 − 𝐶𝐶𝑠𝑠𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡  
∆𝐶𝐶𝑠𝑠𝑡𝑡𝑡𝑡𝑟𝑟𝑡𝑡𝑡𝑡𝑡𝑡𝑐𝑐𝑐𝑐𝑡𝑡 = 𝐶𝐶𝑠𝑠𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑡𝑡𝑐𝑐𝑐𝑐 − 𝐶𝐶𝑠𝑠𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑐𝑐𝑡𝑡  






2.4.2.4.5. Human Prostate cancer qPCR array 
2.4.2.4.5.1. cDNA synthesis 
The RT2 First Strand Kit (QIAGEN, Germany) was used to prepare cDNA for use in the 
Prostate cancer qPCR array. A total of 0.5 μg of RNA was added to 2 μl of Buffer GE, and 
the reaction volume was made up to 10 μl with PCR-grade water. After mixing, the 
sample was incubated at 42°C for 5 min in a thermocycler (Techne Prime, UK), followed 
by immediate incubation on ice for 1 min. Following, the remaining components of the 
reverse-transcription reaction were added: 4 μl of 5x reverse transcription buffer 3 




transcription enzyme mix 3 (RE3) and 3 μl of RNase-free water to a total reaction volume 
of 20 μl. The samples were mixed and incubated at 42°C for 15 min and then for a further 
5 min at 95°C (Techne Prime, UK). Once the incubation steps were competed, 91 μl of 
RNase-free water were added to each reaction and the tubes were then stored at -20°C 
until further use. 
2.4.2.4.5.2. RT2 Profiler PCR array 
The RT2 Profiler Human prostate cancer PCR array (QIAGEN, Germany) was used to 
assess the expression levels of 84 prostate cancer-related genes and to compare 
differences between cells infected for 15 days with different phylogenetic types of P. 
acnes and non-infected cells. 
For each 96-well plate array 1350 μl 2x RT2 SYBR Green Mastermix, 1248 μl RNase-free 
water and 102 µl cDNA synthesis reaction (prepared as described in Section 2.4.2.4.5.1) 
were mixed together and 25 μl of this mix were added to each well. The plates were 
then sealed and centrifuged at 1000 x g for 1 min at room temperature. Analysis was 
performed using LightCycler 480 (Roche, Switzerland) and a programme which included 
an initial activation cycle of 10 min at 95°C, followed by 45 cycles of 15 s at 95°C and 1 
min at 60°C. The programme was concluded by performing a melt curve. Cp values were 
recorded and imported into the SABiosciences web based PCR Array data analysis 
software, version 3.5 (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php; 
QIAGEN, Germany). 
 Bacterial molecular methods 
2.4.3.1. DNA extraction 
A loop of bacteria was resuspended in 1 ml of PBS and then centrifuged for 5 min at 
10,000 rpm. The supernatant was removed, the pellet was resuspended in 400 μl of 
UltraPure® nuclease-free water (Invitrogen, Life Technologies, UK) and the suspension 
was then boiled at 100°C for 10 min. Once cooled, the tubes were centrifuged for 5 min 
at 10,000 rpm. The supernatant containing the crude bacterial DNA preparation was 
moved to a fresh tube and stored at -20°C.Multiplex typing of P. acnes 
A multiplex touchdown P. acnes typing scheme developed by Barnard et al. (2015) was 
used for the routine identification of the phylogenetic group of P. acnes strains used in 




(Invitrogen, Life Technologies, UK), 1x PCR buffer (Invitrogen, Life Technologies, UK), 0.2 
mM dNTPs (Invitrogen, Life Technologies, UK), 0.8 U Platinum Taq polymerase 
(Invitrogen, Life Technologies, UK), and varying concentrations of primers as described 
in Table 2.4. To each reaction, 1 μl of crude bacterial DNA was added. 
The reactions were then amplified with a four-stage programme in a thermocycler 
(Techne Prime, UK): an initial denaturation at 94°C for 1 min, followed by 30 cycles of 
94°C for 1 min, and subsequent 14 cycles of 94°C for 30s, 66°C (with decrement of 0.3°C 
per cycle) for 30 s, and 72°C for 1 min. This was followed by 11 cycles of 94°C for 30 s, 
62°C for 30 s and 72°C for 1 min. The programme concluded with a final extension step 
of 72°C for 10 min. The reaction products were analysed on a 1.5% (w/v) UltraPure® 
agarose (Invitrogen, Life Technologies, UK) stained with 1x GelRed (Cambridge 
Bioscience, UK). 
Bacterial strains representing each major phylogroup were used as positive controls. 
NCTC737 was used as a control for type IA1, Pacn17 for type IA2, W1392 for type IB, PV66 
for type IC, NCTC10390 for type II and Asn14 for type III, and PCR-grade water was used 
as a negative control. 
2.4.3.1. Multilocus sequence typing 
The multilocus sequence typing (MLST) scheme described previously by McDowell et al. 
(2013) was used for the phylogenetic analysis of a number of P. acnes prostate-derived 
isolates. 
2.4.3.1.1. MLST PCR 
Primers and PCR conditions for aroE, atpD, camp2, gmk, guaA, lepA, sodA, and tly were 
described previously (McDowell et al., 2011; McDowell et al., 2013). To summarise, each 
reaction containing 0.2 mM of each primer (primer list can be found in Table 2.5), 1x 
PCR buffer, 2 mM MgCl2, 0.2 mM dNTPs, 1.25 U Taq polymerase, was made up to a final 
volume of 48 μl PCR-grade water and 2 μl of bacterial lysate DNA was added. The PCR 
conditions included an initial denaturation step of 94°C for 1 min, followed by 30 cycles 
of 94°C for 1 min, 56°C for 1 min and 72°C for 2 min, with a concluding extension step of 
10 min at 72°C (Techne Prime, UK) (McDowell et al., 2013). The size of the PCR products 
was confirmed via 1.5% (w/v) UltraPure® agarose (Invitrogen, Life Technologies, UK) gel 





Table 2.4. Multiplex PCR primer sequences 
Gene Specificity Primer Sequence (5’-3’) Final concentration Size (bp) 
16S rRNA All P. acnes strains PArA-1 AAGCGTGAGTGACGGTAATGGGTA 0.2 mM 667 PArA-2 CCACCATAACGTGCTGGCAACAGT 
ATPase Types IA1, IA2, IC 
PAHp-1 GCGTTGACCAAGTCCGCCGA 0.25 mM 494 PAHp-2 GCAAATTCGCACCGCGGAGC 
sodA Types IA2, IB 
PAHp-3 CGGAACCATCAACAAACTCGAA 0.6 mM 145 PAHp-4 GAAGAACTCGTCAATCGCAGCA 
Toxin, Fic family Type IC PAHp-5 AGGGCGAGGTCCTCTTCTACCAGCG 0.1 mM 305 PAHp-6 ACCCTCCAACTGCAACTCTCCGCCT 
atpD Type II PAHp-7 TCCATCTGGCCGAATACCAGG 0.15 mM 351 PAHp-8 TCTTAACGCCGATCCCTCCAT 
recA Type III PAHp-9 GCGCCCTCAAGTTCTACTCA 0.25 mM 225 PAHp-10 CGGATTTGGTGATAATGCCA 
 





Table 2.5. MLST PCR primer sequences 
Gene Function Primer Sequence (5’-3’) Size (bp) Reference 
aroE Shikimate 5-dehydrogenase aroE-F ACCGATTAAGAGTGACTACC 1102 McDowell et al. (2013) aroE-R ACTCCTCGGAAATCTCTACA 
atpD ATP synthase beta chain atpD-F AATTACCCCCGAGACGAA 1261 McDowell et al. (2011) atpD-R CGTGTTCTGGGACAGGAA 
camp2 Co-haemolytic factor 
camp2-F GTCGTAGCCATACACCACACG 
1015 Valanne et al. (2005) 
camp2-R GCACCGAGTGTTGATGTCAATTAGC 
gmk Guanylate kinase 
gmk-F TAGCCATCCGGAGATCGT 
444 
McDowell et al. (2011) 
gmk-R GCGCAACTGCGTGATCTA 








sodA Superoxide dismutase sodA-F TGGAACTGCACCATGACA 488 sodA-R GCTAACGACGTTCCACCA 






2.4.3.1.2. PCR product purification 
PCR products were purified using a QIAquick PCR Purification Kit (QIAGEN, Germany) 
following the manufacturer’s protocol. Briefly, 5 volumes of buffer PB were added to 1 
volume of PCR product. After mixing, the sample was applied to a QIAquick column and 
centrifuged for 45 s at 13,000 rpm. The column was then washed with 750 μl of buffer 
PE (10 mM Tris-HCl pH 7.5; 80% ethanol) and centrifuged as before. Finally, the sample 
was eluted in 50 μl of buffer EB (10 mM Tris-Cl, pH 8.5) and stored at -20°C until further 
use. 
2.4.3.1.3. Sanger sequencing 
Purified PCR products were quantified as described in Section 2.4.1.2 using the Qubit® 
DNA HS assay kit (Invitrogen, Life Technologies, UK), and were then diluted to 5 ng/μl 
for products of less than 1000 bp, and to 10 ng/ml for products over 1000 bp. The Sanger 
sequencing reactions using the BigDye™ Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems, Thermo Fisher Scientific, USA) and capillary electrophoresis on an Applied 
Biosystems 3730xl 96-capillary DNA analyser were carried out by Eurofins Genomics 
(Ebersberg, Germany), using the sequencing primers described in Table 2.6. 
2.4.3.1.4. Assignment of alleles and sequence types 
After sequencing, the FASTA files for the forward and reverse read were combined to 
from the complete sequencing product. This complete sequence was then compared to 
the P. acnes MLST database of known alleles (http://pubmlst.org/pacnes/) hosted at the 
University of Oxford, UK (Jolley et al., 2004). The sequence type and clonal complex for 
each strain were then determined using their 8-gene allelic profile. 
2.5. Protein methods 
 Protein extraction 
Mammalian Protein Extraction Reagent (M-PER®) (Pierce Biotechnology, 
ThermoScientific, USA) was used to extract protein at day 30 of chronic infection 
models. The manufacturer’s protocol was used, as follows: the cells were scraped into 
PBS, and centrifuged at 2,500 x g for 10 min. The supernatant was removed and 250 μl 
of M-PER were added to the sample. The mixture was gently shaken for 10 min, and cell 
debris were removed by centrifugation at 14,000 x g for 15 min. The supernatant, 





Table 2.6. MLST sequencing primers 
Gene Function Primer Sequence (5’-3’) Size (bp) Reference 
aroE Shikimate 5-dehydrogenase As PCR primers (Table 2.5) 424 McDowell et al. (2013) 
atpD ATP synthase beta chain atpD-F TAAGGGTCACGTCTGGAA 453 McDowell et al. (2011) atpD-R ACATCGCGGAAGTACTCA 
camp2 Co-haemolytic factor As PCR primers (Table 2.5) 804 Valanne et al. (2005) 
gmk Guanylate kinase 
gmk-F AGATCGTCGTTTCCAGGT 
400 
McDowell et al. 
(2011) 
gmk-R ACAACGGCGTCAAATTC 
guaA GMP synthase guaA-F GCGTTTGAAGACGTTGAG 493 guaA-R GCTGGTCAGCATTGAGAC 
lepA GTP-binding protein lepA-F GTCAAGGATGTCCGTCAA 452 
lepA-R GCAGGACTGAGAATGGTG 
sodA Superoxide dismutase sodA-F ACAAGCACCACAACACCT 450 sodA-R TAACGTAGTCGGCCTTGA 






 Enzyme-linked immunosorbent assay (ELISA) 
ELISA 3,3',5,5'-Tetramethylbenzidine (TMB) development kits (PeproTech, US) were 
used to quantify the amount of IL-1β, IL-6, IL-8 and TNF-α in conditioned medium from 
acute and chronic infections. All steps were performed at room temperature. Nunc 
MaxiSorp™ 96-well plates (ThermoFisher Scientific, UK) were coated with 100 μl capture 
antibody and incubated overnight. The plates were then washed four times with 300 μl 
PBS-T (0.05% (v/v) Tween-20 (Sigma-Aldrich, UK) in PBS) per well, 300 μl blocking buffer 
(1% (w/v) BSA (Sigma-Aldrich, UK) in PBS) were added to each well and the plate was 
incubated for 1 hour. The plates were washed again as described above, 100 μl of 
standards and samples were added per well and the plates were incubated for 2 hours. 
After another wash, 100 μl of detection antibody were added per well and incubated for 
further 2 hours. The plates were washed again, 100 μl of streptavidin-horseradish 
peroxidase conjugate (S-HRP) were added to each well and were incubated for 30 min. 
Finally, after a wash, 100 μl of TMB (Sigma-Aldrich, UK) were added to each well and 
after 20 min incubation the reaction was stopped with 100 μl 1M HCl. The resulting 
colour change was measured using a spectrophotometer (Epoch, BioTek, US) at 450 nm 
with a correction wavelength at 620 nm. 
2.6. Statistical analysis 
All experiments were performed in triplicate and the data is represented as mean +/- 
standard error of the mean (SEM). Significance was determined using a two-tailed 
Student’s t-test, unless otherwise stated, with p < 0.05 considered significant. Data 
analysis was performed using Microsoft Office Excel (Microsoft Office 365, version 1707, 








Optimization of in vitro model 
of infection 







In vitro infection models allow the study of direct cellular response to infection. While 
the analysis is limited to a single eukaryotic cell type, they do provide the opportunity 
for basic investigation which can then be used in more complex models and can also 
identify potential biomarkers which can be further investigated in patients. In this 
chapter, preliminary experiments focused on the optimisation of the in vitro infection 
models used in this thesis, as well as experiments used for downstream analysis of 
dysregulation following acute and chronic infection. Additionally, a small investigation 
was undertaken into the phylogenetic types of P. acnes isolated from prostatectomy 
samples. 
Multilocus sequence typing (MLST) is a molecular biology technique used for the 
phylogenetic typing of bacterial strains based on small differences in the sequences of 
multiple genes, usually housekeeping genes. Two MLST schemes have been developed 
for the typing of P. acnes. The first “Aarhus” MLST9 scheme, developed by Lomholt and 
Kilian (2010), included 9 housekeeping genes and 2 putative virulence factors. The 
second “Belfast MLST8 method, developed by McDowell et al. (2011), included seven 
genes, and was later updated to include six housekeeping genes and two putative 
virulence factors (McDowell et al., 2011; McDowell et al., 2012a). More recently, a single 
locus sequence typing scheme showing resolution similar to that of the previously 
established MLST schemes was also developed (Scholz et al., 2014). What all three 
schemes have in common is the agreement that P. acnes has six phylogroups: types IA1, 
IA2, IB, IC, II and III, despite each group referring to them using different nomenclature. 
Previous studies have shown different phylotypes tend to be associated with different 
diseases. Type IB has been linked to medical device and soft tissue infections. Type III 
has been associated with spinal disk infections and the skin condition progressive 
macular hypomelanosis (McDowell et al., 2013; Barnard et al., 2016). A study of radical 
prostatectomy isolates of P. acnes showed that prostate isolates differ from those 
normally found on skin, as they were type IB and II, in contrast with type IA1 which is a 
part of the skin microflora (Mak et al., 2013b). 
There are multiple variants of infection models of prostate epithelial cells with P. acnes 




Drott et al. (2010) selected an MOI of 16:1 in short term infections, while Fassi Fehri et 
al. (2011) and Mak et al. (2012) used MOI 50:1 for both acute and chronic infections. 
Finally, an infection model with primary prostate epithelial cells infected with MOI 100:1 
for short-term infections and MOI 30:1 for long-term have also been used (Sayanjali et 
al., 2016). 
P. acnes has demonstrated the ability to remain viable intracellularly in both prostate 
epithelial cells and in macrophages (Mak et al., 2012; Fischer et al., 2013). The methods 
to assess the intracellular presence of P. acnes used in literature vary, with the main 
differences being the antibiotics and the incubation times used. In the context of P. 
acnes and RWPE-1 cells, 2-hour incubation with 300 μg/ml penicillin/streptomycin, 3-
hour incubation with 300 μg/ml gentamycin or 2 hours with 50 μM/ml tetracycline have 
been described (Mak et al., 2012; Fischer et al., 2013; Sayanjali et al., 2016). However, 
none of those studies indicated the use of negative controls, showing whether the 
antibiotics eradicate extracellular bacteria. 
Further methods optimised in this chapter for analysis of cellular response and cellular 
transformation include soft agar assays, quantitative PCR (qPCR) and ELISA. 
Soft agar colony formation assays are widely used to investigate cellular potential for 
anchorage-independent growth – a hallmark of cancer progression and contributing 
factor to metastasis (Borowicz et al., 2014). Previous studies appear to support P. acnes-
driven cellular transformation by employing soft agar assays (Fassi Fehri et al., 2011). 
There are two main approaches to analysing qPCR data. Absolute quantification is based 
on comparing the absolute concentrations of cDNA in each reaction, which are worked 
out by comparing to a standard curve. For relative quantification, a reference gene (also 
called a housekeeping gene) which is constitutively expressed is used to calculate the 
ratio change of a gene of interest. A good housekeeping gene should be stable between 
untreated and treated samples, and should not change with incubation times. Statistical 
packages for comparison of gene stability, such as Normfinder or geNorm, are available 
(Vandesompele et al., 2002; Andersen et al., 2004). 
The colorimetric MTT assay, which investigates the production of formazan from 3-(4,5-




selected as a cost-effective method of analysing cell proliferation, and thus angiogenic 
potential, of conditioned medium from long-term infection model experiments. 
However, the selection of optimal seeding for the HDMEC cells and the selection of 
appropriate controls is needed. 
Sandwich ELISA assays for four inflammatory proteins were selected targeting the 
products of four inflammatory genes of interest, to quantify and corroborate any 
dysregulation seen in qPCR analysis. An illustration of the method can be seen in Figure 
3.1.  
The objectives of this chapter include MLST analysis of prostate P. acnes isolates and 
optimisation of short and long-term infection models, intracellular counts, soft-agar 
assay, qPCR assays, MTT assays and ELISA. 
3.2. Materials and Methods 
 Bacterial culture 
All bacterial strains were routinely cultured on brain heat infusion (BHI) agar, as per 
Section 2.2.1. 
P. acnes strains 00035, ST27, NCTC737 (type IA1), B3 (type IB), NCTC10390 (type II), CFU2 
(type III), P. avidum and P. granulosum were grown to optical density at 600 nm (OD600) 
0.3 and counts were performed (following Section 2.2.2), as broth cultures with a known 
number of bacteria were needed to prepare the infection of eukaryotic cells with the 
appropriate inoculum to achieve the desired MOI. 
Prostate isolates 00035, B2, 00060R (type IA1), B3, 03R3900R (type IB) and CFU2 (type 
III) were cultured for MLST analysis. Further information about the origin of the strains 
can be found in Table 2.2. 
 Multiplex PCR and MLST analysis 
Crude DNA extracts were prepared as outlined in Section 2.4.3.1. The phylogenetic type 
of the prostate isolates was analysed using the multiplex PCR typing scheme (Section 
2.4.3.2). Following, reactions to be sent for sequencing were prepared as described in 








Figure 3.1. Sandwich ELISA method 
In sandwich ELISA the plates are coated with a capture antibody (A). After a blocking step, samples are added and the target protein binds to the 
coating antibody. After a wash a secondary biotinylated antibody is added (C), binding the protein of interest in the well. Horseradish peroxidase 
(HRP)-labelled streptavidin is then added, forming a bond with the biotin in the detection antibody (D). A reaction substrate is added (3,3',5,5'-
tetramethylbenzidine or TMB) which initiates the reaction and leads to the formation of a diamine, resulting in a colour change (E). Finally, the 






2.4.3.1.2) (Qiagen, Germany). The purified PCR products were quantified using Qubit® 
DS HS kit (Section 2.4.1.2), diluted as appropriate based on product size (5 ng/μl if < 1000 
bp; 10 ng/μl if > 1000 bp) and sent for Sanger sequencing as described in section 
2.4.3.1.3 (Eurofins Genomics, Ebersberg, Germany). MLST analysis was performed 
following Section 2.4.3.1.4.  
 Cell culture 
RWPE-1, 22Rv1 and PC-3 cells were cultured as described in Section 2.1.1. 
Prior to the setup of infection models, different seeding densities of the RWPE-1 cells 
were tested to select the optimal density, ensuring the cells remained viable for the 
duration of the co-culture experiments. The cells were seeded at 50,000 cells/ml, 
100,000 cells/ml, 200,000 cells/ml and 300,000 cells/ml and then incubated for several 
days (3, 5, 7 or 14) with no media changes at 37°C in 5% CO2 atmosphere. Viability counts 
were performed at each time point as described in Section 2.1.1. 
Cells were infected as outlined in Section 2.3.1. Both MOI of 15:1 and 50:1 were tested, 
and infection models were maintained for 30 days as described in Section 2.3.3. To 
compare bacterial density between MOIs, bacterial counts were performed at days 10, 
20 and 30. 
 Intracellular bacterial counts 
Intracellular count experiments were set up in 12-well plates as described in Section 
2.3.6 and incubated for 24, 48 and 72 hours to monitor the potential of P. acnes strains 
to become intracellular. At each time point, the medium was removed, the cells were 
washed twice with PBS and then treated with fresh complete medium supplemented 
with 300 μg/ml gentamycin (Gibco, Life Technologies, UK) only, a mixture of 50 units/ml 
penicillin and 50 μg/ml streptomycin (Gibco, Life Technologies, UK), or a combination of 
400 μg/ml gentamycin, 50 units/ml penicillin and 50 μg/ml streptomycin for 3 hours to 
kill any extracellular bacteria. After two washes with PBS, aiming to remove of any 
residual antibiotics, the epithelial cells were lysed saponin (Sigma-Aldrich, UK) to a final 
concentration 0.5% (w/v), and bacterial counts were performed as described in Section 
2.2.2. Bacterial counts were also performed after the 3-hour antibiotic incubation and 




 Soft agar assay 
At day 15 of a long-term infection with the bacterial strain NCTC737, set-up as described 
in Section 2.3.1 and maintained as outlined in Section 2.3.3, cells were used to assess 
the need for antibiotic use in the preparation of soft agar assays. A modification of the 
commonly used methods was necessary as those protocols are targeted at cells cultured 
in medium readily available at 2x strength, such as RPMI-1640 (Borowicz et al., 2014). 
As this is not the case for keratinocyte serum-free medium (KSFM), a higher 
concentration of agarose was used to prevent the dilution of media, as described in 
Section 2.3.7. The bottom layer of the assay was prepared by mixing molten agarose 
(Invitrogen, Life Technologies, UK) with complete KSFM or RPMI-1640 to a final 
concentration 0.5% (w/v). The top layer was prepared by mixing molten agarose with a 
cell suspension at 7,500 cells/ml, to a final concentration 0.3% (w/v) agarose. 
Erythromycin (Sigma-Aldrich, UK) was added to the mixture, to a final concentration of 
20 μg/ml. Wells with no antibiotic added were also prepared as controls. 
The 22Rv1 cell line was used to assess whether antibiotics would influence the 
anchorage independent growth the cells demonstrate. The assay was prepared as 
described above, using RPMI-1640 with both treated and antibiotic-free wells. 
The soft agar assays were incubated for 14 days at 37°C, 5% CO2, and were kept hydrated 
by adding 100 μl of appropriate complete medium (KSFM or RPMI-1640) every 3 days. 
Nitrotetrazolium blue chloride (10 mg/ml, Sigma-Aldrich, UK) was used for staining by 
adding 100 μl to each well; the assays were imaged as described in Section 2.3.7. 
 RealTime Ready assays efficiency calculation 
RNA extracted from the RWPE-1 cell line was used to calculate the efficiency of the 
RealTime ready primer-probe mixes (Roche, Switzerland). Following the protocol 
described in Section 2.4.2.3, cDNA was synthesised to a concentration of 50 ng/ml. A 
serial dilution of cDNA was prepared, and qPCR was performed as outlined in Section 
2.4.2.4.1. To assess the primer-probe efficiency, a standard curve was plotted, and 




 Housekeeping gene selection 
Housekeeping gene selection was performed as outlined in Section 2.4.2.4.3 using cDNA 
from a short-term infection model at time points T0, 24h, 48h and 72h. The genes were 
selected as they are commonly used in literature when studying gene dysregulation in 
prostate cancer (Ohl et al., 2005; Tsaur et al., 2013). 
 Gram staining 
Gram staining to visualised bacteria was performed as described in Section 2.2.3. 
 MTT assay optimisation 
HDMEC cells used for MTT assays were cultured in phenol red-free Medium 200 (Gibco, 
Life Technologies, UK), supplemented with low growth serum supplements (LSGS) 
(Gibco, Life Technologies, UK) as outlined in Section 2.1.1. 
3.2.9.1. Infection models 
Infection models using the RWPE-1 cell line (cultured in KSFM, supplemented with 
epidermal growth factor (EGF) and bovine pituitary extract, as described in Section 
2.1.1), and a range of P. acnes strains were set up as outlined in Section 2.3.1. The 
chronic infections used for the optimisation of MTT assays in this chapter were sustained 
for 30 days. 
The prostate cancer cell line PC-3 was cultured in RPMI-1640, supplemented with 10% 
foetal bovine serum (FBS), as seen in Section 2.1.1. 
3.2.9.2. Conditioned medium processing 
Medium from chronic infections was removed and three 1 ml aliquots were prepared, 
as outlined in Section 2.3.4. For experiments aimed at optimising the seeding density for 
the HDMEC cells, medium from the PC-3 cell line was used. For the remaining MTT assay-
related optimization experiments, pooled conditioned medium from multiple chronic 
infections was used, as large volumes of medium were needed to provide consistency 
between testing conditions. 
3.2.9.3. MTT assays 
The HDMEC cells were detached using 0.25% trypsin-EDTA (Gibco, Life Technologies, 
UK), as described in Section 2.1.1, and were then counted using trypan blue (Sigma 




densities (8 x 104, 5 x 104, 3 x 104, 2 x 104 and 1 x 104 cells/ml) to select the optimal 
seeding density to be used in following experiments. 
Additionally, etoposide (Cayman Chemical Company, USA) concentrations of 2.5, 3.5 
and 5 μM and 0.05% (w/v) saponin (Sigma-Aldrich, UK) were tested as negative controls, 
and cells grown in medium with 20% (v/v) FBS (Gibco, Life Technologies, UK) or in the 
presence of 25 ng/ml, 50 ng/ml or 100 ng/ml epidermal growth factor (EGF, Life 
Technologies, UK) were examined as potential positive proliferation controls. 
Following incubation, the cells were treated with MTT (Sigma-Aldrich, UK) to a final 
concentration 1.2 mM, as described in Section 2.3.10, and incubated for 3 hours. The 
resulting formazan crystals were solubilised with the addition of 100 μl DMSO (Sigma-
Aldrich, UK). After mixing, the absorbance was measured at 570 nm (Epoch, BioTek 
Instruments, USA). 
3.2.9.4. Bacterial culture and MTT assay 
A BHI broth was inoculated with Staphylococcus epidermidis (ATCC® 14990) and 
incubated at 37°C with mild agitation until the culture was turbid. A 1:10 serial dilution 
was performed and 100 μl of the neat sample and each dilution were added to a 96-well 
plate. Each well was then treated with MTT (Sigma-Aldrich, UK) to a final concentration 
of 1.2 mM MTT. The plate was incubated for an hour. Following, the produced formazan 
salt was solubilized with the addition of 100 μl DMSO (Sigma-Aldrich, UK) to each well. 
The plate was mixed briefly, and the absorbance was measured at 570 nm. (Epoch, 
BioTek Instruments, USA), 
3.2.9.5. Statistical analysis 
Statistical analysis was performed using a 2-tailed Student’s t-test, comparing the 
different treatments to untreated controls. 
 ELISA 
Sandwich ELISA assays were performed as outlined in Section 2.5.2 with the capture and 
detection antibodies described in Table 3.1. Additionally, for troubleshooting, available 
components from a Human IL-1 alpha/IL-1F2 ELISA (R&D Systems, US), using the buffers 
recommended by R&D with blocking buffer and reagent diluent being 1% (w/v) BSA in 




antibody and streptavidin-HRP conjugate (S-HRP) dilutions as described in Table 3.2. 
Incubation times recommended did not differ between the two kits. 
3.3. Results 
 Phylogenetic typing of prostate isolates 
The multiplex PCR typing scheme was used to identify the phylogenetic type of all 
available prostate isolates. Figure 3.2.A shows the patterns observed, which correspond 
to type IA1 for strains 00035, 00060R and B2; IB for strains B3 and 03R3900R; type II for 
CFU2. For each strain, eight MLST-PCR reactions were set up and the product size was 
checked as seen in Figure 3.2.B. The PCR products were then purified and sent for Sanger 
sequencing. The results from the sequencing were presented as chromatograms, an 
example of which can be found in Figure 3.2.C. 
The six prostate isolates investigated showed 5 different allelic profiles, with the two 
type IB strains (B3 and 03R3900R) sharing the same alleles and thus sequence type (ST5). 
The type III strain CFU2 had an allelic profile matching ST33. The three type IA1 strains 
belonged to three different sequence types, namely 00035 was ST122, 00060R was ST8 
and B2 was ST1. The complete allelic profiles, sequence types and clonal complexes can 
be found in Table 3.3. A population snapshot of all P. acnes isolates available to date can 
be seen in Figure 3.3. 
 Strain selection for infection models 
For the setup of acute and chronic infections, prostate isolates 00035, B3 and CFU2, 
representing distinct phylotypes were selected (types IA1, IB and III, respectively). Due 
to the unavailability of a clinical prostate type II isolate (as type II is also commonly 
isolated from the prostate) reference strain NCTC10390 was used (Mak et al., 2013b). 
NCTC737, one of the most extensively studied P. acnes isolates, was used as a control. 
Additionally, strain ST27, named after the sequence type it belongs to according to the 
“Aarhus” MLST9 scheme was also used as a control, as strains belonging to ST27 have 
been suggested as “skin health-associated” strains (Lomholt and Kilian, 2010). Finally, 
other Propionibacteria spp., P. granulosum and P. avidum were used due to their close 
relationship with P. acnes and the fact they have both also been isolated from the 







Table 3.1. Peprotech ELISA component concentrations 
 Capture antibody Concentration Detection antibody Concentration Standard range S-HRP 
IL-1β ELISA Mouse anti-human IL-1β 0.25 μg/ml Biotinylated goat anti-human IL-1β 0.25 μg/ml 6 – 750 pg/ml 0.1 μg/ml 
IL-6 ELISA Rabbit anti-human IL-6 0.5 μg/ml Biotinylated rabbit anti-human IL-6 0.1 μg/ml 8 – 2000 pg/ml 0.05 μg/ml 
IL-8 ELISA Rabbit anti-human IL-8 0.125 μg/ml Biotinylated rabbit anti-human IL-8 0.25 μg/ml 1 – 150 pg/ml 0.05 μg/ml 
TNF-α ELISA Mouse anti-human TNF-α 1 μg/ml Biotinylated rabbit anti-human TNF-α 0.05 μg/ml 16 – 2000 pg/ml 0.05 μg/ml 
 
 
Table 3.2. R&D Systems IL-1β ELISA kit component concentration 
 Capture antibody Concentration Detection antibody Concentration Standard range S-HRP 
IL-1β ELISA Mouse anti-Human IL-1β 4 μg/ml Biotinylated goat anti-human IL-1β 0.2 μg/ml 4 – 250 pg/ml 1:40 dilution 
 
 
Table 3.3. MLST sequencing allelic profiles and ST results 
Strain Multiplex Phylotype 
Allelic profile 
ST Clonal Complex aroE atpD gmk guaA lepA sodA tly camp2 
00035 IA1 1 1 1 3 1 13 1 1 122 CC1 
00060R IA1 1 1 1 3 1 1 3 1 8 CC1 
B2 IA1 1 1 1 3 1 1 1 1 1 CC1 
B3 IB 1 1 1 4 1 4 8 6 5 CC5 
03R3900R IB 1 1 1 4 1 4 8 6 5 CC5 














Figure 3.2. Phylogenetic typing of P. acnes strains.  
A. Multiplex PCR results on a 1.5% (w/v) gel stained with GelRed. Strains of known 
phylogenetic type were used as positive controls, and a sample with no DNA was used 
as a negative control. The samples were assessed by comparing their band pattern 
with the controls. A 100 bp ladder (TrackIt™ 100 bp ladder, Invitorgen, UK) was used 
to assess band sizes. 
B. MSLT analysis of strain B3. The band size and integrity for the 8 MLST genes were 
analysed in a 1% (w/v) agarose gel stained with GelRed. TrackIt™ 100 bp (left) and 
1kb (right) ladders were used to assess band size (Invitrogen, UK) and a reaction with 
all primers but no DNA was used as a negative control. 
C. A sample of the chromatogram read for sample B3, forward read of the aroE gene, 








Figure 3.3. eBURST population snapshot of P. acnes 
The current MLST database, containing 392 strains identified using the “Belfast” MLST9 scheme described by McDowell et al. (2013), has a total of 
9 clonal complexes (CC; within each CC the strains match 7 out of the 8 genes investigated) and 19 singletons. The frequency of each type is 
indicated by the size of the mark. The founding genotype of each CC is coloured in orange, and sub-founders are in green. The STs of prostate 
isolates analysed in this chapter are marked in magenta. Background colours were used to highlight the different phylogenetic types. 




 Bacterial counts 
In order to infect the eukaryotic cell line RWPE-1 with bacteria, broth cultures at known 
concentrations were needed. To determine the number of CFU/ml P. acnes strains and 
related Propionibacterium spp. were grown to OD600 0.3 and bacterial counts were 
performed, with the results shown in Table 3.4. 
For infection experiments, fresh broth cultures were prepared and incubated at 37°C for 
16-20 hours anaerobically with mild agitation. As the bacterial concentration at OD600 
0.3 was known, broths were diluted to this optical density and the counts in Table 3.4 
were used to calculate the amount of broth needed to inoculate the eukaryotic cells at 
the desired MOI. 
 Optimal seeding density 
The optimal seeding density was determined by comparing the cell count and 
percentage viability of four different seeding densities over a period of two weeks with 
no media changes or passages of the cells. This was done to assess how long can the 
cells be left with no interference before a decrease in cell numbers and viability, as in 
infection models any media changes or passages would affect the MOI. Figure 3.4 shows 
the number of viable cells/ml and the overall cell viability determined using trypan blue 
exclusion test for cell viability. 
The cells were seeded at 50,000, 100,000, 200,000 and 300,000 cells/ml. By day 3, all 
seeding densities had demonstrated increased cell numbers, with the cells seeded at 
200,000 and 300,000 cells/ml reaching their peak numbers for the whole experiment 
and beginning to drop at the following time points. By day 5, the cells seeded at 100,000 
cells/ml demonstrated the highest numbers. At day 7, the cells seeded at 300,000 
cells/ml showed reduced numbers of cells, while the remaining seeding densities 
showed similar numbers of cells. By day 14, most of the cells in all experiments were no 
longer viable. 
The viability of the cells in all experiments remained above 90% for the first 3 days. By 
day 5, the viability had started to decrease, with the cells seeded at 200,000 and 300,000 







Table 3.4. P. acnes strains counts at OD600 0.3. 
Strain Phylotype Counts at OD600 0.3 
ST27 
IA1 
7.0 x 107 CFU/ml 
NCTC 737 2.2 x 107 CFU/ml 
00035 6.8 x 107 CFU/ml 
B3 IB 1.4 x 108 CFU/ml 
NCTC10390 II 1.7 x 108 CFU/ml 
CFU2 III 6.0 x 107 CFU/ml 
P. granulosum - 1.2 x 108 CFU/ml 









Figure 3.4. Optimisation of seeding density for infection models. 
The RWPE-1 cell line was seeded (Time 0) at 50,000 (blue), 100,000 (orange), 
200,000 (grey) and 300,000 (yellow) cells/ml and the cells were left undisturbed, 
with no media changes for up to 3, 5, 7 or 14 days. Trypan blue viability counts 
were performed at each time point. The number of viable cells (bars) and 
percentage viability (lines) are shown for each seeding density and time point. Each 
experiment had a minimum of three biological replicates and the data is presented 
as mean viable cells/ml (bars) and mean percentage viable cells (lines), +/- 





seeded at 100,000 and 200,000 remained above 90%. At day 7, cells seeded at the two 
lower denstities had viability of 80%, while the higher densities had about 60% viability. 
By day 14, the vibility values for all experiments were below 40%. 
 Multiplicity of infection 
The bacterial counts were compared between MOI 15:1 and 50:1 with two different 
strains, NCTC737 and 00035. The counts, performed every ten days of the chronic 
infection model, showed that there was no statistically significant difference between 
the bacterial counts in the two MOIs at different time points (NCTC737: day 10, p = 0.71; 
day 20, p = 0.49; day 30, p = 0.09; 00035: day 10, p = 0.17; day 20, p = 0.92; day 30, p = 
0.58) despite the inoculum being higher for the 50:1 replicates at the beginning of the 
experiments (Figure 3.5). 
 Intracellular bacterial counts 
Different antibiotic concentrations were tested to establish the best way for intracellular 
count experiments to be conducted. However, in all combinations tested, viable bacteria 
remained in the negative controls. The antibiotic concentration which showed the 
lowest numbers of extracellular bacteria was 400 μg/ml gentamycin, 50 units/ml 
penicillin and 50 mg/ml streptomycin, following three-hour incubation. As a result of 
bacteria remaining viable despite the prolonged treatment with a mixture of antibiotics, 
for accurate assessment of the intracellular bacteria, the number of bacteria seen in the 
negative controls was subtracted from the intracellular counts. The number of 
extracellular bacteria remaining after this treatment can be seen in Table 3.5. 
 Antibiotics prevent the formation of bacterial colonies in soft agar 
A soft agar assay was set-up following a 15-day infection of RWPE-1 cells with strain 
NCTC737 (type IA1), aiming to assess the importance of the addition of antibiotics to the 
top layer of the assay. After 14-day incubation, the soft agar assay with no antibiotic 
added showed the formation of more than 30 colonies, while the assays with antibiotic 
had no visible colonies (p = 0.0009, Figure 3.6). A sample from a colony was taken and 










Figure 3.5. Comparison between MOI 15:1 and 50:1 
Bacteria in the medium (in CFU/ml) at T0, D10, D20 and D30 in long term infection 
models infected with different MOI – 15:1 (blue), 50:1 (orange). 
A. RWPE-1 cells infected with NCTC737. D10, p = 0.71; D20, p = 0.49; D30, p = 0.09  
B. RWPE-1 cells infected with 00035. D10, p = 0.17; D20, p = 0.92; D30, p = 0.58 







Table 3.5. Extracellular P. acnes counts following 3-hour antibiotic incubation 
Strain 24h (CFU/ml) 48h (CFU/ml) 72 h (CFU/ml) 
ST27 1,600 325 75 
NCTC 737 1,600 475 325 
00035 500 1,600 1,550 
B3 225 150 200 
NCTC 10390 275 100 - 
CFU2 - - - 





















Figure 3.6. Soft agar assay optimisation with cells infected for 15 days with NCTC737 
Soft agar colonies in assay with no erythromycin (A) and with 20 μg/ml erythromycin 
added (B), as seen under 2x magnification (left) and with no magnification (right) Soft 
agar colonies. C. No infection control with no magnification. D. Gram stain of colony 
from infected RWPE-1 cells not treated with erythromycin, 100x magnification. E. 
Summary of results, bars represent mean number of colonies between three 





 Antibiotics decrease 22Rv1 cell line’s ability to form colonies on soft agar 
After 14 days incubation, the soft agar assay set up using the cancer cell line 22Rv1, 
treated with erythromycin and control wells, were assessed for colony formation. The 
control wells showed on average 333 colonies had formed, while the number of colonies 
in the treated wells averaged 181, showing a significant decrease in the anchorage-
independent growth of the cells in the presence of erythromycin (p = 0.0006). 
Additionally, the colonies formed in the treated cells were of a noticeably smaller size 
(Figure 3.7). 
 Efficiency calculations 
The efficiencies of all RealTime ready primer-probe mixes were assessed. The standard 
curves for the different groups of genes can be found in Figure 3.8 for housekeeping 
genes, Figure 3.9 for inflammatory genes and Figure 3.10 for epithelial-mesenchymal 
transition genes. The percentage efficiency (E) for each assay is calculated using the 
formula below, and a list of all efficiencies can be found in Table 3.6. 
E = �10−1 𝑚𝑚� − 1� × 100 
All efficiencies calculated were within expected 100 +/- 10% range. 
 HPRT is the most stable housekeeping gene. 
To perform the selection of the most stable housekeeping gene for use in future 
experiments, the investigated samples were separated into two groups based on 
infection status and tested with four possible housekeeping genes: ACTB, GAPDH, HPRT, 
and TBP. 
When using the mean values of the two groups, the statistical package, based on a 
mathematical model estimating the variation of expression, returned HPRT1 as the best 
housekeeping gene with a stability value of 0.167 (based on intergroup variation), 
compared to 0.550, 0.379 and 0.208 for ACTB, GAPDH and TBP, respectively (Figure 
3.11). Intragroup variation was also assessed showing the difference within the non-
infected (group 1) and infected (group 2) groups as follows: ACTB: 0.205 (group 1) and 
5.355 (group 2), GAPDH: 0.680 (group 1) and 1.801 (group 2), HPRT1: 0.015 (group 1) 













Figure 3.7. Soft agar assay optimisation with 22Rv1 cell line 
Colonies in soft agar assay, with no erythromycin (A) and with 20 μg/ml erythromycin 
added (B), as seen under 2x magnification (left) and with no magnification (right). 
C. Difference of the number of colonies seen between antibiotic-free and antibiotic-
treated wells; bars represent the mean number of colonies between three replicates, 
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Figure 3.8. Standard curves for housekeeping genes 
ACTB (A), GAPDH (B), HPRT1 (C) and TBP (D). The data is presented as Cp value vs. log10 cDNA concentration were plotted and the slope value of 


















Figure 3.9. Standard curves for inflammatory genes 
IL1B (A), IL6 (B), IL8 (C) TGFB (D)and TNF (E). The data is presented as Cp value vs. log10 cDNA concentration were plotted and the slope value of 



















Figure 3.10. Standard curves for EMT genes 
CDH1 (A), CDH2 (B), SNAI1 (C), SNAI2 (D), TWIST1 (E) and VIM (F). The data is presented as Cp value vs. log10 cDNA concentration were plotted and 
the slope value of each curve was used to calculate the probe efficiency. cDNA from untreated RWPE-1 cells was used to prepare serial dilutions 





   
Table 3.6. Summary of probe efficiencies 
Function Gene Full name Efficiency 
Housekeeping 
genes 
ACTB Beta-actin 97.2% 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 103.8% 
HPRT1 Hypoxanthine-guanine phosphoribosyltransferase 92.3% 
TBP TATA-binding protein 97.5% 
Inflammatory 
genes 
IL1B Interleukin-1 beta 90.7% 
IL6 Interleukin-6 105.9% 
IL8 Interleukin-8 106.5% 
TGFB Transforming growth factor beta 96.0% 
TNF Tumour necrosis factor 101.2% 
EMT 
genes 
CDH1 E-cadherin 97.0% 
CDH2 N-cadherin 109.3% 
SNAI1 Snail family zing finger 1 (Snail) 98.4% 
SNAI2 Snail family zing finger 2 (Slug) 92.7% 
TWIST1 Twist-related protein 1 97.7% 









Figure 3.11. Normfinder calculated housekeeping gene stability. 






The best combination of genes suggested by the package was HPRT and TBP with a 
stability value of 0.173. 
 Bacteria can produce formazan from MTT 
The MTT assay was used on a bacterial culture to confirm that bacteria can produce 
formazan from MTT. As seen in Figure 3.12, the absorbance reading decreased as the 
culture was diluted, with a mean absorbance reading at 570 nm of 1.5 for the neat 
bacterial broth, 0.6 for the 1:10 dilution and 0.1 for the 1:100 dilution. The sterile broth 
control had a reading of 0.06. 
 MTT assay seeding density optimisation 
An initial experiment was set up with supernatant from the PC-3 cell lines. A serial 
dilution was performed, the cells were incubated overnight, and an MTT assay was used 
to assess the proliferation of the HDMEC cell line at different seeding densities. 
The results showed that the amount of formazan produced following incubation with 
MTT was directly proportional to the seeding density, with the absorbance reading 
increasing with the number of cells (Figure 3.13). In all seeding densities tested, there 
was a significant decrease compared to untreated controls in the absorbance reading of 
cells treated with undiluted conditioned medium (p < 0.001 for cells seeded at 10,000 
and 20,000 cells/ml; p < 0.01 for cells seeded at 30,000, 50,000 and 80,000 cells/ml). 
Only the cells seeded at 20,000 cells/ml showed significant differences in absorbance in 
the dilution series compared to the untreated controls. A significant decrease (p < 0.01), 
was seen in the 1:5 dilution, and p < 0.05 in the 1:10, 1:50, 1:1,000 and 1:10,000 
dilutions. 
Based on these results, 50,000 cells/ml was selected as the seeding density to be used 
in further experiments. 
 MTT assay control selection 
A range of controls were tested to select the optimal combination of positive and 
negative control for use in experiments. Incubation times of 24 and 72 hours were 
tested, with the data for 72-hour incubation seen in Figure 3.14. 
As controls which increase the proliferation rate of the HDMEC cells line (positive 









Figure 3.12. MTT assay used on bacterial culture 
A. Image of S. epidermidis MTT assay with no magnification. 
B. Absorbance measured at 570 nm. Data presented as mean of eight replicates +/- 
standard error; neat broth culture (blue), 1:10 dilution (red); 1:100 dilution (green), 

















Figure 3.13. Seeding density optimisation 
MTT assay (absorbance measured at 570 nm) assessing the effect of medium from the PC-3 on the HDMEC cell line, aiming to compare the 
differences in seeding density. Cells seeded at: A. 10,000 cells/ml; B. 20,000 cells/ml; C. 30,000 cells/ml; D. 50,000 cells/ml; E. 80,000 cells/ml. 
Data presented as mean of three replicates +/- standard error. Significance was calculated comparing to untreated control for each experiment, 







Figure 3.14. Selection of controls 
Different positive controls (aiming increased proliferation rate) and negative controls 
(aiming decreased proliferation rate) were tested on the HDMEC cells. Untreated 
controls (blue) were used as comparison to calculate significance of the observed 
changes following a 72-hour incubation. Three concentrations of EGF (purple, 25 
ng/ml, 50 ng/ml and 100 ng/ml) and complete Medium 200 + 20% FBS (green, p = 
0.037) were investigated as potential positive controls. Three concentrations of 
etoposide (orange, 2.5 μM (p = 0.0002), 3.5 μM (p < 0.0001) and 5 μM (p < 0.0001)) 
and 0.05% (w/v) saponin (red, p < 0.0001) were possible choices for negative controls. 
Data is presented as mean of five replicates +/- standard error. Significance was 






complete Medium 200 with 18% (v/v) FBS (to a final FBS concentration of 20%) were 
trialled; concentrations of etoposide (2.5 μM, 3.5 μM, 5 μM) and 0.05% (w/v) saponin 
were tested as negative controls (controls which decrease proliferation of the HDMEC 
cells). 
The only positive control that led to significant increase in MTT assay absorbance 
reading was complete Medium 200 with 20% FBS (p < 0.05). The EGF concentrations 
tested showed no significant difference in absorbance readings compared to the 
untreated control and showed no dose-dependent response. 
All the potential negative controls tested showed significant decrease in absorbance 
readings (p < 0.001). A dose-dependent response was seen with etoposide treatment, 
with the optical density reading decreasing with increase of the drug concentration. 
Saponin treatment resulted in readings close to those of wells with just medium and no 
cells. 
Based on these findings, 2.5 μM etoposide and Medium 200 + 20% FBS were selected as 
a negative and positive control, respectively. 
 MTT assay incubation time optimisation 
To select the optimal incubation duration for the experiments, the HDMEC cells were 
seeded at 50,000 cells/ml and incubated in the presence of a serial dilution of pooled 
conditioned medium from chronic infections for 24, 48 and 72 hours. After each 
incubation an MTT assay was performed, and the results can be seen in Figure 3.15. 
In all experiments a significant decrease (p < 0.001) in the absorbance reading was seen 
in all cells treated with undiluted conditioned medium. At 24 hours, a significant 
decrease in the absorbance readings compared to the untreated controls was observed 
in six of the dilutions tested, in addition to the decrease in the neat samples. A trendline 
showing an increase in absorbance as the dilution factor increased, was observed. In 
contrast, at 48 and 72 hours the change seen was an increase in the reading (four 
concentrations lead to significant increase at 48 hours and six at 72 hours). Additionally, 
when comparing the three timepoints, significant differences were seen in five of the 
concentrations tested between the 24-hour time points and both 48 and 72 hours (neat, 












Figure 3.15. Incubation time selection 
MTT assay (absorbance measured at 570 nm) assessing the effect of pooled conditioned medium from chronic infection of RWPE-1 cells on the 
HDMEC cell line, comparing the differences in incubation times. Cells seeded at 50,000 cells/ml and incubated for: A. 24 hours; B. 48 hours; C. 72 






at 72 hours only, and 1:10,000 (p = 0.0206) at 48 hours only). Furthermore, a significant 
difference was also seen in the untreated control measurements at 24 hours versus 48 
and 72 hours (p = 0.0271 and p < 0.0043, respectively). Finally, a significant increase was 
observed in the optical density readings for neat (p = 0.0144) and 1:10 (p = 0.0349) 
samples comparing the 48 and 72-hour time points. 
 ELISA 
Four ELISA kits were purchased to detect the amount of IL-1β, IL-6, IL-8 and TNF-α in 
conditioned medium following acute and chronic infection with a range of P. acnes 
phylogenetic strains and P. granulosum as a control. 
Standard curves were prepared for each ELISA kit following the manufacturer’s 
instructions, however, the values of the highest standards were significantly lower than 
expected, with the values remaining low in different repeats, and changes in 
experimental conditions such as incubation with agitation, incubation steps conducted 
at 25°C, and S-HRP and TMB steps incubated at 37°C and up to an hour for TMB (Figure 
3.16 for representative standard curves). 
As changes in the recommended protocol had no effect on the standard curve protocol, 
a trobleshooting experiment using components from an available R&D IL-1β ELISA kit 
were used to eastablish the reason the kits were not performing as expected. Different 
components of the Peprotech and R&D IL-1β kits were used to pinpoint the core of the 
issue (Figure 3.17). 
In this troublshooting comparison experiment, the Peprotech IL-1β ELISA once again 
demonstrated lower than the expected absorbance values at 0.37 for the 750 pg/ml high 
standard (Figure 3.17.A). In contrast, the R&D ELISA showed a reading (absorbance at 
450 nm with background at 620 nm subtracted) of 1.85 (Figure 3.17.B), which is in line 
with the predicated by the manufacturer value. When the R&D ELISA kit was used in 
combination with the buffers recommened by Peprotech, the values were even higher, 
at 3.04 absorbance reading for the top standard (Figure 3.17.C). The combination of R&D 
capture antibody with Peprotech standard and detection antibody showed an 
absorbance reading of 1.23 (Figure 3.17.D), while the reverse combination measured  
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Figure 3.16. Standard curves for Peprotech ELISA kits 



















Figure 3.17. IL-1β ELISA troubleshooting 
Standard curves were performed using a combination of Peprotech and R&D IL-1β ELISA kits, as follows: 
A. Peprotech ELISA reagents; 
B. R&D ELISA reagents; 
C. R&D ELISA using Peprotech buffers (washing, blocking, diluent regent, S-HRP and TMB); 
D. Peprotech blocking and capture antibody, followed by R&D standard, detection antibody, S-HPR and TMB; 
E. R&D blocking and capture antibody, followed by Peprotech standard, detection antibody, S-HRP and TMB; 





R&D buffers, the normalised absorbance readings for the highest standard were at 0.1 
(Figure 3.17.F). 
3.4. Discussion  
Infection models of prostate epithelial cells with P. acnes have been previously used as 
a tool to investigate the potential role of P. acnes infection in oncogenesis (Drott et al., 
2010; Fassi Fehri et al., 2011; Mak et al., 2012; Fischer et al., 2013; Sayanjali et al., 2016). 
Such infections shed light on the basic response of eukaryotic cells to infection with 
different P. acnes strains and can be used as stepping stones for future studies. 
As we used the McDowell et al. (2012a) “Belfast” MLST8 typing we are unable to 
compare our findings to some of the groups who have performed phylogenetic analysis 
of P. acnes prostate isolates, as different typing schemes utilise different genes 
sequences. It would be possible to perform in silico analysis of the published whole 
genome sequences available of P. acnes prostate isolates and elucidate their STs, 
however, this analysis was not performed due to time constraints. All comparisons in 
this Chapter are to an available database, containing STs of a collection of 372 isolates, 
compiled from a range of studies (McDowell et al., 2013). 
The type IA1 isolates in this study belong to three distinct STs. Strain 00035 is a part of 
ST1, which is the ST with the highest number of previously analysed strains, most of 
which have been linked to healthy skin or acne, but also a small proportion of the strains 
have been associated with corneal infections and endocarditis. The most widely used P. 
acnes control strain, NCTC737, also belongs to this ST. Strain 00060R belongs to ST8, 
with the members of this group being acne, skin or dental isolates (McDowell et al., 
2013). The database does not contain any information about strains belonging to ST121 
(as strain B2 used in this study) suggesting that isolates from this ST are rare. 
The type IB strain from our study belongs to ST5, which includes skin and blood isolates 
but more importantly a large proportion of prostate cancer isolates (McDowell et al., 
2013). Combining our isolates with the available database, members of ST5 comprise 
33% of P. acnes prostate isolates discovered to date, with the remaining 67% being split 




Finally, the type III isolate from our study (CFU2) belongs to ST33, which includes 
predominantly spinal disk isolates (McDowell et al., 2013). 
Our findings suggest that the phylotypes of P. acnes isolated from cancerous prostate 
vary. Due to the small sample size, no solid conclusion can be made, however, there is a 
trend suggesting that phylogenetic type IB/ST5 strains are the ones most commonly 
associated with prostate cancer. 
Trypan blue viability counts of the RWPE-1 cells were used to select the optimal seeding 
density. Both cells seeded at 50,000 and 100,000 cells/ml demonstrate good 
proliferation rates with increasing numbers up to day 5 and a high percentage of viable 
cells. The cells seeded at 100,000 cells/ml, however, demonstrated higher numbers and 
a marginally better viability at day 5 and were thus chosen as the optimal seeding 
density. The results from this experiment also suggest that the optimal seeding time 
point for any long-term infection would be day 5, before any loss in viable cells occurs. 
As a variety of P. acnes MOIs have been tested in culture, to select the optimal MOI for 
infections, we compared bacterial numbers in chronic infections between cells infected 
at MOI 15:1 and MOI 50:1, with our results showing that as time progresses there is no 
statistically significant difference in bacterial concentration in the media using the 
different MOIs. As the medium is changed every 3rd day after passage, high number of 
the bacteria are washed off very early in the experiment, with the majority of remaining 
bacteria being either intracellular or attached to the cell surface. Based on the lack of 
significance in bacterial counts between MOIs, 15:1 was selected as the infection ratio 
to be used in future experiments, as it is closer to an in vivo situation where only small 
number of bacteria are found in epithelial and stromal cells (Alexeyev et al., 2007). 
P. acnes has been shown to have the ability to become intracellular both in in vitro 
experiments and via fluorescent in situ hybridisation, using formalin-fixed, paraffin-
embedded (FFPE) prostatectomy samples and needle biopsies (Alexeyev et al., 2007; 
Fischer et al., 2013). To assess the bacterium’s ability to invade eukaryotic cells in 
culture, it is necessary to first remove all extracellular bacteria by treating the cells with 
antibiotics. However, with the different combinations tried in these experiments, there 




time, though up to 4-hour incubation was trialled. Alternatively, any bacteria seen in the 
antibiotic control wells could be a result of eukaryotic death, thus the antibiotics would 
have not acted on the released bacteria for long enough to be effective. To achieve 
accurate numbers for the bacteria present intracellularly, any counts from the antibiotic 
control were subtracted from the intracellular counts in following experiments. 
Our results demonstrated the importance of using antibiotics in soft agar assays using 
infected cells. When no antibiotics were used, colony formation was observed in soft 
agar assays prepared after a 15-day infection. Those colonies differed from colonies 
seen in assays set-up with cancer cell lines as they had rounder edges; this prompted 
further investigation which showed that the colonies were in fact bacterial colonies. 
When antibiotics were used in a soft agar assay with a cancer cell line a significant 
decrease in the number of colonies formed was seen compared to untreated controls, 
indicating a decrease in the ability of cells to grow anchorage-independently. Studies 
have previously shown that antibiotics have the potential to affect cancer cell growth in 
culture by targeting the mitochondria (De Francesco et al., 2017). Such findings suggest 
the possible use of antibiotics as anti-cancer treatment but also highlight an issue with 
the wide-spread antibiotic use is tissue culture experiments, as they may have an effect 
results and cellular behaviour, especially in primary cells. As antibiotics affect eukaryotic 
cells on a metabolic level, it is likely that such activity is not limited to cancer cells. 
Taken together these results show that use of antibiotics is necessary to eradicate any 
bacterial colonies; however, it can lead to a significant decrease in the observed number 
of colonies. 
Quantitative-PCR is widely used for the investigation of transcript level changes. The 
efficiencies of all hydrolysis probe-primer mixes were analysed to confirm that they are 
within the expected range of 100% +/- 10%, which was the case. 
Selecting the correct reference gene is vital for qPCR analysis. Housekeeping genes used 
are constitutively expressed genes which show no difference in expression between 
treated and control samples. It has been suggested that using more than one 
housekeeping gene increases the stability of the comparison. Our results showed that 




combination, thus only HPRT1 was used for further analysis. This finding is in line with a 
previous study of 16 different reference genes, where HPRT1 was shown to be the most 
stable (Ohl et al., 2005). 
In order to optimise the MTT assays, five seeding densities of the HDMEC cells were 
examined and all showed an increase in the MTT assays absorbance reading directly 
proportional to seeding density. This result was expected as the higher the seeding 
density used, the more MTT is converted to formazan, resulting in the higher reading 
observed. The 50,000 cells/ml seeding density was selected, as the cells showed high 
readings but at the same time were not confluent, which would allow any treatment 
with conditioned medium to be continued for a number of days. 
Two possible positive controls were trialled, a range of EGF concentrations and complete 
Medium 200, supplemented to a final concentration of 20% FBS. 
EGF has been used in literature as a potential proliferation inducer at a range of 
concentrations, from 10 ng/ml to 100 ng/ml (Kato et al., 1998; Shao et al., 2008; 
Tomshine et al., 2009). The three dilutions used here showed no significant change in 
the HDMEC cell viability, following a 24 and 72-hour incubation, indicating that EGF is 
not a suitable positive control. Studies have suggested EGF is only effective at 
concentrations below 30 ng/ml and its pro-angiogenic effect is lost at higher 
concentrations (Shao et al., 2008). However, no difference was seen between the cells 
treated with 25 ng/ml and the untreated controls, or in comparison with the samples 
treated with higher levels of EGF. EGF was selected as a possible positive control for the 
MTT assays due to it being readily available, as it is one of the supplements added to 
KSFM used for culture of the RWPE-1 human prostate epithelial cells (together with BPE, 
as outlined in Section 2.1.1). EGF at a concentration of 25 ng/ml has also been used in a 
combination with VEGF as a proliferation control and VEGF is commonly used as a sole 
angiogenesis-inducer (Hussain et al., 2008; Wang et al., 2008b; Hwang et al., 2016). 
However, due to financial constraints, VEGF could not be used in the present study. 
FBS contains a range of components including salts, vitamins, prostaglandins, hormones 
which can affect cell growth (Price and Gregory, 1982). It has long been observed that 
increasing the serum concentration in culture increases the growth rate of cells. The 




(which contains of 2% (v/v) FBS). However, supplementing the medium with FBS to a 
final concentration of 20% (v/v) lead to significantly increased proliferation compared 
to cells cultured in normal complete medium. 
As the MTT experiments were only be used as a preliminary screen, the use of Medium 
200 containing 20% (v/v) FBS was considered a sufficient positive proliferation control. 
Two different treatments were also examined as potential negative controls: etoposide 
and saponin. 
Etoposide is a commercially available anti-cancer drug, which works by targeting DNA 
topoisomerase type II during DNA-replication, thus inhibiting the re-ligation of DNA, 
causing DNA damage and inducing apoptosis in cancer cells (Pommier et al., 2010). A 
range of three concentrations used in literature were tested as potential anti-
proliferation controls (2.5 μM, 3.5 μM and 5 μM) and all three showed significant 
decrease in MTT assay absorbance levels, making them suitable negative controls for 
future experiments (Panigrahy, 2010; Callaghan et al., 2016). The 2.5 μM etoposide 
concentration was selected, as its activity was significant even at the small dose used. 
Finally, saponin at a concentration 0.05% (w/v) was also tested as a negative control, as 
it has been used previously in literature (at a higher concentration of 0.1%) as a negative 
proliferation control (Focaccetti et al., 2015). As expected, this treatment caused a 
significant decrease in the absorbance observed following MTT assay analysis, which is 
a result of the saponin lysing all cells. As no cells remain viable following this treatment, 
saponin was not selected as a negative control, and etoposide was used instead for 
analysis. 
Experiments were also performed to select the optimal exposure time of the HDMEC 
cells to the conditioned medium. Cells were treated with a serial dilution of conditioned 
medium and incubated for 24, 48 and 72 hours. The results demonstrated that the 
length of incubation affected the results significantly. When the cells were only 
incubated for 24 hours, the trendline suggested that the conditioned medium had an 
inhibitory effect on proliferation which was lost as the medium was diluted. The 
opposite was observed when the cells were incubated with the same pooled 




started at the highest proliferation induction when treated with a 1:50 dilution and it 
slowly decreased as the conditioned medium was diluted. 
The reverse trendline seen at 24 hours suggests that there may be an initial cytotoxic 
effect seen in the HDMEC cells when treated with the conditioned medium, which is 
overcome within 48 hours when the cells begin to show increased proliferation and is 
even more clear at 72 hours. Another observation of the importance of incubation time 
on proliferation of the HDMEC cells can be seen in the positive and negative controls 
between 48 and 72 hours. The significance in both increases with the longer incubation. 
Taken together these findings point towards 72 hours being the optimal incubation time 
to be used in future experiments. 
Another interesting observation made in the data at the optimisation stage was that in 
all cases there was a significant decrease in viability when the cells were treated with 
neat conditioned medium. While a drop in viability was seen when the HDMEC cells 
were treated with complete KSFM as a control, by the 72-hour time point such 
difference was lost and there was no significant difference between MTT assay 
absorbance in HDMEC cells cultured in complete Medium 200 versus those cultured in 
complete KSFM. The drop seen when cells were treated with neat conditioned medium 
is thus not due to the change of base medium but likely a result of the conditioned 
medium not having enough nutrients to sustain life in the endothelial cell line. Once the 
conditioned medium was diluted in fresh medium, the effect it has on the proliferation 
of the HDMEC cells can be seen. 
An extensive troubleshooting investigation of the Peprotech ELISA kits demonstrated 
that the issue does not stem from the type of 96-well plate used and that the buffer 
composition or TMB does not interfere in the process, as when a different kit was used 
with the same plates and buffers it showed improved values. When a combination of 
Peprotech capture antibody was used with R&D standard and detection antibody, while 
lower than the advertised OD value of 2, the absorbance reading was still higher than 
that of the Peprotech kit alone, suggesting that the issue does not lie within the 
Peprotech capture antibody coating. When the alternative was tried, and the R&D 
capture antibody was combined with the Peprotech standard and detection antibody, 




when allowing for the difference in standard concentration. Additionally, S-HRP at the 
recommended concentration was tested directly with TMB to confirm that the reaction 
occurs. These findings suggest that the low and inconsistent absorbance readings 
observed with the Peprotech kit were related to the detection antibodies. 
Due to the issues encountered, time limitations and financial constraints it was decided 
not to pursue the quantification of secreted inflammatory proteins further, and solely 
use gene dysregulation to analyse differences. 
The combination of these initial optimisation experiments ensures a stringent and 
robust analysis of infection models in future experiments and the optimised gene 
efficiencies. The selection of a stable housekeeping gene allows for an accurate 
comparison in dysregulation levels following infection with different P. acnes phylotypes 








Acute and chronic models of 
infection 








The dysregulation of inflammatory and epithelial-mesenchymal transition (EMT) genes 
in acute and chronic infection models was investigated, to assess the differences in gene 
expression as a result of infection of human prostate epithelial cells (the RWPE-1 cell 
line) with a range of P. acnes phylotypes. Additionally, cellular and bacterial behaviour 
in the short and long-term infections was evaluated. The molecular findings were 
supplemented with soft agar assays, investigating anchorage-independent growth, 
scratch assays assessing migration, and immunocytochemistry was used to analyse the 
expression of EMT-related proteins. 
 Interleukin-1 beta 
Interleukin-1 beta (IL-1β), a member of the IL-1 superfamily, is expressed as a precursor 
protein which becomes activated by caspase-1 (Dinarello, 1998). Caspase-1 itself also 
requires activation by the formation of the NACHT, LRR and PYD domains-containing 
protein 3 (NLRP3) inflammasome (Agostini et al., 2004). Alternatively, IL-1β can also be 
activated by neutrophilic enzymes, e.g. proteinase-3 and elastase (Dinarello, 2011). IL-
1β has been linked to an increasing number of autoinflammatory diseases. These 
autoinflammatory diseases differ from autoimmune diseases in that they are periodic 
and linked with defects in innate immunity, rather than being progressive and linked to 
dysregulation of the adaptive immune response (Dinarello, 2011). Additionally, IL-1β has 
been shown to be involved in antibody production and the most commonly used 
adjuvant, aluminium hydroxide, initiates caspase-driven IL-1β activation (Marrack et al., 
2009) (Summarised in Figure 4.1). 
Both IL-1α and IL-1β can bind the IL-1 receptor type I (IL1RI) which summons co-
receptors and adaptors, prior to signal initiation. The adaptor molecule that activates 
the IL1R is also a part of Toll-like receptor (TLR) activation (Barton and Medzhitov, 2003). 
The assembled receptor complex initiates a number of downstream pathways, including 
the nuclear factor-kappa B (NF-κB), mitogen-activated protein kinases/extracellular 
signal-regulated kinases (MAPK/ERK) and c-Jun N-terminal kinases (JNK) pathways.  
In the context of prostate cancer, studies have shown that decreased expression of IL-








Figure 4.1. Overview of interleukin 1-beta (IL-1β) signalling 
IL-1β is produced as a precursor protein (pro- IL-1β) which needs to be activated in 
order to become functional. The activation can be done by proteases (e.g. proteinase-
3, elastase) or by cspase-1 (which is activated by the NLRP3 inflammasome). The 
functional IL-1β is then secreted and can bind interleukin receptor type I (IL1RI) which 
recruits adaptor molecules (AM), triggering a number of signalling pathways. 
Legend: ERK – extracellular signal-regulated kinase; JNK – c-Jun N-terminal kinase; 
MAPK – mitogen-activated protein kinase; NF-κB – nuclear factor-kappa B; 








Interleukin-6 (IL-6) is a cytokine which belongs to the IL-6 type family. The IL-6 receptor 
(IL6R) consists of an α-subunit with no signalling functions, and a 130 kDa signal-
mediating glycoprotein, also known as gp130 or IL-6Rβ (Taga et al., 1989). A soluble form 
of the receptor also exists (Lust et al., 1992). Activation of a number of pathways has 
been linked to IL-6 including Janus kinase/signal transducer and activator of 
transcription 3 (JAK/STAT3), NF-κB, MAPK/ERK and phosphatidylinositide 3-
kinases/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) pathways. 
(Guschin et al., 1995). (Illustrated in Figure 4.2) 
IL-6 is elevated in the serum of patients with metastatic prostate cancer and the levels 
correlate with prostate specific antigen (PSA ) results (Adler et al., 1999). In vitro studies 
have also shown that IL-6 can activate the androgen receptor independently of its ligand 
and cause receptor activation in low androgen concentrations, which would be of 
importance in patients with advanced cancer and elevated IL-6 serum levels (Hobisch et 
al., 1998; Chen et al., 2000). 
 Interleukin-8 
Interleukin-8 (IL-8), also known as chemokine C-X-C motif ligand 8 (CXCL8), is a 
chemokine produced by a variety of cells and it has a chemotactic activity on various 
inflammatory cell types. It can bind to two C-X-C motif chemokine receptors, CXCR1 and 
CXCR2. IL-8 dysregulation and abnormal IL-8 receptors are present in a number of 
tumours, including in prostate cancer (Veltri et al., 1999). Abnormal IL-8 activity in 
tumour sites has been linked to alterations in immune cells behaviour, regulation of 
angiogenesis, tumour growth and survival, and to promoting migration of cancer cells 
(Baggiolini et al., 1989; Strieter et al., 1995; Zlotnik and Yoshie, 2000; Strieter, 2002; 
Balkwill, 2003). 
CXCL8 has been suggested as a promoter of androgen-independent growth and as a 
cause of increased proliferation of cancer cells, as it activates the PI3K/AKT/mTOR and 
MAPK/ERK pathways (Knall et al., 1997; MacManus et al., 2007). It has also been shown 
to upregulate CXCR7 (also known as ACKR3) which in turn induces cancer cell growth 
through epidermal growth factor receptor (EGFR) (Luppi et al., 2007). Accelerated 
prostate cancer progression can also be explained by common mutation is phosphatase 






Figure 4.2. Overview of interleukin-6 (IL-6) signalling 
IL-6 binds the ILR6α subunit of the IL-6 receptor, which is inactive until bound to the 
IL6Rβ-subunit (or gp130), initiating a range of signalling pathways. A soluble from of 
the receptor also exists with a soluble α-subunit which binds IL-6 and then guides it to 
the membrane bound gp130, initiating signalling. Adapted from Dayer and Choy 
(2010). 
Legend: AKT – protein kinase B; ERK – extracellular signal-regulated kinase; 
JAK – Janus kinase; MAPK – mitogen-activated protein kinase; NF-κB – nuclear factor-






factor-1 (HIF-1) and NF-κB (Maxwell et al., 2013; Armstrong et al., 2016). Elevated serum 
levels of CXCL8, together with prostate specific antigen (PSA) levels, can be used to 
differentiate benign prostatic hyperplasia (BPH) from prostate cancer (Veltri et al., 
1999). 
 Transforming growth factor beta 
Transforming growth factor beta (TGF-β) is one of the two members of the TGF family. 
It is expressed primarily by endothelial and neuronal cells, and it is involved in the 
regulation of cellular proliferation, differentiation, angiogenesis and wound healing 
(Pepper, 1997; Blobe et al., 2000). TGF-β either binds to type III receptors (which do not 
have a signalling function), and they transfer it to signalling receptors type II, or it binds 
type II receptors directly, which in turn recruit type I receptors (Wrana et al., 1994). Once 
bound, TGF-β activates the phosphorylation of a number of SMAD (a portmanteau of 
Sma (small body size) in Caenorhabditis elegans and MAD (mothers against 
decapentaplegia) in Drosophila) transcription factors. The activated SMADs are then 
translocated to the nucleus and are involved in transcriptional regulation (Nakao et al., 
1997). TGF-β signalling is also involved in the MAPK/JNK, MAPK/ERK and 
PI3K/AKT/mTOR signalling pathways (Lee et al., 2007; Liu et al., 2012; Suwanabol et al., 
2012). A visual representation of the TGF-β activation and signalling can be seen in 
Figure 4.3. 
It has been established that TGF-β plays a direct role in cell cycle regulation by activating 
the production of cyclin-dependent kinase (Cdk) inhibitors, which leads to a downstream 
reaction resulting in cell cycle arrest in the G1 phase (Ravitz and Wenner, 1997). 
Mutations in the receptors, SMADs or TGF-β itself, have been linked to cancer 
progression, as TGF-β can no longer inhibit proliferation or induce apoptosis; mutations 
in TGF-β receptor type II and SMAD4 have been linked to prostate cancer (Blobe et al., 
2000). Increased levels of serum TGF-β1 have been found in prostate cancer patients 
(Ivanovic et al., 1995; Adler et al., 1999). 
TGF-β signalling can act both as tumour suppressor and a tumour promoter (Muraoka-
Cook et al., 2005). While TGF-β can induce apoptosis or inhibit proliferation thus 
inhibiting transformation, at later stages of cancer progression, TGF-β signalling can 








Figure 4.3. Overview of transforming growth factor-beta (TGF-β) signalling 
TGF-β can initiate signalling one of two ways: it can bind the TGFB receptor type III 
(TGFBIII) which has no signalling capabilities and then interacts with TGFBII; 
alternatively, TGF-β can bind TGFBII directly. Following, TGFBI is recruited, which 
initiates multiple signalling pathways. A way of action for TGF-β is via phosphorylation 
of SMAD, which is then translocated to the nucleus, where it can regulate 
transcription. Adapted from Blobe et al. (2000). 
Legend: AKT – protein kinase B; ERK – extracellular signal-regulated kinase;  
JNK – c-Jun N-terminal kinase; MAPK – mitogen-activated protein kinase; 
PI3K – phosphoinositide 3-kinase; SMAD – a portmanteau of Sma (small body size) in 







 Tumour necrosis factor-alpha 
Following its synthesis, tumour necrosis factor alpha (TNF-α) is present as a 
transmembrane protein, and it is not soluble until cleaved by TNF-α-converting enzyme 
(TACE, also called ADAM17) (Issuree et al., 2013). TNF-α can bind to TNF-receptors 
TNFR1 or TNFR2 with opposing results; TNFR1 is involved in programmed cell death 
initiation and inflammation, while TNFR2 mediates cellular survival and regeneration 
(Grell et al., 1995; Probert, 2015). Once it has interacted with TNF-α, the receptor 
signalling complexes activate intricate signalling pathways (Figure 4.4) (Brenner et al., 
2015; Pasparakis and Vandenabeele, 2015). TNFR1 complex I and TNFR2 are linked to 
NF-κB and MAPK-signalling activation (plus AKT-pathway activation for TNFR2) and a 
positive outcome for the cell, while TNFR1 complexes IIa, IIb and III are linked to cell 
death through apoptosis (for the type II complexes) or necroptosis (for type III) (Micheau 
and Tschopp, 2003; Wang et al., 2008a; Aggarwal et al., 2012; Sun et al., 2012; 
Linkermann and Green, 2014; Brenner et al., 2015; Pasparakis and Vandenabeele, 2015). 
When initially discovered, TNF was named after its ability to cause necrosis in tumour 
cells by inducing programmed cell death pathways (Carswell et al., 1975). It has also 
been linked to senescence and cytostatic effects (Sugarman et al., 1985; Braumuller et 
al., 2013). However, evidence suggests that TNF-α also has cancer promoting functions, 
for example by inducing mutations and inhibiting DNA-repair pathways, as well as 
driving proliferation and survival by inducing NF-κB and IL-6 production (Zhao et al., 
2012; Elinav et al., 2013; Hu et al., 2014). Additionally, TNF-α can aid tumour cells in 
evading the immune system and can also promote EMT (Kalliolias and Ivashkiv, 2016). 
 Affected pathways 
4.1.6.1. JAK-STAT3 signalling pathway 
The signal transducer and activator of transcription (STAT) family of transcription factors 
includes a total of 7 members, split into two groups. The first group is activated by only 
a few cytokines and its primary functions include interferon-gamma (IFN-γ) signalling 
and T cell development (Siveen et al., 2014). The second group, which includes STAT1, 
STAT3 and STAT5, play a role in cell cycle progression and apoptosis, and are thus 








Figure 4.4. Overview of tumour necrosis-alpha (TNF-α) signalling 
A. TNF-α exists as a transmembrane protein (tTNF) which can be solubilized (sTNF) if 
cleaved by TNF-α-converting enzyme (TACE). 
B. TNF-α receptor 1 (TNFR1) can bind both soluble and membrane-bound TNF-α. Once 
the ligand is bound, and adaptor called TNFR1-associated death domain (TRADD) is 
recruited. This can then lead to the formation of a number of signalling complexes, 
initiating distinct signalling pathways, including proliferation and survival (type I), 
apoptosis (type II), necroptosis (type III). Additionally, membrane bound TNF-α can 
also interact with TNFR2, which recruits the TNFR-associated factor 2 (TRAF2) adaptor 
molecule, leading to the formation of complex type I and initiating signalling pathways 
involved in proliferation and survival. Adapted from Kalliolias and Ivashkiv (2016). 
Legend: AKT – protein kinase B; MAPK – mitogen-activated protein kinase; 





The Janus kinase (JAK)/STAT3 pathway can be activated by ligand-binding to either 
cytokine-specific receptors, G-coupled receptors or toll-like receptors (Rakoff-Nahoum 
and Medzhitov, 2009; Ritter and Hall, 2009; Jones et al., 2011). STAT3 can be activated 
by a variety of cytokines (including IL-6 and TNF-α), growth factors, carcinogens, and 
environmental stress (Park et al., 1996; Heinrich et al., 1998; Miscia et al., 2002; Carl et 
al., 2004; Chen et al., 2008a). The binding of a ligand to its receptor, for example IL-6, 
leads to the formation of a hexameric IL-6 receptor complex (formed by a IL-6Rβ 
homodimer, and two IL-6/IL-6Rα heterodimers) (Zhong et al., 1994; Catlett-Falcone et 
al., 1999; Heinrich et al., 2003). JAK is then activated and leads to the phosphorylation 
of IL-6Rβ, which in turn activates cytoplasmic STAT3 (Zhong et al., 1994; Catlett-Falcone 
et al., 1999; Heinrich et al., 2003). STAT3 forms dimers and is translocated to the nucleus, 
where it initiates a variety of processes (Chen et al., 2008a; Chen et al., 2008b; de Araújo 
et al., 2008; Weerasinghe et al., 2008). An overview of the pathway can be seen in Figure 
4.5. 
As STAT3 is a crossing point between signalling pathways linked to oncogenesis, it is 
considered an oncogene (Bromberg et al., 1999). In healthy cells, the process has a 
transient nature and is tightly regulated through negative feedback, while constitutive 
activation is seen in a wide range of cancerous cell lines (Sartor et al., 1997; Abdulghani 
et al., 2008; Masciocchi et al., 2011). This activation is a result of paracrine activation of 
STAT3 with growth factors and cytokines, or mutations in the negative-feedback 
proteins (Greenhalgh and Hilton, 2001). 
Activated STAT3 can promote proliferation by directly affecting cell cycle regulation 
proteins, such as cyclin D1, which is involved in the transition between G1 and S-phase 
(Kanda et al., 2004; Xiong et al., 2008; Bollrath et al., 2009; Jarnicki et al., 2010). The 
ability of STAT3 to aid survival through apoptosis-evasion has been demonstrated in 
multiple myeloma and colorectal cancer, where anti-apoptotic signals driven by 
constitutive STAT3-expression were seen (Yu and Jove, 2004; Xiong et al., 2008). A 
variety of cytokines and growth factors both induce STAT3 signalling and are produced 
as a result of its activation; if constitutive activation of STAT3 is present, this leads to a 








Figure 4.5. Overview of the JAK/STAT3 signalling pathway 
The JAK/STAT pathway is key in the regulation of a number of different pathways 
involved in a range of processes, including the RAS/RAF/ERK pathway which can cause 
changes in proliferation and differentiation, the PI3K/AKT pathway which is involved 
in survival and cell cycle control. The phosphorylation of STAT3 by JAK leads to 
translocation of STAT3 to the nucleus where it is involved in the translational 
regulation of a range of genes, e.g. cytokines, MCL1 which plays a role in apoptosis 
and SOCS3 which is involved in a negative feedback loop of the JAK/STAT3 pathway. 
Legend: AKT – protein kinase B; ERK – extracellular signal-regulated kinase; 
JAK – Janus kinase; L – ligand; MCL-1 – myeloid cell leukaemia 1; MEK – mitogen-
activated protein kinase kinase; mTOR – mammalian target of rapamycin; 
P – phosphorylation; PI3K – phosphoinositide 3-kinase; RAF – rapidly accelerated 
fibrosarcoma; RAS – rat sarcoma protein; SHP-2 – protein-tyrosine phosphatase 1D; 







Prostate cancer cell culture studies have shown that if treated with constitutively 
expressed STAT3, cells produce lower levels of E-cadherin, which in turn increases 
migration (Azare et al., 2007). STAT3 signalling is known to play a role in metastasis by 
activating multiple matrix metalloproteases (e.g. MMP-9 in breast cancer and MMP-1 in 
colorectal cancer) which are also involved in migration (Dechow et al., 2004; Tsareva et 
al., 2007). And finally, STAT3-activation is suspected to play a role in angiogenesis, by 
driving autocrine vascular endothelial growth factor (VEGF) activation (Schaefer et al., 
2002). 
4.1.6.2. Nuclear factor-kappa B pathway 
Originally discovered as a nuclear factor which binds the kappa light-chain of 
immunoglobulins in B cells, NF-κB was later shown to be expressed by a wide range of 
cells (Sen and Baltimore, 1986; May and Ghosh, 1998). Currently, there are five known 
members of the NF-κB family: RelA, RelB, c-Rel, NF-κB1 (also called p105 due to its size; 
once processed becomes p50) and NF-κB2 (p100, becomes p52 post-processing), with 
the latter two being secreted as precursor proteins which undergo proteolysis before 
they can be activated (May and Ghosh, 1998). In normal cells, these factors form homo- 
or heterodimers which are bound to members of the IκB (inhibitors of NF-κB) family 
(Hoesel and Schmid, 2013). While bound to the inactivators, the ability of NF-κB to bind 
DNA and initiate transcription is inhibited, and its ability to translocate to the nucleus is 
decreased (Hoesel and Schmid, 2013). 
For NF-κB to become active, it either needs to be released by the inhibitors or NF-κB1 
needs to be proteolyzed by a series of reactions, including ubiquitination of the target 
regions, which is driven by phosphorylation via IκB kinases (IKKs) and NF-κB essential 
modulator (NEMO). A wide range of reactions can lead to the activations of those IKKs, 
including self-activation, MAP3K-family members, TGF-β-activating kinase 1 (Nakano et 
al., 1998; Ninomiya-Tsuji et al., 1999; Tan et al., 1999; Wu et al., 2000; Hayden and 
Ghosh, 2008; Schmid and Birbach, 2008). 
There are two main NF-κB activation pathways. The canonical pathway can be triggered 
by stress (including physical, physiological or oxidative), TLRs, IL-1R, TNFRs, and ligands 
such as TNFα, lipopolysaccharides (LPS), IL-1β, as well as the MAPK/ERK pathway (Yeh 
et al., 2004; Perkins and Gilmore, 2006; Schmid and Birbach, 2008; Hoesel and Schmid, 




(Hoesel and Schmid, 2013). The alternative pathway or non-canonical pathway is 
activated by a range of receptors, including TNFR and it activates IKKα (Xiao et al., 2001). 
Further “atypical” pathways of activation also exist, e.g. genotoxic stress-driven NEMO-
ubiquitination or epidermal growth factor receptor (EGFR) tyrosine related activation of 
NF-κB, as seen in ovarian cancer (Huang et al., 2003; Oeckinghaus and Ghosh, 2009; 
Alberti et al., 2012). Once the IKKs are active, IκBs are released and this allows NF-κB 
dimers to be shifted to the nucleus where they can recognize specific DNA sequences 
and bind them, leading to the possible activation of vast numbers of genes (Hoesel and 
Schmid, 2013). A summary of the canonical and alternative pathways can be found in 
Figure 4.6. 
The inactivation of NF-κB-driven transcription is done mainly through a negative 
feedback loop, where NF-κB inhibitors are upregulated as a result of NF-κB activation; 
once synthesised, the inhibitors bind NF-κB and remove it to the cytosol (Klement et al., 
1996; Pahl, 1999; Oeckinghaus and Ghosh, 2009). This feedback system is effective in 
the case of acute inflammation, where NF-κB levels are tightly controlled, but in cases 
of chronic inflammation, complete deactivation of NF-κB cannot be achieved, as it is 
overrun by activating stimuli (Hoesel and Schmid, 2013). 
In the context of cancer, inflammation plays two contradictory roles. As a key player in 
tumour-immunosurveillance, NF-κB activation triggers a strong immune response, 
particularly involving cytotoxic cells, which neutralise any potential cancerous cells 
(Smyth et al., 2006; Disis, 2010). However, not all cancer cells can be identified, as some 
can escape the immune system, which seems to be more common in the presence of 
chronic inflammation, where constitutive moderate NF-κB levels are present (Dunn et 
al., 2004). Other than chronic infection which creates a cytokine-rich environment, NF-
κB levels can be elevated due to mutation in the NF-κB pathway or mutations in genes 
which activate the signalling pathway (Ben-Neriah and Karin, 2011). Constitutive 
activation can then lead to pro-tumorigenic effects, for example by activating 
antiapoptotic genes, which aim to aid cells in resisting inflammation-related stress; it 
also leads to increased synthesis of multiple cytokines (IL-1β, IL-6, IL-8, TNF-α) and to 








Figure 4.6.Overview of the NF-κB signalling pathway. 
There are two pathways of nuclear factor-kappa B (NF-κB) activation. The classical 
pathway is activated by a range of receptors, including toll-like receptors (TLRs), 
tumour necrosis factor receptors (TNFRs), antigens and bacteria. Once activated the 
receptors recruit the necessary adaptor molecules with in turn activate the IKK 
complex (consisting of IKKα, IKKβ and NEMO). IKK in turn phosphorylates the IκBα, 
p105 and RelA complex, which leads to the degradation of IκBα and the processing of 
p105 to p50. The RelA/p50 dimer is then translocated to the nucleus, where it 
activates the transcription of a range of genes. 
The alternative pathway involves the activation of an IKKα dimer by NF-κB-inducing 
kinase (NIK), which in turn phosphorylates p100. RelB then combines with the 
processed p100 to form a RelB/p52 complex which is translocated to the nucleus 
where it initiates transcription. 
Legend: IκB – inhibitor of kappa-B; IKK – IκB kinase; IL1R – interleukin-1 receptor;  






as a defence mechanism; these ROS can then cause DNA damage in cells and initiate 
oncogenesis (Liou and Storz, 2010). Furthermore, studies have shown the NF-κB aids 
EMT by altering expression of MMPs, and also has the potential to assist in the creation 
of blood supply to the tumour site by upregulation of receptors and angiogenic factors, 
such as VEGF (Yoshida et al., 1999; Huber et al., 2004). 
Interestingly, in the case of hepatocellular carcinoma, the role of the NF-κB pathway 
differs depending on the original cause of cancer: in inflammation-related tumours NF-
κB is seen as an anti-apoptotic pro-cancer factor, but it behaves as a tumour suppressor 
if the cause is chemical (Karin, 2009). 
NF-κB has been shown to directly bind multiple transcription factors, including STAT3, 
SMAD3 and SMAD4 (Hoesel and Schmid, 2013). NF-κB and STAT3 work together on the 
regulation of anti-apoptotic and cell cycle-related genes, as well as on controlling 
cytokine production (Dauer et al., 2005; Yang et al., 2007). STAT3 has the potential to 
acetylate NF-κB and thus retaining it in the nucleus (Hoesel and Schmid, 2013); in an 
environment of constant stimulation (such as tumour microenvironment or chronic 
inflammation) this leads to increased synthesis of cytokines, which in turn activate 
STAT3, creating a cycle of constant activity of both STAT3 and NF-κB (Lee et al., 2009). 
4.1.6.3. MAPK cascades 
MAPK (mitogen-activated protein kinase) pathways consist of an intracellular signalling 
network involved in a variety of cellular processes, including proliferation, growth, stress 
response and apoptosis (Pimienta and Pascual, 2007; Raman et al., 2007; Shaul and 
Seger, 2007). Each cascade consists of three main kinases (MAPK kinase kinase or 
MAP3K, MAPK kinase or MAPKK, and MAPK), which act by sequential phosphorylation, 
leading to the activation of a target proteins by MAPK or accessory activators (Plotnikov 
et al., 2011). There are a number of MAPK-cascades identified: ERK1/2, JNK, and p38-
MAPK, and an overview can be found in Figure 4.7. 
The ERK1/2 cascade is activated by numerous extracellular signals via a wide range of 
receptors. In most cases, this cascade is activated by the Ras GTPase, which recruits 
MAP3K to the site, which leads to the activation of the induction cascade (Niault and 









Figure 4.7. MAPK cascades overview. 
The mitogen-activated protein kinase (MAPK) cascades include a range of different 
kinases which activate each other forming a kinase cascade. In general, a stimulus 
causes activation which initiates the MAPK-kinase kinase (MAPKKK), triggering a 
cascade of downstream phosphorylation/activation reactions which conclude with 
cellular response. 
Legend: JNK – c-Jun N-terminal kinase; MAPKAPK – MAPK-activated kinase;  
MAPKK – MAPK-kinase; MEK – MAPK/ERK kinase; MEKK – MEK-kinase; MKK – dual 
specificity MAPK; MLK – mixed lineage kinase; MNK – MAPK-interacting protein 
kinase; MSK – Mitogen and stress activated protein kinase; RAF – rapidly accelerated 
fibrosarcoma; RAS – rat sarcoma protein; RSK – ribosomal s6 kinase; TRAF – tumour 






variety of pathways which regulate a broad range of cellular processes, including 
proliferation, survival, apoptosis (Yoon and Seger, 2006). If dysregulated, the pathway 
plays a role in more than 50% of cancers, and irregular activation of the pathway was 
seen with no mutations present in any of its components, indicating a role of the ERK1/2 
cascade in oncogenesis induced by pathway activators (Dhillon et al., 2009; Montagut 
and Settleman, 2009). 
The JNK pathway was thought to be solely involved in stress response, where the 
alternative name SAPK (stress-activated protein kinase) originated; it was later shown, 
that like all MAPKs, the JNK pathway is also activated by a wide range of stimuli (Davis, 
1994; Johnson and Nakamura, 2007; Weston and Davis, 2007; Bogoyevitch et al., 2010). 
In this pathway, GTPases are activated, similarly to above, and lead to MAP3K activation, 
and the effects can be seen primarily in the nucleus where they are involved in 
transcription regulation of apoptosis, immune response, etc (Weston and Davis, 2007; 
Dhanasekaran and Reddy, 2008; Plotnikov et al., 2011). Involvement of JNK has been 
observed in multiple cancers, including upregulation of some members of the pathway 
in prostate cancer (Konishi et al., 2008; Wagner and Nebreda, 2009). 
Through an alternative pathway, MAPK p38 aids in the activation of apoptosis, 
senescence, cell cycle progression and cellular survival (Sohn et al., 2007; Maruyama et 
al., 2009; Thornton and Rincon, 2009) 
As a whole, the MAPK-related pathways are involved in regulation of transcription 
factors and transcription, chromatin remodelling, nuclear import, regulation of nuclear 
receptors (such as the androgen receptor) (Plotnikov et al., 2011). 
4.1.6.4. Epithelial-mesenchymal transition 
Epithelial and mesenchymal cells represent two main mammalian cell types. While 
epithelial cells form continual layers with cellular interactions, tight junctions at apical 
and lateral cells within the layers, polarised distribution of organelles within the cells 
and decreased motility, mesenchymal cells do not form layers and have loose or no 
interactions with other cells, lack polar organisation of their organelles and are motile, 
which in the context of cancer allows invasiveness (Martin-Belmonte and Perez-Moreno, 
2012; Ullah et al., 2015). During EMT, some epithelial cells acquire mesenchymal 




allows the cells to return to epithelial morphology and behaviour (reviewed in detail by 
Heerboth et al. (2015)). 
While EMT plays a role in cancer, its primary function is seen during embryonic 
development, where it is involved in important milestones such as gastrulation and 
neural crest formation (Nakaya and Sheng, 2008; Theveneau and Mayor, 2012). EMT-
like processes can also be induced by ERK in wound healing and by EGF after each 
menstrual cycle during post-ovulation ovarian epithelium surface repair (Ahmed et al., 
2006; Arnoux et al., 2008). Despite the similarities in EMT during normal physiological 
processes and cancer, it is important to note that under normal circumstances EMT is 
tightly controlled; in the case of cancer-related EMT, the order of events is not regulated 
and may be a result in dysregulation of upstream EMT-inducing signalling pathways 
(Micalizzi et al., 2010). 
One of the hallmarks of EMT is the loss of E-cadherin. E-cadherin (epithelial cadherin or 
CDH1) is an epithelial cell calcium-dependent cell-cell adhesion molecule. There is tight 
regulation on E-cadherin expression, and the CDH1 gene is considered to be a tumour 
suppressor, as studies have shown loss of CDH1 expression in a range of cancers; in vitro 
studies have demonstrated that re-expression of CDH1 leads to decreased cancer 
aggressiveness, and germline mutations in the gene have been linked to hereditary 
cancers (Vleminckx et al., 1991; Guilford et al., 1998; Suriano et al., 2003). 
In cancer, E-cadherin loss can be due to a mutation, silencing of expression through 
hypermethylation, abnormal post-translational modifications, proteolysis or a result of 
overexpression of E-cadherin suppressors, such as Snail and Slug; once E-cadherin levels 
are decreased, it leads to decreased cellular adhesion (due to loss of tight junctions and 
desmosomes) and increased motility (Berx et al., 1998; Larue and Bellacosa, 2005; Qin 
et al., 2005; Caldeira et al., 2006; Huang et al., 2012; Serrano-Gomez et al., 2016). When 
E-cadherin levels decrease, a “cadherin switch” occurs, and the levels of N-cadherin 
(neural cadherin or CDH2) increase, which leads to altered cell adhesion, loss of 
association with other epithelial cells and increased affinity for mesenchymal cells 
(Wheelock et al., 2008; Yilmaz and Christofori, 2009; Theveneau and Mayor, 2012). 
Furthermore, a change also occurs in cytoskeletal genes, such as the type III 
intermediate filament vimentin, which then causes vimentin-driven increase in cell 




suggested that in addition to its upregulation playing a role in cellular migration, 
vimentin may also aid bacterial invasion into the host cell (Mak et al., 2012). Another 
change occurring during EMT is the increased expression of MMPs, which further assist 
the loss of adhesion by targeting the extracellular domain of CDH1 (Nisticò et al., 2012). 
Multiple transcription factor repressors are involved in the initiation of EMT, including 
Snail, Slug, Twist (Serrano-Gomez et al., 2016). These factors induce the expression of 
each other and work synergistically on target sites (Peinado et al., 2007). A brief 
summary of EMT can be found in Figure 4.8 
Snail and Slug both repress epithelial genes by binding to E-box (enhancer-box) 
sequences on DNA. For example, Snail binding an E-box proximal to the CDH1 promoter 
region leads to the recruitment of a wide range of factors and results in epigenetic 
repression of its expression (Batlle et al., 2000; Cano et al., 2000; Peinado et al., 2007; 
Xu et al., 2009). SNAI1 and SNAI2 expression can be activated by a range of pathways, 
including TGF-β and Wnt/β-catenin, depending on the physiological context; activated 
by MAPK-signalling, Snail can activate the synthesis of MMPs, while if driven by SMAD3-
SMAD4 it can cause E-cadherin suppression (Jordà et al., 2005; Vincent et al., 2009). 
Inhibition of SNAI1 phosphorylation by Wnt/β-catenin, PI3K-AKT, and NF-κB signalling 
increases its stability (Yook et al., 2006; Wu et al., 2009).  
Twist is a member of the basic helix-loop-helix (bHLH) family of transcription factors. It 
can drive the “cadherin switch” by downregulating E-cadherin (e.g. by E-box 
suppression, leading to changes in morphology, increased migration and upregulation 
of vimentin) and inducing CDH2 expression in a process independent of Snail (Yang et 
al., 2004; Yang et al., 2008; Xu et al., 2009; Yang et al., 2010; Yang et al., 2012). TWIST 
expression can be induced by a range of signals, HIF-1α in hypoxia or β-catenin as a 
response to stress, both of which can lead to oncogenesis (Farge, 2003; Yang et al., 2008) 
 Angiogenesis 
The ability of tumours to induce angiogenesis is one of the hallmarks of cancer and it is 
necessary for the progression of malignancy (Hanahan and Weinberg, 2011b). The 
generation of new blood vessels allows nutrients to reach the cancer cells. The new 
vessels can also be used as means to spread the tumour around the body during 






   
 
 
Figure 4.8. Summary of epithelial-mesenchymal transition 
Epithelial cells normally express E-cadherin but when they undergo EMT that 
expression is lost and is replaced by increase in N-cadherin and vimentin. A number 
of signalling pathway, such as Wnt/β-catenin, TGF-β-signalling, JAK/STAT3 signalling 
can lead to an increase in Snail and Slug production which in turn can initiate EMT; 
similarly, hypoxia can increase the production of Twist which also has the ability to 
drive EMT. 
Legend: JAK – Janus kinase; NF-κB – nuclear factor-kappa B; STAT3 – signal transducer 







be split into two categories. The de novo synthesis of blood vessels, seen mainly during 
development is called vasculogenesis; in contrast, if blood vessels originate from pre-
existing blood vessels, the process is called angiogenesis (Vallée et al., 2017). 
The main driver of angiogenesis is hypoxia, or the lack of adequate oxygen supply to 
highly proliferative cells (LaGory and Giaccia, 2016). Oxygen-sensitive prolyl 
hydroxylases are then activated in the hypoxic cell, and they hydroxylate hypoxia-
inducible factor 1 subunit α (HIF-1α) (Bruick and McKnight, 2001). HIF-α can then form 
a dimer with the constitutively expressed HIF-1β subunit; the newly formed complex is 
translocated to the nucleus where it can initiate the transcription of a range of signalling 
pathways involved in immune response (both innate and adaptive immunity, with 
pathways including NF-κB, JAK-STAT3, etc.) and angiogenesis-inducing growth factors 
(Pugh and Ratcliffe, 2003; Ziello et al., 2007; Gorlach and Bonello, 2008; Demaria and 
Poli, 2012). The main angiogenesis promoting factor induced is VEGFA, however, 
placental growth factor (PlGF), fibroblast growth factors (FGF-1, FGF-2, FGF-7), EGF, 
insulin-like growth factor (IGF), platelet-derived growth factor (PDGF) and transforming 
growth factor β (TGF-β) also play a role (van Cruijsen et al., 2005; Lieu et al., 2011; 
Shibuya, 2011; Kim et al., 2012). An overview of the process can be seen in Figure 4.9. 
Once VEGFA is released from the hypoxic cell, it interacts with its receptor, VEGFR2, 
located on the surface of endothelial cells (Abhinand et al., 2016). This leads to the 
differentiation of motile endothelial cells, called tip cells, which begin to break down the 
surrounding extracellular matrix and initiate the formation of vascular sprouts (De 
Palma et al., 2017). Additional factors, such as angopoietin-2 (ANGPT2) and delta ligand- 
like 4 (DLL4) are also necessary for the tight control of the process. In addition to 
hypoxia, some oncogenes can also initiate the process (Felcht et al., 2012). 
Thrombospondin-1 (TSP-1) acts as an inhibitor of the endothelial tip cells (Lawler, 2002). 
Pericytes are accessory cells which are present in small blood vessels. Their main 
function is the regulation of survival and proliferation of endothelial cells, as well as 






Figure 4.9. Hypoxia induced angiogenesis 
Hypoxia activates prolyl hydroxylases (PH) which activate the α subunit of hypoxia 
inducing factor-1 (HIF-1α). HIF-1α then forms a dimer with HIF-1β, and the dimer is 
translocated to the nucleus where it induces the production of a range of molecules, 
including transforming growth factor beta (TGF-β), vascular endothelial growth factor 
A (VEGFA), matrix metalloproteinases (MMPs), epidermal growth factor (EGF), 
fibroblast growth factor (FGF), cyclooxygenase-2 (COX-2) and placental growth factor 
(PlGF). These molecules are then secreted by the hypoxic (cancer) cell. The MMPs can 
target the extracellular matrix (ECM) which allows endothelial tip cells to become 
motile. The remaining growth factors can interact with receptors on the surface of 
endothelial cells, initiating a range of processes, including survival, proliferation, 
migration. The signals also cause the production of platelet-derived growth factor 
(PDGF) by the endothelial cells which is secreted and can interact with pericytes, 
which are important for the formation and sustainability of the basal layer of small 
blood vessels. 
Legend: EGFR – EGF receptor; FGFR – FGF receptor; PDGFR – PDGF receptor;  





4.1.7.1. Angiogenesis and cancer 
Before progression to cancer, tumours originate as hyperplasia, which can then acquire 
mutations to become a carcinoma in situ (De Palma et al., 2017). What both these states 
have in common is that the basal layer of cells is intact, and the cancer cells cannot 
interact with the stromal cells. As a result, angiogenesis is rarely found in these two 
cancer-precursors. Once the cancer becomes invasive and escapes the basal layer it can 
then interact with the stroma, activating the so-called “angiogenic switch”, i.e. initiating 
angiogenesis (Bergers and Benjamin, 2003). It is worth noting that blood vessel created 
within a tumour differ from healthy vessels. They are larger in size, with distorted 
morphology and increased branching; this results in issues with blood flow and can 
cause the vessels to leak (Huang et al., 2004; Baluk et al., 2005). 
4.1.7.2. Angiogenesis and inflammation 
Chronic inflammation and chronic infection also have the potential to induce 
angiogenesis. When the JAK/STAT3 pathway is activated, this causes an increase in the 
production of the pro-angiogenic factor VEGFA, and also leads to an increase in IL-6 
levels, which drives further induction of the JAK/STAT3 pathway (Thomas et al., 2015). 
Additionally, infection summons leukocytes to the site, including monocytes. When the 
monocytes follow the chemokine signalling and extravasate to the location where the 
signalling originates, they differentiate into macrophages (with the help of the 
macrophage colony-stimulating factor or M-CSF) (Bender et al., 2004). The tumour 
associated macrophages can then secrete a range of pro-angiogenic factors, including 
VEGFA, PlGF, VEGFC, as well as a number of cytokines which can summon more 
inflammatory cells to the site (Lewis et al., 2000; Baer et al., 2013). The macrophages 
can also initiate the Wnt/β-catenin signalling in the endothelial cells, thus activating the 
tip cells and initiating migration and sprout formation (Newman and Hughes, 2012). 
Another key player in inflammation, cyclooxygenase-2 (COX-2), is commonly 
upregulated in cancer and precursor neoplasia, including prostate cancer and prostate 
intraepithelial neoplasia (Khor et al., 2007). COX-2 can also promote angiogenesis and 
cancer progression in general, as it can induce the production of MMP-2 and MMP-9 
(which are involved in motility), VEGFA, FGF and PDGF (Fosslien, 2001; Albini et al., 2012; 




and other nonsteroidal anti-inflammatory drugs have been suggested as possible anti-
angiogenic preventative treatment (Sooriakumaran and Kaba, 2005). 
Using molecular techniques, this chapter investigates the dysregulation of inflammatory 
and EMT-related genes, which have the potential to induce oncogenesis, in acute and 
chronic infection models with different phylotypes of P. acnes and P. granulosum, as a 
control strain. It also looks at cellular and bacterial behaviour in the different infection 
models, as well as anchorage-independent growth and migration of chronically infected 
cells. To investigate whether infection has the potential to cause increased endothelial 
cell proliferation rates, endothelial cells were treated with conditioned medium from a 
range of long-term infection models. This allowed for comparison of the angiogenic 
potential of different phylogenetic strains. 
4.2. Materials and Methods 
 Cell and bacterial culture 
RWPE-1 prostate epithelial cells were cultured as outlined in Section 2.1.1. P. acnes 
strains selected in Chapter 3, P. avidum and P. granulosum were routinely cultured as 
described in Section 2.2.1. Infection models were set up following the protocol outlined 
in Section 2.3.1, using multiplicity of infection (MOI) of 15:1, as optimised in Chapter 3 
(Section 3.3.5). Acute infection models were defined as 24, 48 and 72 hours and were 
performed as seen in Section 2.3.2. Chronic infections lasted 15 or 30 days, and were 
maintained as described in Section 2.3.3. 
Human dermal microvascular endothelial cells (HDMEC, HMEC-1 cell line) were routinely 
cultured in Medium 200 supplemented with low serum growth supplement (LSGS) as 
described in Section 2.1.1. 
 RWPE-1 cell viability counts and bacterial counts 
Trypan blue viability counts were performed as described in Section 2.1.1 and bacterial 
counts were done using the Miles Misra counting method outlined in Section 2.2.2. 
 Intracellular bacterial counts 
Intracellular bacterial counts were performed as described in Section 2.3.6, following 




 LDH assay 
The Pierce lactate dehydrogenase (LDH) cytotoxicity assay (ThermoFisher Scientific, UK) 
was used to assess the cytotoxic effect different strains have on prostate epithelial cells 
following the manufacturer’s protocol (summarised in Section 2.3.5). 
 Molecular methods 
To analyse the molecular dysregulation in infected RWPE-1 cells, RNA was extracted 
using the RNeasy Plus Mini-Kit (QIAGEN, Germany) following manufacturer’s protocol 
(see Section 2.4.2.1). RNA was quantified as described in Section 2.4.1.1 for short term 
infections using Nanodrop 1000 (ThermoScientific, UK) or following Section 2.4.1.2 for 
long-term infection using the Qubit® BR Assay kit (Invitrogen, UK). cDNA was synthesized 
as outlined in Section 2.4.2.3 and qPCR was performed following Section 2.4.2.4.1 using 
the reference gene HPRT1, as optimised in Chapter 3, Section 3.3.10. Ratio change was 
calculated using the formula shown in Section 2.4.2.4.3 and efficiencies from Table 3.6 
in Chapter 3. Any change of more than 2-fold was considered significant. 
 Soft agar assays 
Soft agar assays were used to assess anchorage independent growth of RWPE-1 cells 
following a long-term infection. The assays were prepared, stained and imaged following 
Section 2.3.7. 
 Immunofluorescence methods 
Immunofluorescence staining using the PathScan® Duplex IF kit (Cell Signalling) and 
analysis were performed as described in Section 2.3.8. 
 Scratch assay 
Scratch assays were used to assess cell migration. They were performed as outlined in 
Section 2.3.9 and imaged every 24 hours until the scratch had healed. 
 MTT assay 
MTT assays were performed as described in Section 2.3.10. Briefly, the HDMEC cells 
were seeded at 50,000 cells/ml (5 x 104 cells/well), as optimised in Chapter 3 (Section 
3.3.12) and were left overnight to attach. The medium was then replaced with a serial 
dilution of Day 30, long-term infection conditioned medium (and incubated for 72 hours 
(as optimised in Chapter 3, Section 3.3.14) at 37°C, 5% CO2. The conditioned medium 




amount of conditioned medium available (neat, 1:10, 1:50, 1:100, 1:200, 1:500, 1:1,000, 
1:5,000, 1:10,000 and 1:100,000). As a positive proliferation control, the HDMEC cells 
were grown in complete Medium 200 containing 20% (v/v) FBS, and as a negative 
control, the cells were treated with etoposide to a final concentration of 2.5 μM (as 
optimised in Chapter 3, Section 3.3.13). MTT was added to each well to a final 
concentration of 1.2 mM and was incubated for 3 hours. The formed formazan was then 
solubilised with 100 μl DMSO, the plates were mixed and analysed at 570 nm (Epoch, 
BioTek Instruments, US). Student’s t-test (2-tailed) was used to assess the effect 
treatment with conditioned medium from chronic infection models with a range of P. 
acnes strains had on the HDMEC cells in comparison to cells treated with conditioned 
medium from uninfected controls. 
4.3. Results 
 Acute infection models 
4.3.1.1. Cell counts and viability 
Short term infections investigated bacterial and epithelial cell behaviour over a 72-hour 
period (Figure 4.10). Overall, in all short-term P. acnes and P. granulosum infections the 
number of cells/ml increased over time and the cells remained viable. There was no 
significant difference in the number of RWPE-1 cells/ml between infected and non-
infected “mock” infection models at the 24-hour time point. Cells infected with ST27 
and NCTC10390 displayed significantly lower number of cells/ml at 48 hours compared 
to untreated controls, although the significance was lost at 72 hours (p = 0.0199, Figure 
4.10.C and p = 0.0028, Figure 4.10.E, left) and thus it is likely and experimental artefact, 
rather than a genuine result. Cells infected with NCTC737 and B3 showed counts 
significantly lower than untreated controls counts solely at 72 hours (p = 0.0047, Figure 
4.10.B and p < 0.0001, Figure 4.10.D, left, respectively). In cells infected with P. 
granulosum, there was a significant difference in cells/ml at both 24 (p = 0.0142) and 48 
hours (p = 0.0231) but the significance was lost by day 3 (Figure 4.10.G, left). In the case 
of P. avidum acute infection, there was no significant difference at 24 hours, but the cell 
numbers decreased significantly at 48 hours (p = 0.0065) and were undetectable by 72 
































































Figure 4.10. RWPE-1 cell counts and viability (left) and bacterial counts (right) in 
short-term infections 
Left: RWPE-1 cell count (bars) and viability count (lines) values representing 
uninfected (“mock”; grey) and infected cells (orange). Right: bacterial counts. Change 
in the counts presented for each infection model at T0, 24, 48 and 72 hours. Data 
presented as mean of three biological replicates, +/- standard error. * p < 0.05;  
** p < 0.01; *** p < 0.001. 
A. 00035; B. NCTC737; C. ST27; D. B3; E. NCTC10390; F. CFU2; G. P. granulosum;  
H. P. avidum. 
The values for T0 (green) represent counts prior to infection, used to calculate the 
amount of bacterial suspension needed to achieve MOI 15:1, and are thus the same 





In cells infected with NCTC10390, CFU2 and P. granulosum, there was no significant 
difference in cell viability for the duration of the experiment (Figure 4.10.E., Figure 
4.10.F and Figure 4.10.G, left). Cells infected with ST27 had significantly lower viability 
at time points 24 and 48 hours (p = 0.0285 and p = 0.0061, respectively), but the values 
did not significantly differ at 72 hours, although they were still lower for infected cells 
(Figure 4.10.C, left). Cells infected with 00035 also displayed viability lower than “mock” 
infections, which became significant at 48 hours (p = 0.034) and remained significant at 
day 3 (p = 0.005; Figure 4.10.A, left). In the P. avidum infection model, there was a rapid 
decrease in viability and there were no viable cells at the 72-hour time point (Figure 
4.10.H, left). 
4.3.1.2. Bacterial counts 
The decrease in viability in the P. avidum infection model directly correlated with the 
rapid increase of bacterial counts in the infection model, increasing from 3.7 x 107 
CFU/ml at 24 hours to 1 x 109 CFU/ml at day 3 (Figure 4.10.H, right). The counts for 
NCTC10390 underwent a rapid decrease at the 24-hour time point compared to the 
initial inoculum, however, the counts then began to rise slowly, reaching 5 x 105 CFU/ml 
at 72 hours (Figure 4.10.E, right). Both 00035 and ST27 demonstrated an initial decline, 
which was more prominent in 00035, and then increased slowly overtime to 4 x 106 and 
7 x 106 CFU/ml, respectively (Figure 4.10.A and Figure 4.10.C, right). NCTC737 and B3 
both increased steadily for the duration of the experiment with values at 72 hours of 3.8 
x 107 and 6.2 x 107 CFU/ml, respectively (Figure 4.10.B and Figure 4.10.D, right). CFU2 
demonstrated an initial increase, followed by a small dip in numbers at 48 hours and a 
further increase at 72 hours; however, due to the size of the error bars these numbers 
can be interpreted as an initial increase, followed by a plateau (Figure 4.10.F.). In 
contrast with the P. acnes strains and P. avidum, P. granulosum showed a decline in 
numbers overtime, with counts at 72 hours more than 10-fold lower than the initial 
inoculum (Figure 4.10.G, right). 
4.3.1.3. LDH assay 
The cytotoxicity of each strain was measured using a colorimetric LDH assay. Most 
strains were not shown to be cytotoxic, with levels below 4% (Figure 4.11). Strain 00035 







Figure 4.11. Strain cytotoxicity seen in acute infection models 
The cytotoxic effect different strains of P. acnes and P. granulosum have on RWEP-1 
prostate epithelial cells in acute infection models was assessed using an LDH assay and 
presented as percentage (%) cytotoxicity for each time point. The data is represented 
as mean value of three biological replicates. 
If the calculated value was a negative number, the % cytotoxicity was presented as 0% 





the opposite was seen with strain B3 which was more cytotoxic the longer the cells were 
exposed to it (2.3% at 24 hours, 9.6% of 48 hours and 10.2% at 72 hours). The remaining 
strains showed negligible changes in cytotoxicity, and remained below 4% for the 
duration of the experiment. 
4.3.1.4. Intracellular bacterial counts 
Bacterial counts were performed on lysed RWPE-1 cells following an incubation in 
antibiotic, aiming the eradication of any extracellular bacteria. These counts were 
performed to investigate the ability of different P. acnes strains and P. granulosum to 
become intracellular in human prostate epithelial cells. While the absolute counts for 
the different strains varied at each time point, there was no statistical significance 
between time points. The strain with the highest intracellular counts was 00035 at 8 x 
104 CFU/ml (Figure 4.12). ST27, NCTC737 and B3 also displayed the ability to survive 
intracellularly with numbers above 2 x 104 for the duration of the experiment. 
NCTC10390, CFU2 and P. granulosum had intracellular counts lower than 00035 and 
ST27, with NCTC10390, having the lowest counts at 2-3 x 103 CFU/ml. 
4.3.1.5. qPCR analysis of inflammatory and EMT-related genes 
The dysregulation of a number of prostate cancer-related inflammatory genes, as well 
as genes linked with EMT was assessed using qPCR. Any fold-changes of less than 2-fold 
increase or -2-fold decrease were regarded as insignificant. Complete figures for the 
individual results for all genes and all infection models can be found in Appendix B. 
Strain 00035 induced an acute immune response, causing significant increase in the 
expression of IL6, IL8 and TNF; the levels of IL8 and TNF were highest at 24 hours and 
gradually decreased overtime. An induction of IL1B was also present, with a peak spike 
of 5-fold increase at 48h. A similar pattern was seen in SNAI1 with a 10-fold increase also 
at 48 hours, while SNAI2 showed significant downregulation at 72 hours. CDH2 
demonstrated an initial upregulation of 10-fold with values decreasing gradually over 
the time course of the experiment. 
The skin health-associated strain ST27 caused a significant increase in all inflammatory 
genes with values rising over time, and only TGFB showing significance solely at 72 







Figure 4.12. Intracellular counts in acute infection models 
Intracellular counts of P. acnes strains and P. granulosum in RWPE-1 cells at 24h, 48h and 72h post-infection. Values are presented as mean of three 





however, significance was only seen with CDH2 at 24 hours (4.3-fold increase), SNAI1 at 
48 hours (3.5-fold increase) and CDH2, SNAI1 and VIM at 72 hours (14.5-fold, 6.3-fold 
and 4.7-fold upregulation, respectively). 
With the reference strain NCTC737, a significant upregulation in IL6, TNF and TGFB was 
observed, as well as a steady increase in SNAI1 for the duration of the experiment. 
The type IB strain, B3, displayed significantly upregulated IL6, IL8 and TNF, with an 
increase seen at 24h, followed by a steady decrease. IL1B was also upregulated, reaching 
a peak at 48h, however, its values were lower than the above-mentioned cytokines. Out 
of the EMT genes investigated, only SNAI1 showed any noteworthy change of 10-fold 
upregulation at 48 hours. 
Strain NCTC1090 also induced IL6 and TNF, with TNF peaking at 24 hours and decreasing 
thereafter. Significant downregulation was seen in IL1B at 24 hours and in SNAI2 at 72 
hours. 
Infection with the type III strain CFU2, led to a mild increase in TNF and IL6 levels, and a 
decrease in the expression of most other genes, including TGFB and IL8 (-10.5-fold and 
-3.4-fold decrease in expression, respectively). 
Finally, P. granulosum-infected cells expressed higher levels of all inflammatory genes 
(excluding TGFB) compared to untreated controls. In the inflammatory genes levels, a 
clear increase was seen overtime for IL1B, IL6, IL8, and there were no statistically 
significant changes in the expression of the investigated genes with the exception of 
SNAI1 with -2.6-fold decrease of at 72 hours. 
Comparing the gene dysregulation between strains, at 24 hours the cells infected with 
00035 had the highest upregulation of IL6, IL8 and TNF, with expression of these genes 
also being increased by ST27, B3 and P. granulosum. NCTC737 and NCTC10390 also led 
to an increase in IL6 and TNF. NCTC737 also caused the highest upregulation (20.6-fold) 
of TGFB at this timepoint, while CFU2 caused significant downregulation of TGFB (-10.5-
fold). IL1B expression was poorly affected by infection at 24 hours, with the only strain 
showing significant dysregulation being a 5-fold decrease caused by NCTC10390. 
Summary of the inflammatory gene dysregulation can be found in Figure 4.13.A, and 
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Figure 4.13. Gene dysregulation in short-term infection models 
Gene dysregulation in RWPE-1 cells infected with different strains of P. acnes and P. granulosum. The data is presented as mean fold change of three 
biological replicates and is normalised to non-infected controls using HPRT as a housekeeping gene. A. Inflammatory genes; B. Epithelial-





At 48 hours, strains 00035, ST27 and B3 once again led to significant upregulation of IL6, 
IL8 and TNF, while strains NCTC737, NCTC10390 and P. granulosum only caused 
significant upregulation of IL6 and IL8. CFU2 infected cells also displayed upregulation 
of IL6 and TNF but at levels lower compared to the other strains tested. IL1B was 
upregulated in cells infected with 00035, ST27, B3 and P. granulosum, and no significant 
downregulation was seen at this time point. TGFB expression was only affected by two 
strains: NCTC737 infection led to a 22.7-fold upregulation, while CFU2 caused a mildly 
significant downregulation at -2.3-fold. 
By day 3, NCTC737 had caused a 440-fold increase in the expression of IL6 compared to 
uninfected controls; an almost 300-fold increase was also observed in cells infected with 
ST27. 
Overall, IL6 was significantly upregulated in infections with all strains, with expression 
levels ranging between 5.7-fold and 440-fold. TNF exhibited high expression levels in all 
infection models with highest fold-change seen in ST27 and P. granulosum (70-fold and 
71.2-fold increase, respectively), and the lowest of 3.6-fold in cells infected with CFU2. 
IL1B levels were affected by ST27 (34-fold increase), P. granulosum (6.2-fold increase) 
and B3 (3.2-fold increase) and no downregulation was seen. IL8 expression was 
increased by infection with 00035, ST27, B3 and P. granulosum, and increased 
expression of TGFB was seen in infection models with ST27, NCTC737 and P. 
granulosum. At the 72-hour time point, only two infection models showed significant 
upregulation of all 5 inflammatory genes tested (ST27 and P. granulosum), while no 
significant downregulation in expression was seen. 
At 24 hours, dysregulation of the EMT genes investigated was within +/- 3-fold 
difference for most genes and strains. Exception to this was CDH2 cells infected with 
00035 and ST27, where the observed upregulation was 10-fold and 4.3-fold, 
respectively. SNAI1 also showed a mild increase in expression in the 00035 and B3 
infection models, with fold change of 3-fold and 2.7-fold, respectively. SNAI2 was 
downregulated 3.1-fold in cells infected with NCTC737, and VIM expression was 
decreased 3.6-fold in the CFU2 infection model. Figure 4.13.B presents heatmaps of the 




The 48-hours timepoint uncovered significant upregulation of the expression of SNAI1 
in 00035, ST27, NCTC737, and B3-infected cells (10.8-fold, 3.2-fold, 6.4-fold, and 10.6-
fold, respectively) and downregulated -3.1-fold in the CFU2 infection model. Changes 
were also seen in the expression of CDH2 in cells infected with 00035 and ST27, as well 
as in SNAI2 in the NCTC737 infection model. 
At 72 hours, significant upregulation in CDH2 was only seen in the ST27 infection model 
(14.5-fold). SNAI1 had significantly increased expression in cells infected with ST27, 
NCTC737, B3 and P. granulosum (6.3-fold, 8.1-fold, 2.8-fold and 2.8-fold, respectively). 
VIM also showed an increase with ST27 treatment (4.7-fold). Finally, downregulation in 
SNAI2 was seen in the presence of 00035 (-4.7-fold) and NCTC10390 (-3.8-fold). SNAI1 
was downregulated in cells infected with CFU2, and CDH1 expression was significantly 
decreased in the NCTC737 infection model 
 Chronic infection model 
4.3.2.1. Cell counts and viability 
Trypan blue viability counts were performed at every passage point in all long-term 
infection models for the duration of the experiment. The RWPE-1 cells remained viable 
in all chronic infection models, for the 30 days of the experiments. The NCTC10390 
infection models was only continued for 15 days due to time constraints. Overall, there 
was no significant difference in cell numbers between infected and non-infected cells 
(Figure 4.14.D, Figure 4.14.E and Figure 4.14.F, left). Where significance was seen, it was 
only in one (Figure 4.14.C, left, D20, p = 0.0476 and Figure 4.14.G, left, D20, p = 0.0057) 
or two time points (Figure 4.14.A, left, D20, p = 0.0254 and D25, p = 0.0017 and Figure 
4.14.B, D10, p = 0.001 and D30, p = 0.0422) but the significance was lost in following 
counts. The viability counts also showed no significant difference between “moc”k and 
infected cells, and again, if any significance was seen it was lost by the following time 
point (Figure 4.14). 
4.3.2.2. Bacterial counts 
Bacterial counts in the media were assessed in all chronic infection models at every 
passage time point. There were two trends seen in bacterial numbers. Strains 00035, 
























































Figure 4.14. RWPE-1 cell counts and viability (left) and bacterial counts (right) in 
long-term infections 
Left: RWPE-1 cell count (bars) and viability count (lines) values representing 
uninfected “mock” (grey) and infected cells (orange). Right: bacterial counts. Change 
in the counts presented for each infection model at T0, day 5 (D5), day 10 (D10), day 
15 (D15), day 20 (D20), day 25 (D25) and day (30). Data presented as mean values of 
three biological replicates, +/- standard error. * p < 0.05; ** p < 0.01; *** p < 0.001 
A. 00035; B. NCTC737; C. ST27; D. B3; E. NCTC10390; F. CFU2; G. P. granulosum 
The values for T0 (green) represent counts prior to infection, used to calculate the 
amount of bacterial suspension needed to achieve MOI 15:1, and are thus the same 






models, meaning the RWPE-1 cells remained challenged with bacteria for the duration 
of the experiment (Figure 4.14.A, Figure 4.14.B and Figure 4.14.D, right). In contrast, 
bacterial counts in infection models ST27, NCTC10390, CFU2 and P. granulosum, showed 
a rapid decrease, with bacteria being undetectable by day 10 in the NCTC10390 and P. 
granulosum infection models (Figure 4.14.E and Figure 4.14.G, right), by day 15 in the 
case of ST27 (Figure 4.14.C) and by day 20 in the CFU2 infection model (Figure 4.14.F, 
right). 
4.3.2.3. qPCR 
Real-time qPCR analysis was performed to investigate the dysregulation of inflammatory 
and EMT-related genes at day 15 and day 30 of chronic infections (Figure 4.15). 
Complete figures for the individual results for all genes and all infection models can be 
found in Appendix C. 
Strain 00035 caused significant increase in expression of all inflammatory genes 
investigated at day 15, namely increase in IL1B, IL6, IL8, TGFB and TNF with 13.8-fold, 
9.7-fold, 8.5-fold, 13.2-fold and 2.6-fold, respectively. Three of these genes were still 
upregulated at day 30 – IL6 (6.7-fold), IL8 (9.8-fold), and TNF (20.5-fold). 
The ST27 infection showed a mild upregulation of IL1B, IL6 and IL8 at day 15 with fold 
change of 3.1-fold, 3-fold and 3.4-fold, respectively; only a 2.2-fold increase in IL6 
expression was seen in this infection at day 30. 
NCTC737 showed significant dysregulation in all genes tested at the day 15 time point 
with downregulation seen in TNF, and increase seen in the rest of the genes. By day 30, 
the downregulation of TNF was lost, however, the rest of the genes remained 
upregulated.  
The B3-infections showed a mild upregulation of IL6, IL8 and TGFB (4.1-fold, 2.3-fold and 
3.6-fold, respectively) and a downregulation of TNF (-2.2-fold) at day 15, and an 
upregulation of all inflammatory genes at day 30 (ranging between 3.1-fold and 7.7-
fold). 
Cells infected with NCTC10390 were only sustained for 15 days, and thus dysregulation 
information is only available for this time point, showing significant increase in IL1B, IL8 
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Figure 4.15. Gene dysregulation in long-term infection models. 
Gene dysregulation in RWPE-1 cells infected with different strains of P. acnes and P. granulosum. The data is presented as mean fold 
change of three biological replicates and is normalised to non-infected controls using HPRT as a housekeeping gene. A. Inflammatory 







Infections with CFU2 demonstrated only a significant change in the expression of IL1B 
(2-fold increase) at day 15. At day 30 this infection model demonstrated an increase in 
IL1B and IL8 (2.3-fold and 3.8-fold, respectively) and a marginal decrease of IL6 
expression (-2.1-fold). 
The P. granulosum infection models only showed dysregulation of IL8 (-2.3-fold 
decrease) at day 15, and significant increase of IL6 and IL8 (19.6-fold and 4.1-fold) at day 
30. 
Only a few EMT genes were dysregulated in the infection models investigated. No 
significant changes were seen in cells infected with ST27 for the duration of the 
experiment. 
RWPE-1 cells infected with 00035 showed upregulation of below 2.5-fold for CDH2, 
TWIST and VIM at day 15, and downregulation of -2.1-fold and -2.5-fold for CDH1 and 
SNAI1, respectively. 
NCTC737-infected cells, demonstrated a decrease in the expression of CDH1 (-2-fold), 
SNAI2 (-2.6-fold) and TWIST1 (-6-fold) and a 2.9-fold increase for CDH2 at day 15; at day 
30 this infection model showed increase in CDH1, CDH2, SNAI1 and VIM (2.6-fold, 5.3-
fold, 6.6-fold and 10.4-fold respectively). 
In the B3 infection model, 3-fold upregulation of CDH2 and 2.2-fold upregulation of 
SNAI1 were seen at day 15, together with a -4.2-fold decrease in TWIST1 expression. At 
day 30 an increase was seen in all genes investigated, ranging between 2.4 and 7.3-fold. 
The NCTC10390 infection model was only investigated at the day 15 time point. All EMT 
genes tested were upregulated, with values ranging between 2-fold and 10.3-fold. 
At day 15 the CFU2 model showed a mild upregulation in two genes with fold increase 
of 2.2 and 2.1 for CDH2 and TWIST, respectively. At day 30, this infection model showed 
increased expression levels of CDH1 (4.4-fold), SNAI1 (2.1-fold), SNAI2 (2-fold), TWIST 
(2-fold) and VIM (3.1-fold).  
Finally, P. granulosum-infected cells had significant dysregulation of 2-fold in three 
genes: an increase in CDH2 and SNAI1, and a decrease in TWIST. A significant 




4.3.2.4. Soft agar assay 
Soft agar assays were used to assess whether infection leads to anchorage-independent 
growth. Soft agar assays were performed at day 15 or day 30 post-infection with 
different strains. 
No colonies were formed following most of the infections. Strains tested following a 15-
day infection included ST27, B3, NCTC10390 and CFU2 (Figure 4.16). Additionally, cells 
infected with 00035, NCTC737, ST27, B3, CFU2 and P. granulosum were also investigated 
for anchorage-independent growth following a 30-day infection (Figure 4.17). Only cells 
infected with 00035 for 30 days formed colonies in the soft agar. An average number of 
7 colonies were formed per experimental well in all three biological replicates (Figure 
4.17.G and Figure 4.17.H). 
4.3.2.5. Immunofluorescence analysis 
A commercially available immunostaining kit was used to investigate any changes in the 
expression of E-cadherin and vimentin in cells, following a long-term infection of 15 or 
30 days. 
In cells infected with B3 for 15 days there was a statistically significant increase in E-
cadherin expression (p = 0.012). There were no significant changes in E-cadherin levels 
in cells infected with ST27, NCTC10390 or CFU2 at this time point. A change of protein 
expression was also seen in vimentin levels; a decrease in the cells infected with ST27 
and an increase in the NCTC10390 infection models at the day 15 timepoint with p-
values p = 0.033 and p = 0.022, respectively (Error! Reference source not found.). 
There was no significant difference in the expression of E-cadherin and vimentin in the 
30-day infection models compared to untreated controls (Figure 4.19 and Figure 4.20). 
4.3.2.6. Scratch assays 
Scratch assays were used to assess differences in cell migration between untreated 
controls and infected RWPE-1 cells. Cells treated with mitomycin were used as controls 
in a subset of experiments to demonstrate that any wound closure is due to migration 






A B C D E 
 
    
     
F     
 
    
Figure 4.16. Soft agar assays after 15-day infections. 
No magnification images of soft agar assays set up with RWPE-1 cell following a 15-day long-term infection, showing that no colonies were formed 
following infection with the strains listed below, i.e. the cell have not acquired anchorage-independent growth. 
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Figure 4.17. Soft agar assays after 30-day infections. 
No magnification images of soft agar assays set up with RWPE-1 cell following a 30-day long-term infection, showing that no colonies were formed 
in infection models following infection with the strains A-F, i.e. the cell have not acquired anchorage-independent growth. 
A. Not infected; B. NCTC737; C. ST27; D. B3; E. CFU2; F. P. granulosum; G. 00035 (left – no magnification; right – x2 magnification); H. Number of 
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Figure 4.18. Quantified immunofluorescence of E-cadherin and vimentin following a 15-day infection 
RWPE-1 cells infected with strains of P. acnes for 15 days were used for immunofluorescence analysis of E-cadherin (green) and vimentin (red) 
protein expression. A. Mean normalised integrated density for different infection models. The data is presented as mean of three biological 
replicates, +/- SEM.  * p = 0.05; B-F. Representative images acquired under x40 magnification, with staining for E-cadherin (green) and vimentin 










Figure 4.19. Quantified immunofluorescence of E-cadherin and vimentin following 
a 30-day infection 
RWPE-1 cells infected with P. acnes strain 00035 for 30 days were used for 
immunofluorescence analysis of E-cadherin (green) and vimentin (red) protein 
expression. A. Mean normalised integrated density. The data is presented as mean 
of three biological replicates, +/- SEM. B-C. Representative images acquired under 
x40 magnification, with staining for E-cadherin (green) and vimentin (orange), and 
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Figure 4.20. Quantified immunofluorescence of E-cadherin and vimentin following a 30-day infection 
RWPE-1 cells infected with P. granulosum and strains of P. acnes for 30 days were used for immunofluorescence analysis of E-cadherin (green) and 
vimentin (red) protein expression. A. Mean normalised integrated density for different infection models. The data is presented as mean of three 
biological replicates, +/- SEM. B-E. Representative images acquired under x40 magnification, with staining for E-cadherin (green) and vimentin 





In the scratch assays prepared with cells following 15-day infection, there was no 
significant difference in wound closure rates at 24 and 48 hours post-scratch between 
uninfected and cells infected with B3, NCTC10390 and CFU2 (Figure 4.21). In cells 
treated with mitomycin, there was a significant decrease of the wound closure rate. 
Following a 30-day infection with 00035, the RWPE-1 cells did not show difference in 
wound closure rate compared to untreated controls (Figure 4.22.A). Similarly, there was 
no significant difference between mock infections and cells infected with ST27 or B3 
(Figure 4.22.C and Figure 4.22.D). Cells infected with NCTC737 showed higher wound 
closure rate compared to untreated controls at each timepoint (p = 0.0094 at 24 hours 
and p = 0.0028 at 48h, Figure 4.22.B). Finally, the cells infected with CFU2 and P. 
granulosum, exhibited significantly higher scratch healing rate at 48 hours (p = 0.034 
Figure 4.22.E and p = 0.032, Figure 4.22.F, respectively). 
4.3.2.7. MTT assays 
MTT assays were used to assess whether treatment of HDMEC cells with conditioned 
medium from long-term infection models (maintained for 30 days) with a range of 
phylogenetic strains has any effect on the proliferation of endothelial cells. To better 
compare each treatment, the absorbance reading as normalised to the untreated 
control in each experiment. The value was then used to calculate the percentage change 
compared to the untreated control. Cells treated with medium from “mock” infections 
(i.e. non-infected RWPE-1 cells) were used as a comparator and the statistical analysis 
assessed the difference between the response to different infections and non-infected 
RWPE-1 cells. Figure 4.23 presents comparison between the MTT results for HDMEC 
cells treated with medium from non-infected cells and different infection models. 
In most cases, there was no significant difference in the MTT assay results between cells 
treated with conditioned medium from infection models and medium from “mock” 
controls. An exception was seen when conditioned medium from the NCTC737 infection 
model was used, which caused a significant decrease in optical density readings at 























Figure 4.21. Scratch assays following 15-day chronic infection 
Scratch assays were performed on RWPE-1 cells following a chronic 15-day infection. 
Data is shown as mean percentage wound closure of three biological replicates +/- 
SEM, with “mock” (black) and infected cells (orange). Dotted lines represent 
mitomycin C treated controls. Images (representative images shown on the right) 
were taken at x2 magnification, with the mean scratch size at T0 and 48 hours 














































Figure 4.22. Scratch assays following 30-day chronic infection 
Scratch assays were performed on RWPE-1 cells following a chronic 30-day infection. 
Data is shown as mean percentage wound closure of three biological replicates +/- 
SEM, with “mock” (black) and infected cells (orange); * p = 0.05; ** p = 0.01. Images 
(representative images shown on the right) were taken at x2 magnification, with the 
mean scratch size at T0 and 48 hours indicated. 





















   
Figure 4.23. MTT assay of HDMEC cells treated with conditioned medium. 
MTT assay (absorbance measured at 570 nm) assessing the effect conditioned medium from chronic infection of RWPE-1 prostate epithelial cells 
with different phylotypes of P acnes has on the proliferation of the endothelial cell line HDMEC. Conditioned medium used: A. 00035 (red); 
B. NCTC737 (green); C. ST27 (blue); D. B3 (orange); E. CFU2 (pink); F. P. granulosum (turquoise). The data is presented as mean of three biological 
replicates +/- standard error. Significance was calculated in comparison to cell treated with conditioned medium from uninfected RWPE-1 cells 






The focus of the initial stages of this study was to evaluate eukaryotic and bacterial 
behaviour in the infection model optimised in Chapter 3. To investigate the numbers 
and viability of the RWPE-1 prostate cells in the infection model, the inexpensive trypan 
blue exclusion assay was used, which allowed the monitoring of cell viability at each 
passage with no loss of cells. The cell counts were also used to ensure that mock and 
infected cells are seeded at 100,000 cells/ml at every passage, rather than using a 1:5 
ratio, as done in previous studies (Drott et al., 2010). Seeding the cells at their optimal 
density at each timepoint allowed limiting the stress on the RWPE-1 cells as a result of 
them being split too sparsely or too densely. For example, if infection with a strain 
increases proliferation rates, by the time the cells are split, these cells are likely to have 
reached confluence. In contrast, if a strain has a negative impact on proliferation or if it 
leads to cell death, the number of viable cells would be lower compared to the example 
above. Thus, splitting both at a set ratio would not be adequate to accommodate the 
difference in viable cell numbers and would result in differences which may have a 
severe effect on behaviour. 
Our results showed that prostate epithelial cells remain viable following infection with 
P. acnes strains representing all phylogenetic types related to prostate cancer. The 
phylogenetic types IA2 and IC were not investigated, as there have been no links found 
between these two lineages and patient prostate tissue samples. P. granulosum and P. 
avidum strains were tested as controls, as the organisms are closely related with P. 
acnes. While the cells survived both acute and chronic infections with P. granulosum, P. 
avidum infection led to cell death 48 hours post-infection in the short-term models and 
a long-term infection was thus not trialled, leaving P. granulosum as the sole non-P. 
acnes control. 
With both short term and long-term infections, statistical significance was rarely seen in 
viable cell numbers or cell viability between controls and infected cells; if such a 
significance was seen it was a single occurrence and did not represent a trend with 
infected cells being less viable or demonstrating higher numbers, suggesting the optimal 




Bacterial numbers, however, showed two clear and consistent trends, especially in the 
long-term infections. The first group consisted of bacterial strains that remained viable 
in the 5% CO2 tissue culture environment, namely the type IA1 strains 00035 and 
NCTC737, the type IB stain B3. The second group was formed by strains that did not 
remain viable in the infections and their numbers in the cell culture medium decreased 
over time; strains in this group included the type IA1 ST27, type II strain NCTC10390 and 
type III strain CFU2. P. granulosum was also a part of the second group with the notable 
difference that its numbers had started decreasing at each time point of the short-term 
infection, as well as the long-term. These differences in bacterial survival might be a 
result of the type I strain being more aerotolerant than types II and III. 
An investigation of the cytotoxic effect different strains of P. acnes and P. granulosum 
had on the RWPE-1 showed that only two of the 6 strains tested caused more than 5% 
cytotoxicity; 00035 cytotoxicity decreased as the experiment progressed indicating the 
relatively high percentage cytotoxicity was a result of an initial shock to which the cells 
slowly became accustomed as infection progressed and the cytotoxicity of type B 
increased overtime, with the increasing bacterial numbers being a possible explanation 
here. 
The ability of P. acnes to survive intracellularly in a range of cells, including macrophages 
(THP-1 cell line) and RWPE-1 cells, has been demonstrated previously (Mak et al., 2012; 
Fischer et al., 2013). It has also been shown that P. acnes is present in patient prostate 
tissue samples both in the cells and as an extracellular biofilm-like aggregate (Alexeyev 
et al., 2007). Here we compared the ability of representatives of the different prostate-
related phylogenetic types of P. acnes to remain viable intracellularly in short-term 
infections. Overall, the type I strains investigated (both IA1 and IB) showed higher 
intracellular numbers compared with types II and III. The type II strain, NCTC10390, 
demonstrated significantly lower numbers compared with all other strains investigated 
and they did not increase with prolonged exposure, suggesting that type II strains may 
not possess the ability to invade epithelial cells. 
The role inflammation plays in oncogenesis, especially prostate cancer, has been widely 
studied. In the case of prostate cancer, lesions are often associated with inflammatory 
cells, including macrophages and neutrophils, which are suspected of further driving 




(Babior, 2000). Cytokines and chemokines play the main role in recruiting these 
leukocytes to the site of the developing tumour. Thus, inflammatory gene dysregulation 
is important at the start of the oncogenic process. The dysregulation of prostate cancer-
related inflammatory genes (IL1B, IL6, IL8, TNF and TGFB) was investigated in both acute 
and chronic infections (Adler et al., 1999; Veltri et al., 1999; Blobe et al., 2000; Ricote et 
al., 2004; Tse et al., 2012). Although there are conflicting findings in the literature, the 
consensus is that prostate cancer is linked to upregulation of IL6, IL8, TNF and TGFB 
expression, and downregulation in IL1B (Ivanovic et al., 1995; Hobisch et al., 1998; Veltri 
et al., 1999; Ricote et al., 2004; Tse et al., 2012). All those inflammatory genes are 
involved in complex signalling pathways that, if dysregulated, have the potential to drive 
oncogenesis. 
The protein levels of IL-6 and IL-8 have previously been investigated in similar in vitro 
infection models and the result of those studies match our findings: both cytokines are 
upregulated in response to acute infection with P. acnes (Drott et al., 2010; Fassi Fehri 
et al., 2011). The expected upregulation of IL6 and TNF levels was observed in all acute 
infections, while IL8 was upregulated in most acute infections. The upregulation of IL-6 
and IL-8 can have downstream effects on the NF-κB and PI3K/Akt pathways. The 
anticipated downregulation in IL1B was only noted in the case of NCTC10390-infection 
at 24 hours in the acute infections; TGFB upregulation did not occur in the initial 48 
hours of infection but was observed in 3 of the tested strains at 72 hours. These results 
suggest that the potential for infection-driven oncogenesis is present at the early stages 
of infection through some of the prostate cancer-linked pathways in published 
literature, e.g. NF-κB, PI3K/Akt, JAK/STAT3. 
The number of significantly dysregulated genes in chronic infections is reduced, as is the 
fold-increase. Nevertheless, significant upregulation is seen in at least one of the 
inflammatory genes of interest both at day 15 and day 30 in all of the infections. The 
notable examples are 00035-infected cells which show upregulation of all inflammatory 
genes at day 15, and B3 which leads to upregulation of all inflammatory genes tested at 
day 30. These data, once again, confirm that the potential for oncogenesis as a result of 
infection is present. 
To have a clearer understanding of the role of inflammatory gene dysregulation in 




cells needs to be studied. In the controlled environment of tissue culture experiments, 
the interactions between different cell types is difficult to study; however, co-culture 
experiments (infected prostate epithelial cells and leukocytes) or treating immune cells 
with conditioned medium from infected prostate epithelial cells would give insight on 
the behaviour of the inflammatory cells in the context on P. acnes infection, especially 
as most of the cytokines studied directly affect inflammatory cells. 
EMT-related genes are considered a marker of cellular transformation. The genes whose 
expression is investigated here (CDH1, CDH2, SNAI1, SNAI2, TWIST and VIM) are all 
interconnected. The overall expression changes in short term infections show rapid 
changes in expression between time points with no clear trends in expression 
dysregulation. EMT gene expression changes are also seen in the chronic infection 
models, however, the expression patterns do not match what would be expected if the 
cells were undergoing EMT. For example, while the B3 infection model day 30 
demonstrated significant increase in SNAI1, a significant increase is also seen in CDH1 
expression, a gene whose expression is suppressed by Snail. 
Previous studies using RWPE-1 infected cells to investigate the effect of P. acnes 
infection have demonstrated that vimentin plays an enabling role in P. acnes cell 
invasion into host cells (Mak et al., 2012). While our results do not show a link between 
high intracellular counts and increased VIM expression in acute infections or at day 15 
of chronic infections, it is possible that the baseline expression of vimentin is sufficient 
to aid the invasion of some strains. However, at day 30 both NCTC737 and B3-infected 
cells demonstrated increased vimentin expression which was paired with the high levels 
of bacteria in the medium, suggesting the possibility of bacteria-driven vimentin-
overexpression, aiming an increase in the ability of P. acnes to invade epithelial cells. 
A hallmark of EMT is the so called “cadherin switch”, or the downregulation of E-
cadherin and the upregulation of N-cadherin (encoded by CDH1 and CDH2, respectively) 
(Wheelock et al., 2008). E-cadherin is a calcium-dependent adhesion molecule and while 
its production is not limited to epithelial cells, changes in CDH1 expression are a useful 
tool for detecting the transition of epithelial cells to mesenchymal (Carvell et al., 2007; 
Zeisberg, 2009). As the adhesion molecule is lost in epithelial cells, the cells can acquire 
increased motility; E-cadherin also interacts with a number of pathways, including Wnt 




the infection models used here are comprised solely of epithelial, E-cadherin is a marker 
suitable for detection of EMT. 
In the acute infection models, this pattern is seen on several occasions, but it is not 
consistently present between timepoints. Of exceptional interest is the CDH1/CDH2 
expression at day 30 in the 00035 infection, where the “cadherin switch” is seen, despite 
the small dysregulation levels (-2.1-fold for E-cadherin and 1.3-fold for N-cadherin). 
These results, together with 00035 at day 30 being the only infection model which 
formed colonies in soft agar assays, indicate that 00035 has the potential to drive cellular 
transformation. Quantifying the immunofluorescence of E-cadherin in the 00035 
infection models also supports a decrease of CDH1 on the protein level, although the 
immunofluorescence results were not statistically significant. Despite the data 
suggesting cellular transformation, the cells infected with 00035 showed no increased 
migration compared to untreated cells. The likely explanation is that further mutations 
are necessary for the cells to acquire increased motility (Simpson et al., 2008). In 
addition to the EMT changes seen, the observed increase in IL6, IL8 and TNF expression 
in this infection model at both day 15 and day 30, are consistent with what is observed 
in prostate cancer. 
With all remaining infections, the results of soft agar assay experiments showed no 
colony formation. This could either mean that the cells have not acquired anchorage-
independent growth, or that the antibiotic used in the assay has suppressed the 
formation of colonies, as demonstrated in Chapter 3 (Section 3.3.7). Additionally, it 
could be possible that challenging the prostate epithelial cells with bacteria for 4 weeks 
is insufficient time to cause cellular transformation. The results of qPCR analysis of 
mRNA levels and immunostaining analysis of protein expression for some infections are 
somewhat conflicting. A simple explanation for the differences is that the 
immunostaining experiments are performed 3-4 days after the mRNA extractions used 
for qPCR analysis, thus the values for protein and mRNA are not related to cells in the 
same passage or at the same growth stage. 
Immunostaining was used to identify the presence and quantify E-cadherin and vimentin 
expression levels at the protein level. The method used allowed the easy comparison of 
expression between different infection models and comparison to untreated cells by 




for analysis of the immunostaining images would be to identify cells expressing E-
cadherin and vimentin and analyse them separately. This would clarify whether the 
increase or decrease in fluorescence was due to an overall change in expression of the 
proteins across all cells, or whether it was due to subpopulations of cells having 
significantly higher expression than others. However, due to time constraints this 
analysis was not performed, and a more general approach was used.  
Further studies using immunofluorescence, identifying cells harbouring intracellular 
infection and interrogating their specific EMT gene expression compared to infection-
free cells would clarify the role of infection in oncogenesis: whether it is the infected 
cells that undergo transformation or if surrounding cells change as a result of signalling 
from the infected cells.  
Scratch assays were performed to assess cell migration following a long-term infection. 
Studies have found that there are at least 66 different genes involved in cell migration, 
thus the gene expression assessed in this study is insufficient to make conclusions about 
the cause of any migration seen (Simpson et al., 2008). Significantly increased cell 
migration relative to untreated controls can be seen in cells infected for 15 days with 
B3, and in 30-day infections with NCTC737, CFU2 and P. granulosum. A correlation 
between increased levels of the EMT marker vimentin and increased migration was 
observed following a 30-day infection with NCTC7373 and B3. It is worth noting, that 
where a mitomycin control was used the migration of both infected and uninfected cells 
differed significantly from that of mitomycin-treated control cells, suggesting that 
increased wound closure rate could be a result of increased migration or increased 
proliferation. Due to time constraints, not all experiments were repeated in the 
presence of a mitomycin control, thus comparisons between infected and not infected 
cells can only be interpreted as trends and not definitive results. 
As the creation of blood supply to a tumour is a crucial step in cancer progression, it is 
important to investigate whether infection of the prostate could drive angiogenesis and 
thus enable cancer development and future metastasis. 
The MTT assay was used here to assess whether proliferation rates are increased or 
decreased as a result of treatment with conditioned medium from chronically infected 




MTT to formazan, which is only done by metabolically active cells. It was selected for 
these initial investigations as it is cost effective and would allow the screening of a range 
of different strains, permitting the unrestricted use of replicates. Any conclusions about 
increased or decreased proliferation rates were made by comparing the absorbance 
readings of treated to untreated cells and assuming that the change in absorbance is a 
result of change in proliferation and not due to differences in metabolism. Further 
experiments using proliferation assays, such as the BrdU assay, can be used to confirm 
the results observed here. 
A limitation of the assay is that the reduction of MTT to formazan is done mainly by the 
mitochondria, and as mitochondria and bacteria share many similarities, the conversion 
can also be done in bacterial cells. During processing of the conditioned medium a 
centrifugation step is taken to pellet any bacteria in the medium, however, this does not 
guarantee the removal of all bacterial cells. The filter-sterilisation of conditioned 
medium was also not possible, as it could remove secreted protein and growth factors 
(filtering is not recommended for complete KSFM) and could thus alter the results of the 
experiment. Antibiotics were also not used as the HDMEC cells were cultured routinely 
in antibiotic-free medium and are sensitive to changes in the medium composition, thus 
the addition of antibiotics could also affect the results from the experiments. However, 
as a rather long incubation time of 72 hours was selected, if bacteria were present, they 
would cause the medium to become cloudy and when the MTT was added they would 
cause a rapid colour change, which would be easy to distinguish from non-contaminated 
wells. 
The dilutions of conditioned medium that could be used for experiments were limited 
by the amount of conditioned medium stored, thus dilutions such as 1:2, 1:5 and 1:10 
were not possible. The selected dilutions spanned over five orders of magnitude, thus 
allowing the investigation of the effect of minute amounts of conditioned medium have 
on the endothelial cells. 
The role of P. acnes infection of the prostate in angiogenesis has not previously been 
investigated. Overall, the results here do not show statistically significant difference in 
MTT assay results between HDMEC cells treated with medium from 30-day chronic 
infections, compared to uninfected controls. The exception is seen in cells treated with 




the lack of observed dysregulation is that the infected prostate cells alone do no not 
produce enough growth factors to induce a change in the behaviour of the HDMEC cells. 
It is worth noting that in the context of tumour-associated angiogenesis, the immune 
cells summoned to the location of the forming tumour also play an important role in 
angiogenesis in the area, as they also release a number of pro-angiogenic factors 
(Stockmann et al., 2014; Mortara et al., 2017). Thus, the examination here, focusing 
solely on the epithelial cells, does provide information about only a portion of the 
potential pro-angiogenic signals in cancer. 
A future experiment could investigate what effect conditioned medium from immune 
cells infected with P. acnes, has on angiogenesis (for example the monocytic cell line 
THP-1), as it would provide additional insight of the role of P. acnes in angiogenesis in 
the context of prostate cancer. 
The findings from the experiments in this chapter were used to select strains for 
infection models whose gene dysregulation will be further investigated in Chapter 5, 
using qPCR arrays with 84 prostate cancer-specific genes. Day 15 was selected as the 
time point for further analysis as bacterial numbers for most strains are undetectable 
past this point. Prostate isolates 00035, B3 and CFU2, representing three different 
phylogenetic types were selected for qPCR array analysis. Both NCTC737 and 00035 are 
type IA1 strain and show significant gene dysregulation in both short and long-term 
infections, and while NCTC737 shows a trend towards migration induction, the 00035 
strain was chosen for further analysis as it is a prostate-derived isolate and it is the only 
strain showing colony formation in soft agar and downregulation in CDH1 expression in 
chronic infections. B3, a type IB isolate, and CFU2, were selected as they are both 
prostate isolates and both infections are still challenged with bacteria at day 15; 
additionally, the B3 infection model shows a trend towards increased cellular migration 
as a result of infection. 
The results from this study present data supporting the role of some strains of P. acnes 
in prostate oncogenesis and highlight the strain-specific differences in immune response 
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In this chapter, the QIAGEN Profiler Prostate Cancer qPCR array was used to detect 
dysregulation of prostate cancer-related genes. The array consists of 84 genes which 
have been shown to play a role in prostate cancer, 5 housekeeping genes and 7 controls. 
The 84 genes tested are involved in different pathways affecting cancer progression, 
including the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) and the androgen 
signalling pathways, apoptosis, cell cycle control, fatty acid synthesis, and metastasis. 
Two further groups exist within the selection. First is the group of transcription factors, 
which regulate the expression of a range of genes; the second group consists of genes 
which are dysregulated in prostate cancer by promoter methylation. Finally, a number 
of genes are included in the array as they are known to be up- or downregulated in 
prostate cancer. 
 Phosphoinositide 3-kinase/protein kinase B signalling 
The PI3K/AKT signalling pathway has been linked to the progression of a number of the 
hallmarks of cancer, including survival, motility and cell cycle control, angiogenesis, as 
well as recruitment of inflammatory cells (Beagle and Fruman, 2011; Hanahan and 
Weinberg, 2011a; Soler et al., 2013; Hirsch et al., 2014). It can be activated by a range 
of receptors, e.g. B cell and T cell receptors, cytokine receptors, tyrosine kinase 
receptors and G-protein coupled receptors, all of which lead to the activation of PI3K 
and the subsequent production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
(Aman et al., 1998; Genot et al., 2000; Wegiel et al., 2008; Lemmon and Schlessinger, 
2010; Law et al., 2016). PIP3 can then activate phosphoinositide-dependent protein 
kinase-1 (PDK1) and also partially activate AKT; once phosphorylated by mechanistic 
target of rapamycin (mTOR) complex 2 (mTROC2), AKT gains full enzymatic activity 
(Alessi et al., 1996; Yang et al., 2015). An overview of the pathway can be seen in Figure 
5.1. 
AKT is a serine-threonine protein kinase and has three isoforms, with similar structure 
and once activated, it phosphorylates a wide range of downstream processes, including 
cell cycle progression, proliferation, and EMT (Scheid and Woodgett, 2001; Vivanco and 
Sawyers, 2002; Manning and Cantley, 2007). AKT can also be activated by other 








Figure 5.1. Overview of PI3K/AKT signalling 
The phosphoinositide 3-kinase/protein kinase B signalling (PI3K/AKT) signalling pathway is a complex network of processes involved in cellular 
regulation. By inhibiting proteins involved in apoptosis, such as FOXO1 or BCL-2, the pathway can have a direct effect on outcome for the cell. The 
pathway can also induce Girdin and inhibit Palladin, both of which play a role in migration. PI3K/AKT signalling can also influence glycolysis via PFKB2. 
Cell cycle proteins such as CDK2, cyclins A and D1 and also under its influence thus altering cell cycle progression. The nuclear factor-kappa B (NF-κB) 
pathway can be affected by PI3K/Akt by induction of IKKα. Activation of the mTROC2 complex can cause alterations in protein synthesis. 
Legend: BAX – BCL-2-associated X protein; BCL-2 – B-cell lymphoma 2; BIM – BCL-2-like protein; CDK2 – Cyclin-dependent kinase; FOXO1 – Forkhead 
box protein O1; GSK-3 – glycogen synthase kinase 3; IKKα – inhibitor of kappa B kinase; MDM2 – mouse double minute 2; mTORC – mechanistic target 
of rapamycin complex; p53 – protein 53; PDK1 – 3-phosphoinositide dependent protein kinase-1; PFKFB2 – 6-phosphofructo-2-kinase/fructose-2,6-






while phosphatase and tensin homolog (PTEN) can act as its inhibitor by 
dephosphorylating PIP3 (Maehama and Dixon, 1998; Stronach et al., 2011). AKT’s 
involvement in different pathway is mediated by its interactions with various molecules. 
By direct inhibition of forkhead box “O” (FOXO) or inhibition of B-cell lymphoma 2 (Bcl-
2) family proteins, AKT is involved in apoptosis (Datta et al., 1997; Brunet et al., 1999). 
By phosphorylating and degrading inhibitor of κB (IκB), AKT initiates the NF-κB signalling 
pathway (Bai et al., 2009). Loss of at least one PTEN allele is seen in 60% of prostate 
cancers and complete loss of PTEN has been linked to disease progression and 
androgen-independent growth (Phin et al., 2013). 
Activation of AKT leads to downregulation of E-cadherin expression and produced E-
cadherin protein to be contained within perinuclear organelles, thus stimulating EMT; 
AKT also induces the production of matrix metalloproteinases (MMPs) and can aid cell 
invasion (Kim et al., 2001; Park et al., 2001; Grille et al., 2003). AKT has been suggested 
as an oncogene and its activation is seen in various cancers, including prostate cancer 
(Staal, 1987; Bellacosa et al., 1995; Nakatani et al., 1999; Sun et al., 2001). 
mTOR is involved in cellular growth and proliferation and it acts as a response to stress 
and mitogenic signals (Wullschleger et al., 2006). It belongs to the class IV PI3K 
superfamily, and it forms two complexes, mTORC1 and mTORC2 (Sabatini, 2006; 
Wullschleger et al., 2006). The most notable consequence of mTOR activation by AKT is 
the effect it has on protein signalling, thus having the ability to provide cancers cell with 
enhanced protein synthesis if dysregulated (Hay and Sonenberg, 2004).  
In the context of prostate cancer, the PI3K/AKT pathway may have mutations that cause 
its dysregulation; loss of function of the tumour suppressor PTEN has also been reported 
(Cairns et al., 1997; Sun et al., 2009). Additionally, IL-6 driven constitutive activation of 
the PI3K/ AKT-signalling pathway causes upregulation of cyclin A (encoded by CCNA1), 
which promotes oncogenesis and cancer progression (Wegiel et al., 2008). 
 Androgen receptor signalling 
The androgen receptor (AR) is a transcription factor which is involved in the 
transcriptional activation of a range of processes in the cell. The main way of activating 
the AR is described in the Introduction of this thesis (Section 1.1.2.5.4.4.1, Figure 1.4) 




translocation of the nucleus (Lonergan and Tindall, 2011). Alternatively, AR-signalling 
can be initiated either by IL-6 activation which then drives Janus kinase/Signal 
transducer and activator of transcription (JAK/STAT3) and RAS-signalling leading to AR 
activation or by activation of receptor tyrosine kinases (e.g. epidermal growth factor 
(EGF) activating the EGF receptor (EGFR), insulin-growth factor 1 (IGF-1) binding the 
insulin receptor, vascular endothelial growth factor (VEGF) binding to the VEGF receptor 
(VEGFR)), which can also lead to activation of the PI3K/AKT pathway. 
 Apoptosis 
Apoptosis, also referred to as programmed cell death, is initiated when the cell receives 
lethal stimuli, either intrinsic (such as signals for DNA damage, or metabolic stress) or 
extrinsic (from neighbouring cells, e.g. cytokines, IGF-1, EGF) (Ichim and Tait, 2016). 
When apoptosis is initiated, the nucleus condenses and the cell shrinks; the membrane 
begins to form blebs which mature into apoptotic bodies and the DNA is fragmented 
(Figure 5.2). The remnants of the cell are then engulfed by phagocytes. Different 
caspases (members of the cysteine-aspartic acid protease family) play a key role in the 
regulation of the process. The complex process of apoptosis and its role in 
carcinogenesis is reviewed in detail by Turner et al. (2014). Here, we will only highlight 
the role of the genes investigated in this chapter. 
The apoptotic pathway leads to the activation of a number of initiator caspases which 
in turn stimulate downstream executioner caspases (including caspase-3) and it has 
been shown that decreased expression of the precursor-caspase-3 or activated caspase-
3 decreases sensitivity to apoptosis signalling in prostate cancer and thus aids cancer 
progression (Rodríguez-Berriguete et al., 2015). 
The B-cell CLL/lymphoma 2 (BCL-2) is a key regulator of apoptosis which has been shown 
to be dysregulated in a range of malignancies (Asmarinah et al., 2014; Seong et al., 
2015). In normal cells, BCL-2 has an anti-apoptotic activity as it inhibits the release of 
the caspase-activating cytochrome C from mitochondria. In cancer, upregulation of BCL-
2 allows cells to avoid apoptosis (Yang et al., 1997a; Placzek et al., 2010). In prostate 
cancer, this increase in expression is likely a result of the activation of the PI3K/NF-κB 






Figure 5.2. Overview of apoptosis 
Once the cell receives apoptotic signals it begins to shrink and the chromatin in its 
nucleus condenses. This is followed by fragmentation of the nucleus and the 
development of cell membrane blebs. This leads to the formation of apoptotic 






The main function of the tumour suppressor gene p53 is to prevent cells with DNA-
damage from proliferating, thus preventing oncogenesis; loss of functional protein 
means this tight control of damage prevention is lost (Zilfou and Lowe, 2009). In healthy 
cells, DNA damage or cellular stress is detected by p53, and it can activate programmed 
cell death by inducing p53-regulated apoptosis-inducing protein 1 (p53AIP1) to enter 
the mitochondria, thus disturbing the mitochondrial membrane. Additionally, 
ubiquitinated p53 can inhibit the antiapoptotic activity of BCL-2 (Matsuda et al., 2002; 
Amaral et al., 2010). Studies in cellular models of prostate cancer have shown that loss 
of functional p53 leads to resistance to chemo- and radiotherapy, as the cells can 
proceed through the cell cycle despite treatment (Chappell et al., 2012).  
Death domain-associated protein (or DAXX) is involved in apoptosis and the regulation 
of autophagy, and has been shown to be upregulated in prostate cancer (Yang et al., 
1997b; Puto et al., 2015). Another inducer of the apoptosis cascade is tumour-necrosis 
factor (TNF)-related apoptosis-inducing ligand (or TRAIL) and its binding to decoy 
receptors, with the TNF-receptor superfamily 10D (encoded by TNFRSF10D) being 
investigated by the qPCR array. 
A brief overview of the process can be found in Figure 5.3. 
 Cell cycle 
The cell cycle is a series of processes a cell undergoes in order to divide and produce two 
daughter cells. 
Once division is initiated the cell enters the interphase state which consists of three 
stages G1, S and G2 (Figure 5.4.A). The Gap/Growth 1 (G1) phase is initiated by mitogens 
and the phase involves accumulation of nutrients and organelles for the upcoming 
cellular division (Massague, 2004). During the G1 phase the cell must progress through 
the cell division restriction point. Until this point the retinoblastoma (Rb) tumour 
suppressor protein is hypophosphorylated (Figure 5.4.B). If no issues are detected by 
p53, this tumour suppressor allows the cell cycle to progress and leads to the activation 
of two main protein complexes cyclin E-cyclin dependent kinase 2 (CDK2) and cyclin D-
CDK4/6 and cyclin E-CDK2 which leads to the hyperphosphorylation of Rb and inhibits 







Figure 5.3. Overview of the apoptosis pathway 
Signalling via TNF-related apoptosis-inducing ligand (TRAIL) leads to the recruitment of Fas-associated protein with death domain (FADD) and tumour 
necrosis factor receptor type 1-associated DEATH domain (TRADD) which initiate downstream signalling. The activation of the activator caspase 8 is 
followed by the formation of functional executioner caspase 3 which can cause DNA fragmentation and can indirectly initiate apoptosis. Death 
domain-associated protein (DAXX) and the withdrawal of survival signalling lead to the translocation of BCL-2-associated protein X (BAX) and BCL-
2-like protein 11 (BIM) to the mitochondria which inhibit the anti-apoptotic B-cell lymphoma 2 (BCL-2) and B-cell lymphoma-extra large (BCL-xL). If 
active, BCL- and BCL-xL inhibit the release of cytochrome C (Cyt C) from the mitochondria. DNA damage, for example, activated Puma, NOXA and 
BAX, which inhibit BCL-2 and BCL-xL, the inactivation of cytochrome C release. Cytochrome C can also indirectly activate apoptosis. 










Figure 5.4. Cell cycle overview 
A. Cell cycle progression. The cell cycle consists of Gap/Growth phase (either G1 phase 
which prepares the cell for division, or G0 phase of arrested development), the 
synthesis phase (S phase), G2 phase preparing proteins necessary for the division and 
mitosis (M-phase; cell division). 
B. Restriction point of the cell cycle. The restriction point is controlled by activating 
(e.g. growth factors) and inhibiting signalling, which affect the formation of cyclin D-
CDK4/6 and cyclin E-CDK2 complexes which hyperphosphorylate retinoblastoma 
protein (Rb). This leads to the release of E2F, initiating transcription. If Rb is not 
phosphorylated, it remains bound to E2F, inhibiting transcription. 
Legend: CDK – cyclin-dependent kinase; E2F – E2 factor; EGF – epidermal growth factor 
p16INK4a – cyclin-dependent kinase inhibitor 2A; p53 – protein 53; PDGF – platelet-





(Giacinti and Giordano, 2006). If any issues are detected at this G1/S checkpoint the cell 
may enter the G0 phase (resting state) or apoptosis may be initiated. The resting state 
of the cell can be either reversible (called quiescence which occurs when insufficient 
nutrients are available, and the cell cannot proceed with division or when DNA damage 
is discovered and proceed until the issue is repaired) or irreversible (differentiation or 
senescent) (Linke et al., 1996). 
When the cell proceeds to the S-phase (or synthesis phase) it undergoes replication and 
as a result at the end of the S-phase chromosomes are duplicated (Takeda and Dutta, 
2005). Once the S-phase is complete, the cell enters a second growth-phase (G2) when 
it produces proteins necessary for undergoing mitosis and proceeds through the G2/M 
checkpoint where any damaged DNA is detected and repaired; if DNA damage remains 
unrepaired then it could have fatal consequences for the newly divided cell, or it can 
lead to oncogenesis (Otto and Sicinski, 2017). 
The final stage of the cell cycle is mitosis (or the M-phase) where the cell divides. An 
illustration of the process can be found in Figure 5.5. Mitosis begins with the prophase 
where the DNA is condensed into chromosomes, continues with loss of nuclear structure 
and arrangement of the chromosomes along the metaphase plane. The cell then 
undergoes the anaphase, where the two daughter chromosomes are pulled apart by the 
kinetochore microtubules. Finally, the cells enter the telophase, where the nucleus is 
once again formed, and a cleavage furrow leads to the separation of the two new 
daughter cells (cytokinesis). 
Loss of heterozygosity or loss of function mutations in either p53 or Rb, which play a role 
in the tight regulation of the process, can drive uncontrolled cell division and progression 
of the cell cycle even if DNA damage is present (Demidenko et al., 2005). Furthermore, 
abnormal expression of cyclins (e.g. cyclin A and cyclin E) and CDKs (including CDK4), as 
well as CDK-inhibitors, such as p16 (also known as cyclin-dependent kinase inhibitor 2A 
(CDKN2A) or p16Ink4A), may lead to cell cycle progression despite p53 stop signals (Opitz 
et al., 2001). Downregulation of p16Ink4A has been shown to be an indicator of metastatic 
prostate cancer (Chakravarti et al., 2007). 
Caveolin-1 and 2 (encoded by CAV1 and CAV2, respectively) are membrane proteins 






Figure 5.5. Mitosis 
Cellular division has six distinct stages. The interphase includes the Gap/Growth 1 (G1), 
synthesis (S) and G2 phases, during the cell prepares for division. It also includes a 
restriction point and two checkpoints, ensuring that only healthy cells proceed 
through division. During the prophase, chromatin condenses to from chromosomes 
and the nucleus is lost. The metaphase includes the arrangement of the chromosomes 
along the metaphase plane. During the anaphase the sister chromatids are pulled 
apart towards the opposite ends of the cell. The telophase includes the re-formation 
of the nuclear membrane surrounding the two newly formed nuclei, and this is 





stromal cells drives prostate cancer metastasis, while other studies have demonstrated 
that increased plasma levels of both CAV1 and CAV2 are associated with aggressive 
prostate tumours (Chakravarti et al., 2007; Sugie et al., 2015). 
 Fatty acid synthesis 
As healthy prostate cells require citrate as part of the prostatic fluid secretions, they 
mainly produce energy using glycolysis; however, when cells become cancerous they 
require larger energy supplies and thus switch to the more energy-efficient Krebs cycle 
(the citric acid cycle) (Costello and Franklin, 2000). This contrasts what happens in other 
cells where there is a switch from efficient to energy-inefficient metabolism if they 
undergo oncogenesis. When the newly-cancerous prostate cells do switch to utilising 
the Krebs cycle for energy the citric acid that would be secreted in a healthy cell, turns 
into building blocks for the synthesis of fatty acids. As a result, studies have shown that 
genes involved in fatty acid and cholesterol biosynthesis are altered in prostate cancer, 
including acetyl-CoA carboxylase alpha (ACACA), fatty acid synthase (FASN), 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR), AMP-activated protein kinase (AMPK, 
encoded by PRKAB1), sterol regulatory element-binding protein 1 (SREBF1) (Heemers et 
al., 2001; Van de Sande et al., 2005; Hager et al., 2006; Beckers et al., 2007; Kim et al., 
2014).  
ACACA is involved in the conversion of acetyl-CoA to malonyl-CoA which is the first step 
of the de novo fatty acid synthesis pathway in the cells. This process is ATP-dependent 
and is the rate-limiting step for the pathway. The next step in the synthesis of long chain 
fatty acids in catalysed by the homodimer fatty acid synthase (FASN) which has three 
enzymatic domains, and converts acetyl-CoA and malonyl-CoA to palmitate (a 16-carbon 
long chain fatty acid) in the presence of reduced nicotinamide adenine dinucleotide ( 
NADH). A separate pathway, also utilising acetyl-CoA leads to the synthesis of 
cholesterol (with cholesterol being a building block of steroid hormones such as 
androgens), with a key regulator being HMGCR (which is in turn transcriptionally 
controlled by SREBF and by AMPK-phosphorylation, targeting it at the protein level) (Wu 







Figure 5.6. Glycolysis and fatty acid synthesis 
Glycolysis is the breakdown of glucose to produce pyruvate and energy. The process 
has two stages: Stage 1 where energy is invested concluding with the formation of 
two 3-carbon molecules (glyceraldehyde 3-phosphate, G3P) from a 6-carbon 
precursor. Stage 2 is initiated by the conversion of G3P to 1,3-bisphosphoglycerate 
(1,3BPG) by glyceraldehyde phosphate dehydrogenase (GAPDH). The reaction 
concludes with the formation of pyruvate, which is converted to acetyl-CoA and is 
translocated to the mitochondria where in initiates the tricarboxylic acid cycle (TCA or 
Krebs cycle). In the first step of the TCA acetyl-CoA is converted to citrate. The citrate 
is then converted to isocitrate by the enzyme aconitase; however, in prostate cells 
this reaction is inhibited by the high concentration of accumulated zinc ions. 
In addition to being a key component of the TCA cycle, citrate can be translocated to 
the cytoplasm, where it can be reverted to acetyl-CoA, which can have multiple fates. 
Acetyl-CoA can be used for de-novo fatty acid synthesis, by being converted to 
Malonyl-CoA by acetyl-CoA carboxylase-alpha (ACACA), and then can be used to 
synthesise palmitate via the activity of the enzymatic complex fatty acid synthase 
(FAS, encoded by FASN). Both FAS and ACACA can be stimulated by sterol regulatory 
element-binding factor 1 (SREBF). Alternatively, acetyl-CoA can initiate the 
Mevalonate pathway, where it can be converted to mevalonate by 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGCR). AMP-activated protein kinase (AMPK) can 
act as a direct or indirect inhibitor for HMGCR and SREBF, respectively. Additionally, 
AMPK activity can be inhibited by calcium/calmodium-dependent protein kinase 
kinase 1 (CAMKK1). 
The newly synthesised mevalonate can then enter the cholesterol biosynthesis 
pathway, where it can be converted to squalene and then cholesterol, which has a 
number of functions, including the formation of steroid hormones (including 






 Wnt/β-catenin pathway 
The Wnt/β-catenin pathway is key both in development and in sustaining homeostasis, 
damage repair and growth in adult life (Alonso and Fuchs, 2003; Pinto and Clevers, 2005; 
Malhotra and Kincade, 2009; Nemeth et al., 2009; Beers and Morrisey, 2011; Monga, 
2011; Whyte et al., 2012). It is also commonly dysregulated in a range of cancers, and it 
plays a role in genetic instability, apoptosis, cellular migration (Alberici and Fodde, 2006; 
Pećina-Šlaus, 2010; Rawson et al., 2011; Hoffmeyer et al., 2012; Frisch et al., 2013; 
Webster and Weeraratna, 2013). The pathway’s dysregulation in cancer can be a result 
of activation of pathway components which promote tumour progression; alternatively, 
it could be due to mutations or loss of function of genes which normally suppress it 
(Polakis, 2012). An example of the involvement of the Wnt/β-catenin pathway in cancer 
can be seen in colorectal cancer with a mutation in the adenomatous polyposis coli (APC) 
tumour suppressor gene, which is a known negative regulator of β-catenin activity; loss 
of both alleles of APC leads to loss of regulation of β-catenin functions and also causes 
chromosomal instability (Lengauer et al., 1998; Polakis, 2007). The APC tumour 
suppressor gene can also mediate the activity of β-catenin which in turn has the 
potential to affect the production of cyclin D1; incapacitated APC would not inhibit the 
activity of β-catenin, leading to increased cyclin D1 production and the potential for the 
cell to undergoes uncontrolled proliferation (Shtutman et al., 1999). APC also forms 
complexes with other proteins which plays a key role in apoptosis induction if high levels 
of DNA damage are present during the cell cycle (Jaiswal and Narayan, 2008). 
The Wnt/β-catenin pathway can be involved in oncogenesis by aberrant activity of 
pathway ligands, epigenetically silenced antagonists of the pathway (which is seen in 
many cancers, including prostate cancer) or through β-catenin-independent signalling 
(Rhee et al., 2002; Wong et al., 2002; Milovanovic et al., 2004; Kikuchi and Yamamoto, 
2008; Kypta and Waxman, 2012). An overview of Wnt/β-catenin signalling can be seen 
in Figure 5.7. 
A more direct example of how the pathway may be involved in oncogenesis, especially 
EMT, is that one of the transcription factors activated by the pathway is Slug (encoded 
by SNAI2), which can induce EMT; additionally, the pathway also inhibits the 







Figure 5.7. Wnt/β-catenin signalling pathway 
If the Wnt/β-catenin pathway is not activated β-catenin is translocated to the cytoplasm where it is inactivated by phosphorylation (P, by CK1 and 
the APC/Axin/GSK-3 complex) and ubiquitination (UB), leading to its degradation. If the signalling is activated, Dishevelled (Dvl) binds the 
APC/Axin/GSK-3 complex, preventing it from initiating the degradation of β-catenin. Thus, β-catenin is translocated to the nucleus where it can 
initiate the transcription of a range of target genes, leading to decreased adhesion and increase migration. 
Legend: APC – adenomatous polyposis coli; β-TrCP – F-box/WD repeat-containing protein 1A; CK1 – casein kinase 1; DKK – Dickkopf related proteins; 









Metastasis is a complex process which allows cancer cells to travel to distant sites in the 
body and to form secondary tumours in distinct organs, for example prostate cancer 
most commonly metastasizes to the bone. To become metastatic, the cancer cells need 
to undergo EMT (which is discussed in more detail Chapter 4, Section 4.1.6.4) and to 
gain the ability to invade the surrounding areas. The cancerous cells can then enter the 
blood stream (intravasation) and travel around the body. If the cancer cells escape the 
blood stream (extravasation) at a different location they can undergo mesenchymal-
epithelial transition (MET) and form distant metastasis.(Quail and Joyce, 2013).  
One of the key players in metastasis is E-cadherin (encoded by CDH1), as its loss is vital 
for cells to undergo EMT. Tissue inhibitors of metalloproteases (TIMPs) have been 
shown to play a role in the dysregulation of the switch of cadherins (from E-cadherin to 
N-cadherin in EMT), e.g. TIMP1 downregulates E-cadherin, while TIMP2 has an opposing 
effect and loss of TIMP3 has been linked to E-cadherin and β-catenin-signalling 
dysregulation (Hojilla et al., 2007; Bourboulia et al., 2013; D'Angelo et al., 2014). Other 
genes involved in metastatic cancer whose dysregulation is assessed in this chapter 
include cyclic AMP-responsive element-binding protein (CREB1), Myc-associated factor 
X (MAX), N-myc downregulated gene family member 3 (NDRG3). 
Phosphorylated CREB1 has been shown to be upregulated in prostate cancer and bone 
metastases, and is absent in benign prostate samples, indicating a role for CREB1 in 
metastasis and cancer progression (Wu et al., 2007). 
Myc is a transcription factor which has low level of expression in healthy cells; its 
production is tightly controlled and can be activated by a number of pathways (including 
the Wnt/β-catenin and JAK/STAT3 pathways); a known inhibitor of Myc is TGF-β-
signalling (Bromberg et al., 1999). To become an active transcription factor Myc forms a 
heterodimer with MAX and together they can bind enhancer boxes (E-boxes) and initiate 
the transcription of a range of genes (Eilers and Eisenman, 2008). Examples of genes 
controlled by Myc include upregulation of cyclin D and cyclin E (which are involved in 
the tight control of cell cycle progression), BCL-2 (which plays a role as a regulator of 
apoptosis) and fatty acid synthase, as well as downregulation in a range of genes, e.g. 
cell cycle inhibitors (Perez-Roger et al., 1999; Beier et al., 2000; Eischen et al., 2001; 




MAX complex, is a protein involved in proliferation, growth and differentiation (Shimono 
et al., 1999; Zhang et al., 2008). 
 Promoter methylation 
The field of epigenetics focuses on investigating phenotypic changes which are not a 
result of DNA alterations and it plays an important role in the normal functionality of 
cells, for example in differentiated cells; it does, play a role in disease, and specifically 
cancer (Jones and Laird, 1999; Jones and Takai, 2001; Egger et al., 2004). One form of 
epigenetic modification is the methylation of the cysteine residue of the so-called CpG 
islands (clusters of CpG sequences in the genome, usually in close proximity to gene 
promoter regions) (Bird, 1986). Studies discovered that constitutively expressed genes 
lack such methylation, while if the same genes were methylated their expression was 
lost (Bird, 1986). 
Bacteria have the ability to affect DNA methylation. Examples include Fusobacterium sp. 
accelerating DNA methylation in a subgroup of ulcerative colitis-related genes (Tahara 
et al.). Additionally, H. pylori has been shown to play a role in aberrant CpG island 
methylation of gastric cells and the methylation observed has been linked to gastric 
cancer (Maekita et al., 2006; Matsusaka et al., 2014). 
In cancer, methylation can play a role in two ways. First, hypomethylation of genes 
which would normally have suppressed expression may lead to the activation of 
oncogenes which drive cancer progression (Chen et al., 1998). Alternatively, 
hypermethylation of promoters can lead to loss of expression of tumour suppressor 
genes, for example CDH1. 
A number of genes have been shown to be epigenetically modified in prostate cancer, 
including CDH1, CAV1, APC, RASSF1A, CRBP1, TIMP3 (Cui et al., 2001; Li et al., 2001; 
Jeronimo et al., 2004). 
5.2. Materials and methods 
 RNA extraction and quantification 
RNA was extracted as described in Section 2.4.2.1 using the RNeasy Plus Mini-Kit 
(QIAGEN, Germany) following the manufacturer’s protocol, and was quantified using the 




 cDNA synthesis 
For cDNA synthesis, the recommended RT2 First Strand Kit (QIAGEN, Germany) was used 
as detailed in Section 2.4.2.4.5.1. The infection models used for cDNA synthesis and the 
following qPCR array analysis were 00035, B3 and CFU2 at day 15, selected based on the 
Chapter 4 findings. 
 RT2 Profiler Human Prostate Cancer PCR array 
The qPCR arrays were prepared as described in Section 2.4.2.4.5.2, mixing 1350 μl 2x 
RT2 SYBR Green Mastermix (QIAGEN, Germany), with the cDNA synthesised in Section 
5.2.2 and water. Each qPCR array consisted of 84 prostate cancer related genes, 5 
housekeeping genes, 1 genomic DNA control, 3 reverse-transcription (RT) controls and 
3 positive PCR controls (PC). The 5 housekeeping genes (ACTB, B2M, GAPDH, HPRT1 and 
RLPL0) were used by the analysis software to select the most stable gene or a 
combination of genes. The genomic DNA control was used in the place of a standard no-
RT control, and it targeted a non-coding DNA region was selected as a target of the assay. 
The cDNA kit was preloaded with a synthetic mRNA sequence with a poly-A tail which 
was transcribed along with the sample mRNA. This RT-control was used to determine 
the efficiency of the reverse transcription and was used as a comparator between 
different samples. Finally, the PC wells contained a small amount of DNA and primers, 
which were used as a control between qPCR arrays, and should not differ between 
plates. For analysis, the recommended threshold of 35 cycles was used, thus excluding 
any Cp values above 35. 
Table 5.1 presents a list of all genes included in the array (including housekeeping genes 
and controls), and the signalling pathways they are involved in; it also includes genes 
not involved in pathways but with promoters known to be methylated in prostate cancer 
and genes known to be up- or downregulated in prostate cancer. 
Out of the 84 genes included in the array, in the context of prostate cancer 59 are linked 
to at least one signalling pathway, while the remaining 25 are either known to have 





Table 5.1. List of genes included in the qPCR array and their main functions 
Gene Accession number Full name 
Function 
1 2 3 4 5 6 7 8 9 UD 
IGF1 NM_000618 Insulin-like growth factor 1 (somatomedin C) + + + +      D 
PTEN NM_000314 Phosphatase and tensin homolog + + + +       
TIMP2 NM_003255 Tissue inhibitor of metalloproteinases 2 + + +     +   
NFKB1 NM_003998 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 + + +      +  
GNRH1 NM_000825 Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) + + +        
IL6 NM_000600 Interleukin 6 + + +        
TIMP3 NM_000362 Tissue inhibitor of metalloproteinases 3 + + +        
EGFR NM_005228 Epidermal growth factor receptor + +  +       
CCND1 NM_053056 Cyclin D1 + +  +       
AR NM_000044 Androgen receptor + +      + +  
FOXO1 NM_002015 Forkhead box O1 + +       +  
VEGFA NM_003376 Vascular endothelial growth factor A + +         
CDKN2A NM_000077 Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) +  + +    + +  
TP53 NM_000546 Tumour protein p53 +  + +     +  
BCL2 NM_000633 B-cell CLL/lymphoma 2 +  + +       
MAPK1 NM_002745 Mitogen-activated protein kinase 1 +  +        
CCND2 NM_001759 Cyclin D2 +   +      D 
CDH1 NM_004360 Cadherin 1, type 1, E-cadherin (epithelial) +       +   
DAXX NM_001350 Death-domain associated protein +        +  
PDPK1 NM_002613 3-phosphoinositide dependent protein kinase-1 +         U 
AKT1 NM_005163 Protein kinase B +          
CAV1 NM_001753 Caveolin 1, caveolae protein, 22kDa  +      +   
TNFRSF10D NM_003840 Tumour necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 






Gene Accession number Full name 
Function 
1 2 3 4 5 6 7 8 9 UD 
NRIP1 NM_003489 Nuclear receptor interacting protein 1  +       +  
TGFB1I1 NM_015927 Transforming growth factor beta 1 induced transcript 1  +         
CASP3 NM_004346 Caspase 3, apoptosis-related cysteine peptidase   + +       
ETV1 NM_004956 Ets variant 1   +      + U 
APC NM_000038 Adenomatous polyposis coli    +    +   
CCNA1 NM_003914 Cyclin A1    +    +   
PTGS2 NM_000963 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 
   +    +   
PPP2R1B NM_002716 Protein phosphatase 2, regulatory subunit A, beta    +      D 
CAV2 NM_001233 Caveolin 2    +       
PTGS1 NM_000962 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 
   +       
SREBF1 NM_004176 Sterol regulatory element binding transcription factor 1     +    +  
ACACA NM_198834 Acetyl-CoA carboxylase alpha     +      
CAMKK1 NM_032294 Calcium/calmodulin-dependent protein kinase kinase 1, alpha     +      
FASN NM_004104 Fatty acid synthase     +      
HMGCR NM_000859 3-hydroxy-3-methylglutaryl-CoA reductase     +      
PRKAB1 NM_006253 Protein kinase, AMP-activated, beta 1 non-catalytic subunit     +      
STK11 NM_000455 Serine/threonine kinase 11     +      
CREB1 NM_004379 CAMP responsive element binding protein 1      +   +  
MAX NM_002382 MYC associated factor X      +   +  
KLHL13 NM_033495 Kelch-like 13 (Drosophila)      +     
NDRG3 NM_022477 NDRG family member 3      +     
PES1 NM_014303 Pescadillo homolog 1, containing BRCT domain (zebrafish)      +     





Gene Accession number Full name 
Function 
1 2 3 4 5 6 7 8 9 UD 
SEPT7 NM_001788 Septin 7      +     
MKI67 NM_002417 Antigen identified by monoclonal antibody Ki-67       +    
TMPRSS2 NM_005656 Transmembrane protease, serine 2       +    
MSX1 NM_002448 Msh homeobox 1        + +  
RARB NM_000965 Retinoic acid receptor, beta        + +  
SFRP1 NM_003012 Secreted frizzled-related protein 1        +  D 
SLC5A8 NM_145913 Solute carrier family 5 (iodide transporter), member 8        +  D 
ARNTL NM_001178 Aryl hydrocarbon receptor nuclear translocator-like        +  U 
DKK3 NM_015881 Dickkopf homolog 3 (Xenopus laevis)        +   
DLC1 NM_006094 Deleted in liver cancer 1        +   
EDNRB NM_000115 Endothelin receptor type B        +   
GPX3 NM_002084 Glutathione peroxidase 3 (plasma)        +   
GSTP1 NM_000852 Glutathione S-transferase pi 1        +   
MGMT NM_002412 O-6-methylguanine-DNA methyltransferase        +   
PDLIM4 NM_003687 PDZ and LIM domain 4        +   
RASSF1 NM_007182 Ras association (RalGDS/AF-6) domain family member 1        +   
ZNF185 NM_007150 Zinc finger protein 185 (LIM domain)        +   
RBM39 NM_004902 RNA binding motif protein 39         + U 
SOX4 NM_003107 SRY (sex determining region Y)-box 4         + U 
SUPT7L NM_014860 Suppressor of Ty 7 (S. cerevisiae)-like         + U 
EGR3 NM_004430 Early growth response 3         +  
ERG NM_182918 V-ets erythroblastosis virus E26 oncogene homolog (avian)         +  
NKX3-1 NM_006167 NK3 homeobox 1         +  
SHBG NM_001040 Sex hormone-binding globulin         +  






Gene Accession number Full name 
Function 
1 2 3 4 5 6 7 8 9 UD 
GCA NM_012198 Grancalcin, EF-hand calcium binding protein          D 
LGALS4 NM_006149 Lectin, galactoside-binding, soluble, 4          D 
LOXL1 NM_005576 Lysyl oxidase-like 1          D 
TFPI2 NM_006528 Tissue factor pathway inhibitor 2          D 
USP5 NM_003481 Ubiquitin specific peptidase 5 (isopeptidase T)          D 
CAMSAP1 NM_015447 Calmodulin regulated spectrin-associated protein 1          U 
DDX11 NM_004399 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11          U 
ECT2 NM_018098 Epithelial cell transforming sequence 2 oncogene          U 
HAL NM_002108 Histidine ammonia-lyase          U 
IGFBP5 NM_000599 Insulin-like growth factor binding protein 5          U 
KLK3 NM_001648 Kallikrein-related peptidase 3          U 
MTO1 NM_012123 Mitochondrial translation optimization 1 homolog (S. cerevisiae)          U 
SOCS3 NM_003955 Suppressor of cytokine signalling 3          U 
ACTB NM_001101 Actin, beta 
Housekeeping genes 
B2M NM_004048 Beta-2-microglobulin 
GAPDH NM_002046 Glyceraldehyde-3-phosphate dehydrogenase 
HPRT1 NM_000194 Hypoxanthine phosphoribosyltransferase 1 
RPLP0 NM_001002 Ribosomal protein, large, P0 
PPC SA_00103 Positive PCR Control 
Controls RTC SA_00104 Reverse Transcription Control 
HGDC SA_00105 Human Genomic DNA Contamination Control 
Function indicated what role the different genes have in prostate cancer: 1. AKT and PI3K signalling pathway; 2. Androgen receptor signalling; 
3. Apoptosis; 4. Cell cycle; 5. Fatty acid synthesis; 6. Metastasis; 7. Other prostate cancer-related genes; 8. Genes in methylated promoters in prostate 





 Data analysis 
The qPCR array data was analysed using the SABiosciences RT2 Profiler PCR Array Data 
Analysis software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php), 
version 3.5. Once the data was uploaded, the software prompted the selection of a 
housekeeping gene to be used, based on a list of calculated most stable options. The 
data was then normalized, using the selected control gene and the ΔΔCT method was 
used for further analysis (Livak and Schmittgen, 2001). Briefly, the raw data was 
normalized to the housekeeping gene by subtracting the CT value for housekeeping gene 
from the CT value of the gene of interest. The mean value of all housekeeping genes is 
used, if multiple genes are selected). 
∆𝐶𝐶𝑇𝑇 = 𝐶𝐶𝑇𝑇 (𝑡𝑡𝑠𝑠𝑟𝑟𝑠𝑠 𝑠𝑠𝑟𝑟 𝑖𝑖𝑟𝑟𝑡𝑡𝑠𝑠𝑡𝑡𝑠𝑠𝑠𝑠𝑡𝑡) − 𝐶𝐶𝑇𝑇 (ℎ𝑠𝑠𝑜𝑜𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠𝑠𝑠𝑠𝑠𝑖𝑖𝑟𝑟𝑡𝑡 𝑡𝑡𝑠𝑠𝑟𝑟𝑠𝑠) 
Following, the mean ΔCT value for all biological replicates was calculated; the mean ΔCT 
was then used to calculate the ΔΔCT by subtracting the ΔCT of the control group from the 
ΔCT of the test group. 
∆∆𝐶𝐶𝑇𝑇 =  ∆𝐶𝐶𝑇𝑇 (𝐿𝐿𝐿𝐿𝑠𝑠𝐿𝐿 𝑔𝑔𝑃𝑃𝑡𝑡𝑃𝑃𝑔𝑔) −  ∆𝐶𝐶𝑇𝑇 (𝐿𝐿𝑡𝑡𝑓𝑓𝐿𝐿𝑃𝑃𝑡𝑡𝑡𝑡 𝑔𝑔𝑃𝑃𝑡𝑡𝑃𝑃𝑔𝑔) 
Finally, the fold-change (FC) difference was calculated by converting the ΔΔCT to a linear 
scale from a log2 scale using the equation below: 
FC =  2(−∆∆𝐶𝐶𝑇𝑇) 
Once calculated, the fold-change values represented the difference in expression 
between control and test groups, with values higher than 1 representing upregulation 
and values lower than 1 – downregulation. A better visual representation of this 
information is referred to as “fold-regulation” where all fold-change values lower than 
1 are presented as negative inverse fold-change, i.e. -1 is divided by the fold-change, 
resulting in a negative value. For example, a fold-change of 0.2 would be presented as a 
fold-regulation of -5. 
The data was represented using scatter plots and volcano plots. The scatter plots 
compared the normalised expression for all genes in each infection model to the 
uninfected controls. Each scatter plot has a single solid trendline indicating a baseline, 
where no difference was observed between the two treatments, and two dashed lines, 




used to present fold-dysregulation versus p-value. Each graph has a single black 
horizontal line, representing a threshold p-value p = 0.05. Additionally, three vertical 
lines can be seen. A single thick grey line indicating a baseline fold-change of 1, and two 
thin grey lines surrounding it, marking fold-deregulation in expression of more than -2-
fold downregulation or more than 2-fold upregulation. 
The statistical significance of the dysregulation observed was assessed using Student’s 
t-test, comparing each infection model to untreated controls. 
5.3. Results 
 qPCR array housekeeping gene selection 
Out of the 5 housekeeping genes used in the qPCR array the software detected HPRT1 
as the most stable gene with values showing standard deviation between groups of 
0.111, with mean CT values for each group seen in Table 5.2. 
 qPCR array data 
All control samples passed the respective assessments, meaning that the data was 
comparable between all arrays, there was no differences in how effective the cDNA 
synthesis was between different cDNA reactions and there was no genomic DNA 
contamination in the samples. 
Fold regulation and p-values were calculated for all of the genes in the qPCR array and 
for each infection model tested. Three biological replicates were used for each infection 
model investigated. The gene dysregulation was assessed as statistically significant 
change based on 2-fold change of fold regulation combined with p-values p < 0.05. If 
only one of the criteria was present, then the change was considered a trend. 
In the 00035 infection model a total of 56 genes showed signs of dysregulation 
compared to untreated controls, with 44 upregulated genes and 12 downregulated 
genes; 64% (36 genes) of the dysregulated genes showed statistically significant change, 
while 36% were only showing a trend (one gene had a statistically significant difference 
between mock and infected samples but the dysregulation was not greater than 2-fold 
Table 5.2. Housekeeping gene selection for qPCR array analysis (CT values) 
Gene 
Mocks 00035 B3 CFU2 
M1 M2 M3 I1 I2 3 I1 I2 3 I1 I2 3 
HPRT1 25.8 25.7 26.2 25.8 26.1 25.7 25.8 25.6 25.7 26.1 26.1 25.9 






and 19 genes had fold-regulation of more than 2-fold upregulation or -2-fold 
downregulation with p > 0.05). Table 5.3 presents the fold regulation and p-values for 
this infection model, while Figure 5.8 represents scatter and volcano plots. Gene 
ontology and STRING analyses can be found in Appendix D Figure 1. Out of the 
statistically significantly dysregulated genes, 13 were associated with methylated 
promoter regions in prostate cancer, 9 are transcription factors involved in the control 
of numerous processes, 7 are involved in the PI3K/AKT signalling pathway. Androgen 
receptor signalling and apoptosis involved 6 of the genes investigated, 5 of the genes 
participate in cell cycle control, and two have been linked to prostate cancer metastasis. 
Some genes are involved in more than one of the signalling pathways listed above, as 
seen in Table 5.1. 
Cells infected with the type IB strain B3 had 9 genes with increased expression and 3 
with decreased (a total of 12 genes). Out of these genes, only one was significantly 
dysregulated (TFPI2 with 3.5-fold upregulation, p = 0.0002); additionally, only one gene 
showed a fold-regulation change greater than 2 but no significance (SOCS3, 2.5-fold 
increase, p = 0.12). The remaining 10 genes showed p-values p > 0.05, but fold-change 
in the -2-fold decrease to 2-fold increase range. Results for this infection model can be 
seen in Table 5.4 and scatter and volcano plots in Figure 5.9. Gene ontology and STRING 
analyses can be found in Appendix D Figure 2. 
The third set of infection models investigated were cells infected with the type III strain 
CFU2. These arrays showed dysregulation in 59 genes, 57 of which were upregulated 
and 2 downregulated (only one of which, ETV1, showed statistical significance with 4.29-
fold decrease and p = 0.0002). Significant dysregulation was seen in 23 genes (39%) and 
only p-value significance was seen in 36 genes (61%). The results for the CFU2 infection 
model can be found in Table 5.5; scatter and volcano plots can be seen in Figure 5.10. 
Gene ontology and STRING analyses can be found in Appendix D Figure 3. Out of the 23 
genes showing significant changes in expression, 6 either have methylated promoters in 
the context of prostate cancer or are known transcription factors. There are 5 
dysregulated genes in this infection model that play a role in both PI3K/AKT signalling 
and the androgen receptor signalling (namely FOXO1, GNRH1, TIMP2, TIMP3, and 






Table 5.3. qPCR array results for the 00035 infection model 
Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
IL6 1811.96 0.0000 + + +        
SOCS3 42.13 0.0031          U 
GPX3 41.07 0.0000        +   
TNFRSF10D 27.16 0.0031  +      +   
TMPRSS2 18.42 0.0000       +    
PTGS2 14.62 0.0000    +    +   
SFRP1 12.76 0.0004        +  D 
B2M 10.85 0.0004 Housekeeping gene 
LGALS4 9.19 0.0001          D 
TFPI2 8.96 0.0000          D 
EGR3 8.71 0.0018         +  
CCNA1 8.55 0.0058    +    +   
SOX4 6.06 0.0007         + U 
DKK3 5.88 0.0001        +   
NKX3-1 5.15 0.0043         +  
IGFBP5 4.94 0.0001          U 
LOXL1 4.89 0.0001          D 
DLC1 4.88 0.0046        +   
GNRH1 4.51 0.0124 + + +        
MSX1 3.83 0.0010        + +  
VEGFA 3.77 0.0003 + +         
RASSF1 3.34 0.0057        +   
BCL2 3.21 0.0186 +  + +       
TIMP2 2.73 0.0005 + + +     +   
DDX11 2.68 0.0212          U 
CCND1 2.57 0.0053 + +  +       
SUPT7L 2.30 0.0010         + U 
ARNTL 2.26 0.0015        +  U 
HMGCR 2.20 0.0013     +      
RBM39 2.08 0.0040         + U 
GSTP1 1.56 0.0016        +   
SEPT 1.73 0.0045      +     
MAPK1 1.62 0.0079 +  +        
CAV1 1.84 0.0100  +      +   
FOXO1 1.51 0.0161 + +       +  
CASP3 1.53 0.0173   + +       
PDPK1 1.35 0.0223 +         U 
CLN3 1.69 0.0245          D 
PES1 1.95 0.0266      +     
PPP2R1B 1.21 0.0283    +      D 
GCA 1.36 0.0339          D 






Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
HAL 1.76 0.0459          U 
ACTB 1.26 0.0462 Housekeeping gene 
PDLIM4 -11.60 0.0033        +   
ETV1 -8.40 0.0001   +      + U 
CCND2 -3.10 0.0012 +   +      D 
GAPDH -2.77 0.0092 Housekeeping gene 
TIMP3 -2.39 0.0013 + + +        
PTGS1 -2.27 0.0222  
ERG -2.21 0.2790         +  
RPLP0 -1.74 0.0041 Housekeeping gene 
MGMT -1.86 0.0108        +   
CDH1 -1.59 0.0156 +       +   
KLHL13 -1.86 0.0200      +     
NDRG3 -1.67 0.0228      +     
FASN 1.71 0.0895     +      
SHBG 1.44 0.2908         +  
CAMSAP1 1.41 0.0808          U 
NFKB1 1.38 0.0530 + + +      +  
MAX 1.22 0.1713      +   +  
CAV2 1.21 0.0596    +       
APC 1.18 0.1162    +    +   
SCAF11 1.16 0.2588      +     
PRKAB1 1.15 0.3233     +      
TGFB1I1 1.11 0.6894  +         
IGF1 1.10 0.4953 + + + +      D 
DAXX 1.06 0.7154 +        +  
PTEN 1.02 0.8460 + + + +       
HPRT1 1.00 - Housekeeping gene 
SREBF1 1.00 0.9054     +    +  
ACACA -1.00 0.9885     +      
AR -1.01 0.8874 + +      + +  
SLC5A8 -1.01 0.8874        +  D 
EDNRB -1.01 0.8874        +   
NRIP1 -1.05 0.7961  +       +  
KLK3 -1.06 0.6492          U 
ECT2 -1.06 0.5336          U 
CDKN2A -1.08 0.2504 +  + +    + +  
CAMKK1 -1.12 0.5185     +      
MTO1 -1.15 0.2078          U 
CREB1 -1.16 0.0907      +   +  
USP5 -1.25 0.3491          D 
AKT1 -1.29 0.2835 +          






Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
RARB -1.46 0.2100        + +  
STK11 -1.54 0.1933     +      
TP53 -1.56 0.0539 +  + +     +  
MKI67 -1.82 0.1645       +    
Role in prostate cancer indicates which pathways the genes are involved in: 1. PI3K/AKT 
signalling pathway; 2. Androgen receptor signalling; 3. Apoptosis; 4. Cell cycle;  
5. Fatty acid synthesis; 6. Metastasis; 7. Other prostate cancer-related genes; 8. Genes in 
methylated promoters in prostate cancer; 9. Transcription factor; UD indicates whether 










Figure 5.8. 00035 infection model qPCR array results. 
A. Scatter plot with values dysregulated more than +/- 2-fold shown in colour; upregulated (green), downregulated (red). The thick black line indicates 
no fold change, and the two dashed lines mark +/- 2-fold dysregulation. 
B. Volcano plots of fold change versus p-value. Values dysregulated more than +/- 2-fold shown in colour. Black horizontal line indicates p = 0.05; 
upregulated genes (green), downregulated genes (red). The solid grey line indicated no fold change, and the two dashed grey lines mark +/- 2-fold 
dysregulation. 
Legend: A5 – ARNTL; A6 – BCL2; A12 – CCNA1; B1 – CCND1; B2 – CCND2; B8 – DDX11; B9 – DKK3; B10 – DLC1; C2 – EGR3; C3 – ERG; C4 – ETV1;  
C8 – GNRH1;C9 – GPX3; C12 – HMGCR; D2 – IGFBP5; D3 – IL6; D6 – LGALS4; D7 – LOXL1; D12 – MSX1; E4 – NKX3-1; E6 – PDLIM4; E12 – PTGS1;  
F1 – PTGS2; F3 – RASSF1;F4 – RBM39; F7 – SFRP1; F10 – SOCS3; F11 – SOX4; G2 – SUPT7L; G3 – TFPI2; G5 – TIMP2; G6 – TIMP3; G7 – TMPRSS2;  








Table 5.4. qPCR array results for the B3 infection model 
Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
TFPI2 3.53 0.0002          D 
SOCS3 2.49 0.1200          U 
ETV1 1.97 0.0004   +      + U 
B2M 1.47 0.0008 Housekeeping gene 
NKX3-1 1.76 0.0022         +  
DLC1 1.44 0.0053        +   
ARNTL 1.40 0.0057        +  U 
TIMP2 1.31 0.0282 + + +     +   
IL6 1.81 0.0327 + + +        
TIMP3 -1.60 0.0124 + + +        
FOXO1 -1.46 0.0474 + +       +  
CAV1 -1.16 0.0490  +      +   
LGALS4 1.68 0.1698          D 
PTGS2 1.55 0.1335    +    +   
SOX4 1.52 0.239         + U 
BCL2 1.48 0.1772 +  + +       
VEGFA 1.46 0.0695 + +         
GPX3 1.38 0.2295        +   
CCND1 1.36 0.0511 + +  +       
DDX11 1.34 0.3634          U 
TNFRSF10D 1.32 0.576  +      +   
GNRH1 1.30 0.0836 + + +        
CCNA1 1.25 0.1023    +    +   
PES1 1.25 0.3404      +     
NRIP1 1.24 0.054  +       +  
CCND2 1.23 0.1077 +   +      D 
TGFB1I1 1.23 0.4035  +         
NFKB1 1.22 0.1106 + + +      +  
LOXL1 1.22 0.3398          D 
USP5 1.22 0.5144          D 
FASN 1.21 0.5573     +      
SHBG 1.19 0.6497         +  
RASSF1 1.19 0.6591        +   
CAMSAP1 1.18 0.4205          U 
DAXX 1.16 0.3201 +        +  
PDPK1 1.12 0.1913 +         U 
RBM39 1.12 0.5765         + U 
MKI67 1.12 0.9317       +    
CDKN2A 1.11 0.1412 +  + +    + +  
CAMKK1 1.11 0.6345     +      
STK11 1.11 0.7425     +      






Gene Fold regulation 
p-
value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
MTO1 1.09 0.5013          U 
GCA 1.08 0.3115          D 
SUPT7L 1.08 0.6284         + U 
GAPDH 1.08 0.6943 Housekeeping gene 
PRKAB1 1.07 0.5955     +      
CLN3 1.07 0.8123          D 
ACACA 1.06 0.6596     +      
SREBF1 1.05 0.8791     +    +  
AKT1 1.03 0.9094 +          
CASP3 1.02 0.8471   + +       
SCAF11 1.01 0.9869      +     
HPRT1 1.00 - Housekeeping gene 
APC -1 0.9722    +    +   
PPP2R1B -1 0.9735    +      D 
SEPT7 -1.01 0.8963      +     
CAV2 -1.01 0.9489    +       
MAPK1 -1.02 0.8889 +  +        
MSX1 -1.02 0.902        + +  
HMGCR -1.03 0.7852     +      
IGF1 -1.03 0.8308 + + + +      D 
RPLP0 -1.04 0.6227 Housekeeping gene 
MGMT -1.04 0.6343        +   
ACTB -1.05 0.5821 Housekeeping gene 
CDH1 -1.05 0.6917 +       +   
DKK3 -1.05 0.6971        +   
PTEN -1.07 0.3873 + + + +       
MAX -1.07 0.5794      +   +  
ECT2 -1.08 0.5213          U 
TP53 -1.09 0.3631 +  + +     +  
SFRP1 -1.09 0.6054        +  D 
ZNF185 -1.1 0.5285        +   
PDLIM4 -1.11 0.4994        +   
CREB1 -1.12 0.1473      +   +  
HAL -1.12 0.3615          U 
AR -1.14 0.2943 + +      + +  
SLC5A8 -1.14 0.2943        +  D 
EDNRB -1.14 0.2943        +   
TMPRSS2 -1.14 0.2943       +    
PTGS1 -1.18 0.2801    +       
RARB -1.18 0.5158        + +  
IGFBP5 -1.19 0.1244          U 
EGFR -1.19 0.3488 + +  +       






Gene Fold regulation 
p-
value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
KLK3 -1.21 0.2212          U 
EGR3 -1.21 0.578         +  
KLHL13 -1.3 0.1973      +     
ERG -1.95 0.3507         +  
Role in prostate cancer indicates which pathways the genes are involved in: 1. PI3K/AKT 
signalling pathway; 2. Androgen receptor signalling; 3. Apoptosis; 4. Cell cycle;  
5. Fatty acid synthesis; 6. Metastasis; 7. Other prostate cancer-related genes; 8. Genes in 
methylated promoters in prostate cancer; 9. Transcription factor; UD indicates whether 











Figure 5.9. B3 infection model qPCR array results. 
A. Scatter plot with values dysregulated more than +/- 2-fold shown in colour; upregulated (green), downregulated (red). The thick black line indicates 
no fold change, and the two dashed lines mark +/- 2-fold dysregulation. 
B. Volcano plots of fold change versus p-value. Values dysregulated more than +/- 2-fold shown in colour. Black horizontal line indicates p = 0.05; 
upregulated genes (green), downregulated genes (red). The solid grey line indicated no fold change, and the two dashed grey lines mark +/- 2-fold 
dysregulation. 






Table 5.5. qPCR array results for the CFU2 infection model 
Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
IGFBP5 10.08 0.0059          U 
LGALS4 3.43 0.0119          D 
GPX3 3.08 0.0007        +   
CAMKK1 3.07 0.0010     +      
SOX4 3.07 0.0010         + U 
DDX11 3.02 0.0024          U 
RBM39 3.02 0.0006         + U 
FOXO1 2.57 0.0015 + +       +  
RASSF1 2.56 0.0143        +   
EGR3 2.52 0.0050         +  
TIMP2 2.43 0.0081 + + +     +   
FASN 2.36 0.0066     +      
CLN3 2.28 0.0025          D 
GNRH1 2.26 0.0004 + + +        
ZNF185 2.23 0.0033        +   
PTGS1 2.19 0.0047    +       
PDLIM4 2.12 0.0033        +   
MKI67 2.10 0.0460       +    
VEGFA 2.08 0.0043 + +         
SREBF1 2.07 0.0343     +    +  
DLC1 2.04 0.0005        +   
TIMP3 2.02 0.0015 + + +        
B2M 1.49 0.0008 Housekeeping gene 
PTEN 1.72 0.0010 + + + +       
ARNTL 1.94 0.0014        +  U 
CAV1 1.62 0.0016  +      +   
MAX 1.72 0.0024      +   +  
MAPK1 1.54 0.0032 +  +        
HMGCR 1.83 0.0036     +      
CREB1 1.43 0.0038      +   +  
GCA 1.62 0.0043          D 
SUPT7L 1.75 0.0046         + U 
SFRP1 1.78 0.0064        +  D 
PPP2R1B 1.48 0.0064    +      D 
DAXX 1.70 0.0069 +        +  
CAV2 1.64 0.0079    +       
NRIP1 1.50 0.0079  +       +  
PDPK1 1.72 0.0081 +         U 
CDH1 1.58 0.0116 +       +   
DKK3 1.88 0.0119        +   
APC 1.67 0.0129    +    +   






Gene Fold regulation 
p-
value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
ACACA 1.71 0.0137     +      
SCAF11 1.54 0.0145      +     
LOXL1 1.88 0.0147          D 
NDRG3 1.47 0.0166      +     
KLHL13 1.42 0.0176      +     
SEPT7 1.44 0.0191      +     
CAMSAP1 1.74 0.0205          U 
GSTP1 1.27 0.0217        +   
EGFR 1.44 0.0225 + +  +       
USP5 1.92 0.0247          D 
CASP3 1.32 0.0275   + +       
BCL2 1.95 0.0355 +  + +       
NFKB1 1.38 0.0399 + + +      +  
ECT2 1.30 0.0431          U 
HAL 1.78 0.0463          U 
ETV1 -4.29 0.0002   +      + U 
CDKN2A -1.24 0.0277 +  + +    + +  
TMPRSS2 1.78 0.1346       +    
TGFB1I1 1.59 0.0716  +         
STK11 1.59 0.1194     +      
SOCS3 1.52 0.6729          U 
AKT1 1.50 0.0696 +          
RARB 1.47 0.1572        + +  
PES1 1.41 0.1147      +     
SHBG 1.39 0.3689         +  
ACTB 1.38 0.0521 Housekeeping gene 
TNFRSF10D 1.38 0.5153  +      +   
NKX3-1 1.23 0.0936         +  
PTGS2 1.12 0.3279    +    +   
KLK3 1.10 0.3987          U 
MTO1 1.09 0.4084          U 
AR 1.09 0.4969 + +      + +  
IGF1 1.09 0.4969 + + + +      D 
EDNRB 1.09 0.4969        +   
SLC5A8 1.09 0.4969        +  D 
MGMT 1.07 0.6460        +   
PRKAB1 1.04 0.7647     +      
TP53 1.03 0.7311 +  + +     +  
RPLP0 1.02 0.8422 Housekeeping gene 
HPRT1 1.00 - Housekeeping gene 
CCND2 -1.01 0.8673 +   +      D 
GAPDH -1.01 0.8764 Housekeeping gene 






Gene Fold regulation p-value 
Role in prostate cancer 
1 2 3 4 5 6 7 8 9 UD 
TFPI2 -1.09 0.2544                   D 
CCNA1 -1.16 0.1663       +       +     
IL6 -1.20 0.4211 + + +               
ERG -1.34 0.4980                 +   
Role in prostate cancer indicates which pathways the genes are involved in: 1. PI3K/AKT 
signalling pathway; 2. Androgen receptor signalling; 3. Apoptosis; 4. Cell cycle;  
5. Fatty acid synthesis; 6. Metastasis; 7. Other prostate cancer-related genes; 8. Genes in 
methylated promoters in prostate cancer; 9. Transcription factor; UD indicates whether 









Figure 5.10. CFU2 infection model qPCR array results. 
A. Scatter plot with values dysregulated more than +/- 2-fold shown in colour; upregulated (green), downregulated (red). The thick black line 
indicates no fold change, and the two dashed lines mark +/- 2-fold dysregulation. 
B. Volcano plots of fold change versus p-value. Values dysregulated more than +/- 2-fold shown in colour. Black horizontal line indicates p = 0.05; 
upregulated genes (green), downregulated genes (red). The solid grey line indicated no fold change, and the two dashed grey lines mark +/- 2-fold 
dysregulation. 
Legend: A7 – CAMKK1; B5 – CLN3; B8 – DDX11; B10 – DLC1; C2 – EGR3; C4 – ETV1; C5 – FASN; C6 – FOXO1; C8 – GNRH1; C9 – GPX3; D2 – IGFBP5; 
D6 – LGALS4; D11 – MKI67; E6 – PDLIM4; E12 – PTGS1; F3 – RASSF1; F4 – RBM39; F11 – SOX4; F12 – SREBF1; G5 – TIMP2; G6 – TIMP3; G11 – VEGFA; 






infection model. Fatty acid synthesis-related genes show significant upregulation only in 
3 genes; only one gene involved in the cell cycle (SREBF1, 2.07-fold increase and p = 
0.0343) is affected as a result of infection. 
5.4. Discussion 
The results presented in this chapter confirm that the response of prostate epithelial 
cells to infection differ depending on the P. acnes strain which is used to challenge them. 
 Housekeeping genes 
The housekeeping gene selection algorithm used by the QIAGEN software selected 
HPRT1 as the most stable housekeeping gene out of the 5 options available, which is in 
line with our findings from Chapter 3 using the Normfinder software (Section 3.3.10). 
What is interesting is that the 00035 infection model demonstrated statistically 
significant dysregulation in two of the housekeeping genes B2M and GAPDH (10.85-fold 
upregulation, with p = 0.0004 and -2.77-fold downregulation, p = 0.0092) which 
highlights the importance of careful selection of stable housekeeping genes. 
Beta-2-microglobulin (B2M), is one of the components of class I major histocompatibility 
complex (MHC). It has been shown to be upregulated in prostate cancer, as it has 
androgen receptor (AR)-dependent expression (Mink et al., 2010). Cell culture 
experiments suggest that B2M expression has a higher specificity as a prognostic marker 
for AR activity than PSA (Gross et al., 2007). GAPDH is a key regulator of glycolysis, but 
it has also been shown to be affected by a number of factors dysregulated in cancer 
(Zhang et al., 2015). For example, hypoxia-driven increase in GAPDH can lead to 
activation of the PI3K/AKT signalling pathway, causing increased cellular proliferation 
(Zhang et al., 2015). Other studies have shown that GAPDH expression is indirectly 
controlled by p53, however, the mechanism is unclear (Chen et al., 1999). 
Despite the fact that both genes have been described in the literature as dysregulated 
in cancer progression, they have both been included as potential housekeeping control 
in the qPCR array, highlighting a limitation of the use of pre-designed commercially 
available arrays. 
 B3 infection model 
The cells infected with B3 only showed significant dysregulation of only two genes, 




While the SOCS3 gene is associated with promoter methylation and is silenced in roughly 
40% of prostate cancers, the results from this infection model contradict those previous 
findings (Pierconti et al., 2011). As the members of the SOCS family are involved in the 
control of IL-6, JAK/STAT3, ERK/MAPK, PI3K/AKT, NF-κB signalling, it is not surprising 
that there is an increase it its levels, albeit non-significant (Larsen and Ropke, 2002; Rui 
et al., 2002; Park et al., 2003; Wang et al., 2005). The second gene upregulated in the B3 
infection model is TFPI2. TFPI2 is normally downregulated in cancer and in vitro 
experiments have shown that if levels of TFPI2 are increased the tumour becomes less 
aggressive (Konduri et al., 2001). 
As neither of the genes dysregulated in this infection model are involved in the 
progression of cancer, and due to the low number of dysregulated prostate cancer-
related genes, infection with the type IB strain B3 seems to be an unlikely cause of 
oncogenesis. This contradicts previous findings where a type IB strain (prostate isolate 
P6) was shown to drive cancer-related changes in the RWPE-1 cell line (Fassi Fehri et al., 
2011; Mak et al., 2012). The difference in the results observed is likely due to the 
difference in sequence type of the IB strains used, as with strain B3 being identified as 
ST5 (Chapter 3, Section 3.3.1) and strain P6 belonging to ST119 (Mak et al., 2013a). 
 00035 and CFU2 infection models 
Unlike the B3 infection model, both cells infected with 00035 (type IA1) and cells 
infected with CFU2 (type III) demonstrated dysregulation of multiple genes, 36 and 23, 
respectively, showed both more than 2-fold dysregulation and p-value p > 0.05. 
5.4.3.1. PI3K/AKT signalling and apoptosis 
Out of all pathways investigated by the qPCR array, the PI3K/AKT pathway had the 
highest number of dysregulated genes in both infections (6 genes in the 00035 models, 
and 5 in cells infected with CFU2), four of which were common between the two 
infection models. 
The PI3K/AKT pathway has the power to inhibit BCL2, which plays a key role in apoptosis, 
and is upregulated in the 00035 infection model (3.21-fold increase, p = 0.0186); this 
suggests that the increased level of Bcl-2-driven inhibition could make cells resist 
apoptosis, even if death signals are received. Furthermore, studies have shown that 




suggesting that infection with this strain could lead to castration resistance (Cory et al., 
2003; Lin et al., 2007). In contrast, the cells infected with CFU2 demonstrated high 
expression of FOXO1 (2.57-fold, p = 0.0015) which is a promoter of apoptosis and 
increased levels of FOXO1 have been shown to decrease AR-driven cell proliferation, 
implying that CFU2 infection opposes androgen resistance. (Ma et al., 2009). These 
findings highlight the difference in the effect different phylogenetic types have on 
prostate epithelial cells and support the potential role of infection in the development 
of treatment-resistant cancer. They also support the hypothesis that some strains have 
the potential to drive oncogenesis (strain 00035), while other have a cancer-protective 
role (strain CFU2). 
TRAIL (encoded by TNFRSF10) plays a role in death signalling and apoptosis activation 
and is significantly upregulated in the 00035 infection model (27.15-fold, p = 0.0026). 
TRAIL expression can be activated through a number of pathways and genes, including 
NF-κB signalling, STAT3 signalling, FOXO1, cytokines and infection, with the latter being 
the most likely reason for its upregulation in this case (Allen and El-Deiry, 2012). 
Another gene dysregulated in the 00035 infection that has normal expression in the 
CFU2 model is IL6. The explanation for the difference here is most likely due to the 
significantly higher number of bacteria still present in the medium at this time point (as 
seen in Chapter 4, Section 4.3.2.2), which initiate cytokine signalling pathways, aimed at 
the eradication of the infection by the immune system, which cannot be achieved in the 
closed system of an infection model. A similar reason is also likely behind the 
upregulation of TRAIL. 
TIMP2 and TIMP3 are both dysregulated in the two infections. TIMP2 is upregulated in 
both infection models (2.73-fold, p = 0.0005 in 00035 and 2.46-fold, p = 0.0081 in CFU2-
infected cell). TIMP2 has been shown to be downregulated in prostate cancer which 
contradicts the findings here, though the exact mechanism of its involvement in cancer 
is not clear (Bratland et al., 2003). With TIMP3, a difference in expression is seen 
between the two infections – a significant increase in cells infected with CFU2 (2.02-fold, 
p = 0.0015) and a decrease in 00035 infection models (-2.39-fold, p = 0.0013). The latter 
results are in line with findings in prostate cancer studies which have shown that the 
TIMP3 promoter region is usually methylated (97% of cases) and thus the gene 




to confirm the downregulation here is a result of an epigenetic change. Conversely, the 
upregulation in the CFU2 models again hints towards this model exhibiting some cancer-
protective gene dysregulation, as increase of TIMP3 has been linked to increase in 
apoptosis and improved susceptibility to treatment (Jeronimo et al., 2004). 
MMPs are the primary target of TIMPs and are a family of 28 endopeptidases which 
have been implicated in cancer progression, angiogenesis and EMT. The different MMPs 
and their functions have been reviewed in detail by Kessenbrock et al. (2010). As no 
information is available for the expression of MMPs which are targeted by the TIMPs 
investigated by the qPCR, it is difficult to interpret the significance of their upregulation. 
Further experiments, aiming to quantify the protein levels of the different TIMPs and 
the MMPs they target would give insight into the importance of the molecular 
dysregulation observed here. 
Both infections have a statistically significant increase in VEGFA (3.77-fold upregulation, 
p = 0.0003 in 00035-infected cells and 2.08-fold, p = 0.0043 in CFU2 infections) which is 
a known promoter of angiogenesis as it acts specifically on endothelial cells, leading to 
increased proliferation, survival and migration (Hoeben et al., 2004). 
Overall, the gene dysregulation in this pathway points towards apoptosis resistance and 
androgen-independent growth in the 00035 infection, findings consistent with prostate 
cancer. In contrast, cells infected with CFU2 demonstrate increased apoptosis and 
androgen-dependence. 
5.4.3.2. Cell cycle-related genes 
Another gene which is dysregulated in both infection models is E26 transformation 
specific (ETS) translocation variant 1 (ETV1, -8.4-fold, p = 0.0001 and -4.29-fold, p = 
0.0002 in 00035 and CFU2 infections, respectively), which has been shown to work in 
concert with the AR (Baena et al., 2013). It is worth noting that the RWPE-1 cell line used 
in this study requires stimulation with androgen to express the AR and is thus not a 
suitable model to investigate this interaction. Studies have shown that in prostate 
cancer the ETV1 gene is commonly translocated and is under the influence of TMPRSS2; 
the downregulation of ETV1 combined with the high level of expression of TMPRSS2 
(18.42-fold increase, p < 0.0001) in the 00035 infection model strongly suggest that no 




transcription factor family is ETS-related gene (ERG), which similarly to ETV1, has been 
shown to be translocated, thus forming a complex with TMPRSS2 (Tomlins et al., 2005). 
Similarly to ETV1, ERG shows a trend in expression towards a decrease in infected cells, 
as the downregulation is not significant (-2.21-fold, p = 0.27) once again suggesting that 
no translocation has occurred. 
Cyclins A, D1, and D2 are all dysregulated in the 00035 infection model (8.55-fold 
increase, p = 0.0058; 2.57-fold increase, p = 0.0053; -3.1-fold decrease and p = 0.0012, 
respectively). Cyclin A1, one of the regulators of the cell cycle is significantly 
upregulated, which could be a result of IL-6-driven activation of the PI3K/AKT and ERK 
signalling pathways (Wegiel et al., 2008). This increase can lead to dysregulation of the 
cell cycle and promote uncontrolled cell division but cyclin A1 has also been shown to 
cause expression of VEGFA, which would allow angiogenesis and enhance cancer 
progression (Wegiel et al., 2005). The dysregulation of cyclins D1 (upregulated) and 
cyclin D2 (downregulated) are in agreement with the expectation for prostate cancer; 
increased CCND1 expression is suggested to have a role in androgen-independent 
growth and metastasis, and decrease in CCND2 transcription is also linked to metastatic 
growth (Drobnjak et al., 2000; Chen et al., 2017). 
The dysregulation seen in the cell cycle-related genes also point towards cancer-like 
dysregulation in the 00035 infection models with dysregulation suggesting uncontrolled 
division, androgen-independence and metastasis. 
5.4.3.3. Wnt/β-catenin signalling pathway 
Two genes involved in the suppression of Wnt/β-catenin signalling are upregulated in 
both 00035 and CFU2-infected cells (secreted frizzled-related protein 1 (SFRP1), which 
acts as an inhibitor of Frizzled, and Dickkopf-related protein (DKK), which inhibits the 
Frizzled-associated lipoprotein receptor-related protein, or LRP). The upregulation of 
the two inhibitors suggest that infected cells do not have increased migration and 
decreased adhesion resulting from β-catenin signalling. Additionally, the upregulation 
seen in the infection models of β-catenin targets, e.g. CCND1, is also not a result of 
activation of this signalling pathway. Both SFRP and DKK have methylation in their 
promoter regions in prostate cancer, and are thus downregulated, allowing the 




Expression of both prostaglandin G/H synthase 1 (PTGS1) and PTGS2 is under the 
influence of the Wnt/β-catenin signalling pathways and both genes are dysregulated in 
the infection models. PTGS1 (also known as cyclooxygenase 1 or COX-1) is 
downregulated in the 00035 infection and upregulated in the CFU2-infection (-2.27-fold 
and p = 0.0222, and 2.19-fold and p = 0.0047, respectively). COX-1 a has primarily 
housekeeping function being responsible for the normal functioning of the cell and the 
dysregulation seen here is most likely due to the stress resulting from infection. COX-2 
in only dysregulated in the 00035 infection model, where a 14.62-fold increase is seen 
(p < 0.0001); this increase is likely a result of cytokine signalling activated by the ongoing 
infection. High levels of COX-2 are suspected to play a role in promoting tumorigenesis 
by helping the cells to resist apoptosis in the earlier stages of cancer progression and 
driving angiogenesis at the later stages (Tsujii and DuBois, 1995; Gallo et al., 2001). 
The dysregulation seen in COX-2 further supports a role of 00035 infection in apoptosis 
evasion. 
5.4.3.4. Fatty acid synthesis and related pathways 
A total of five genes involved in fatty acid and cholesterol biosynthesis are dysregulated 
in the CFU2 infection models, with HMGCR also having increased expression in cells 
infected with 00035. Additionally, GAPDH, involved in glycolysis is also dysregulated in 
00035 infections. Due to the low number of fatty acid synthesis pathway members 
dysregulated in the cells infected with 00035, no conclusions of the significance can be 
made. 
In contrast, in the CFU2 infection model, the dysregulated genes are related in function 
and may influence each other’s activity. FAS (encoded by FASN, with 2.36-fold 
upregulation, p = 0.0066) is the key enzyme in de novo fatty acid synthesis and is 
commonly upregulated in prostate cancer (Flavin et al., 2010). An upregulation is also 
seen in the FAS activator SREBP (encoded by SREBPF1); 2.07-fold, p = 0.0343). An 
upstream increase in expression of CAMKK1 (3.07-fold increase, p =0.000954), which 
acts as an inhibitor for AMPK, which is in turn normally downregulates the production 
of SREBP. There is an increase in CAMKK1 expression, AMPK-inhibition of SREBP1 is not 
seen, and an expected increase in FAS is observed. Additionally, SREBP-induced increase 
is also seen in ACACA, which acts as a limiting step in de novo fatty acid synthesis, 




a trend towards increased expression (1.83-fold, p = 0.00356) is seen in HMGCR, the 
enzyme controlling the conversion of acetyl-CoA to mevalonate, the rate limiting step 
of the mevalonate pathway and cholesterol biosynthesis (products of which are steroid 
hormones, including testosterone and DHT) (Murtola et al., 2012). 
Taken together these findings suggest an induction of the fatty acid synthesis pathway 
by infection with strain CFU2, which is line with prostate cancer behaviour but as no 
other dysregulation pointing towards cancer-like behaviour in this infection model, this 
increase in fatty acid synthesis and its related pathways is likely a metabolic switch 
aiming lipogenesis as means of storing energy (Wu et al., 2014). 
5.4.3.5. Promoter methylation 
Promoter methylation plays an important role in silencing gene transcription, especially 
in cancer. Out of the dysregulated genes in the array following infection with the type 
IB and type III strains there are a total of 11 genes that have methylated promoters in 
prostate cancer, 9 are dysregulated in the 00035 infection and 6 in the cells infected 
with CFU2. Only one of those genes, PDLIM4 shows decrease in expression levels 
(00035-infection model, -11.6-fold downregulation, p = 000033), which would be the 
expected outcome if the promoter had become hypermethylated; methylation of the 
PDLIM4 gene has been suggested as a molecular biomarker for prostate oncogenesis 
(Vanaja et al., 2006). However, further analysis is necessary to confirm that the 
downregulation is as a result of epigenetic changes. 
5.4.3.6. Transcription factors and other prostate cancer-related genes 
A number of transcription factors commonly involved in prostate cancer are also 
included in the array, with 6 transcription factors having no functions related to the 
pathways outlined above being included, making the analysis of the significance of their 
upregulation difficult. 
The homeobox protein NKX3.1 is a known tumour suppressor in prostate cancer and the 
disease is commonly associated with loss of heterozygosity of the NKX3.1 gene (Sakr et 
al., 1994; Suzuki et al., 1995; Vocke et al., 1996). Dysregulation of the NKX3.1 gene is 
seen in the 00035 infection model, namely an increase of 5.15-fold (p = 0.0043). 
However, the PCR array does not provide information whether both alleles of the genes 




Another transcription factor investigated is Aryl hydrocarbon receptor nuclear 
translocator-like protein 1 (ARNTL), also known as BMAL1, which forms an E-box-binding 
complex with circadian locomotor output cycles kaput (CLOCK) and plays a central role 
in circadian rhythm maintenance (Jung et al., 2003). Downregulation of CLOCK and 
increase in ARNTL have been linked to prostate cancer, and melatonin has been 
suggested as a regulator of this dysregulation and a potential management agent for the 
disease (Otalora et al., 2008; Jung-Hynes et al., 2010; Savvidis and Koutsilieris, 2012). 
Upregulated in both infections is GNRH1 (4.51-fold, p = 0.0124 and 2.26-fold, p = 0.0004, 
for 00035 and CFU2 infection, respectively), encoding GnRH, the gonadotropin releasing 
hormone. In vitro models of prostate cancer (PC-3, LNCaP, DU145) have previously been 
shown to produce GNRH transcripts and it was suggested that they play an autocrine 
role in cells, though clarity is needed on any such mechanism (Bahk et al., 1998) 
Another gene that is not involved in the pathways outlined here is CLN3, also called 
battenin, which is involved in lysosomal function and mutations in CLN3 have been 
linked to the neurodegenerative disorder Batten disease (Cotman and Staropoli, 2012). 
Overexpression of the CLN3 gene has been observed in a range of cancers cell lines, as 
well as in breast tumour specimens and it is upregulated in the CFU2-infection model 
(2.28-fold, p = 0.002481); it has been suggested as a possible drug target, as its silencing 
was shown to inhibit ovarian cancer progression and induce apoptosis. (Rylova et al., 
2002; Makoukji et al., 2015; Mao et al., 2015). However, its exact involvement in cancer 
progression is unclear 
 Summary 
The study was limited to only investigating 3 sets of infection models and a set of 3 
untreated controls due to financial constraints. It would, however, have been interesting 
to see what the dysregulation pattern of a prostate isolate of the phylogenetic type II 
would be, as well as the health associated strain ST27. Additionally, investigation of the 
dysregulation following longer infection (e.g. 30 days) would cause further 
dysregulation. 
A limitation of the method used here is the design of the array. Firstly, the genes selected 
are not all related to specific pathways, making it challenging to analyse the data 




included. An additional challenge to the analysis is that the array is not specifically 
designed for cell culture experiment analysis, but it is prepared in such a way, so it could 
work with patient samples, an example here being the inclusion of GNRH, which acts on 
the pituitary gland to stimulate the production of luteinising hormone (LH) and follicle 
stimulating hormone (FSH), and significance in the prostate alone is unclear. 
The findings of this chapter confirm that different phylogenetic types of P. acnes induce 
different response in the prostate epithelial cells, and also suggest that the type IA1 
strain 00035 is pro-oncogenic, as the dysregulation seen in the PI3K/AKT signalling 
pathway, apoptosis, cell cycle and Wnt/β-catenin-related genes all suggest 00035 
infection causes the prostate epithelial cells to exhibit cancer-like behaviour. In contrast, 
the CFU2 type III infection model, while also showing dysregulation, appears to be more 
cancer protective, as most of the dysregulation seen in the CFU2 infection model aims 











A wide range of studies have investigated the potential role of inflammation in the 
development of prostate cancer (extensively reviewed by Sfanos and De Marzo (2012)), 
with multiple observations supporting the part inflammation plays in oncogenesis. 
Multifocal inflammation is seen in the prostate gland in men of all ages, as demonstrated 
by autopsy studies (8% of teenagers, 28% of men aged 20-39, and 60% in men in aged 
between 40 and 59); the presence of inflammation with no evidence of prostate cancer 
suggests that the inflammation is not a result of immune response to a developing 
cancer (Boström, 1971). Possible causes of the inflammation seen within the prostate 
include infection, reactive oxygen species, or autoimmune disease. 
There is a long history of conflicting studies regarding the variety and prevalence of 
organisms which comprise the prostate microflora, with some studies suggesting that 
the gland is sterile (Hochreiter et al., 2000; Lee et al., 2003). As culturing techniques 
improved, Cohen et al. (2005) discovered a statistically significant (p = 0.007) association 
between the presence of P. acnes in cultures of radical prostatectomy samples (35% of 
culture positive samples) and acute and chronic inflammation in the prostate gland, and 
suggested that an asymptomatic infection with Propionibaterium acnes may play a role 
in the development of prostate adenocarcinoma. 
Studies have provided evidence for the potential of infection as a cause of the 
inflammation seen in prostate cancer. History of sexually transmitted infections is 
considered a risk factor for the development of malignancy (Dennis and Dawson, 2002). 
Additionally, single nucleotide polymorphisms in immune response-related genes have 
also been linked to increased risk of prostate oncogenesis, including macrophage 
scavenger receptor 1 (MSR-1), toll-like receptors (TLRs) 1, 4, 6 and 10 which are involved 
in the recognition of bacterial invaders, and ribonuclease L (RNaseL), linked to response 
to viral infection (Carpten et al., 2002; Xu et al., 2002; Zheng et al., 2004; Sun et al., 
2005). Furthermore, increased plasma levels of a number of cytokines are also seen in 
prostate cancer, and especially in castration therapy-resistant cancer, including 
interleukin (IL)-1β, IL-6 (with significantly higher expression in prostate cancer tissues 
compared to disease-free controls), IL-8, tumour necrosis factor (TNF-α) (Nakashima et 




The role of an infectious agent is also supported by the similarity of multifocal 
inflammation observed in prostate cancer relative to other malignancies with a known 
infective cause including gastric cancer induced by Helicobacter pylori, hepatocellular 
carcinoma initiated by hepatitis infection, and human papilloma virus (HPV)-related 
cervical cancer (Larson et al., 1997; Colombo, 2000; Faraji and Frank, 2002). 
The isolation of P. acnes from the prostate by Cohen et al. (2005) highlighted a perfect 
candidate for an infectious agent which could have the potential to drive oncogenesis 
by causing a chronic asymptomatic infection. Due to P. acnes’ requirement for anaerobic 
growth conditions and long incubation times, as well as resistance to commonly used 
lysis enzymes, such as lysozyme, P. acnes is difficult to detect using routine culturing 
techniques and with routinely used nucleic acid extraction procedures, which is why its 
presence in the prostate was not discovered earlier. Prostate cancer is a disease with 
high incidence, and if a bacterium is involved in its origin, it would tend towards a higher 
prevalence. This is another characteristic met by P. acnes as it is a member of the normal 
skin flora and the urinary tract microflora (Shannon et al., 2006a; Grice and Segre, 2011). 
The bacterium also has the ability to evade the immune system, as it can survive 
intracellularly in macrophages; this would allow it to cause a long-lasting infection 
(Fischer et al., 2013). Finally, there are similarities in the immune response seen in acne 
(which has also been linked to P. acnes) and prostate cancer. Both are linked to a delayed 
type hypersensitivity reaction, including increased levels of macrophages and CD4+ T 
helper (TH) cells (McClinton et al., 1990; Jeremy et al., 2003; Shannon et al., 2006b). 
Following the initial discovery by Cohen et al. (2005) and with the development of 
superior sequencing systems, multiple studies have since confirmed the presence of P. 
acnes in the prostate (Alexeyev et al., 2006; Sfanos et al., 2008; Chen and Wei, 2015; 
Cavarretta et al., 2017). Using fluorescent in situ hybridization, Alexeyev et al. (2007) 
demonstrated that P. acnes can be found both intracellularly and as extracellular 
biofilm-like aggregates; employing an immunohistochemical approach, Bae et al. (2014) 
showed the presence of P. acnes in both epithelial cells and macrophages. The presence 
of P. acnes was also found to be associated with a 4-fold increase of the risk of 
developing prostate cancer (OR: 4.5; 95%; CI: 1.93-11.26) (Davidsson et al., 2016). A 
number of in vitro infection models have also been employed, demonstrating that P. 




epithelial cells, including changes in vimentin levels, secretion of prostate cancer-related 
cytokines, dysregulation of nuclear factor-kappa B (NF-κB) and Janus kinase/signal 
transducer and activator of transcription 3 (JAK/STAT3) signalling, and cell cycle 
alterations (Drott et al., 2010; Fassi Fehri et al., 2011; Mak et al., 2012; Davidsson et al., 
2016; Sayanjali et al., 2016). A recent study, using primary prostate cells suggested that 
P. acnes infection may have a cancer-protective role, while using the same strain was 
previously used by the same group to demonstrate cancer-inducing behaviour in the 
RWPE-1 cell line (Fassi Fehri et al., 2011; Mak et al., 2012; Sayanjali et al., 2016). 
6.2. Summary of findings 
 Predominant isolates 
The predominant sequence of prostate isolates identified using the ‘Belfast’ MLST8 
scheme was identified as sequence type 5 (ST5), comprising 33% of all prostate isolates 
in the database. 
 Stable infection model 
Optimising the infection model limited the extrinsic factors which affect the prostate 
epithelial cells during experiments, to allow the direct effects of P. acnes on the host 
cells to be investigated, and provided a stable foundation for follow up experiments. It 
also enabled us to highlight any caveats associated with this particular in vitro infection 
model, which may prove important in the context of previously published work where 
this method was used. 
 Ability for intracellular survival 
P. acnes strains 00035, NCTC737, ST27 (type IA1) and B3 (type IB) appear to have a 
significantly higher ability to invade prostate epithelial cells, compared to the remaining 
phylogenetic types examined. 
 Phylotype-specific response to infection 
The optimised acute and chronic infection models demonstrated stable eukaryotic cell 
and viability counts, in both acute and chronic infections and the cells remained viable 
for the duration of the experiments. There were two groups of bacterial behaviour 
observed in the 5% CO2 humid environment – type IA1 strains (00035 and NCTC737) and 
phylotype IB (strain B3) showed growth in this environment, while ST27 and types II, III 




remained challenged with bacteria for 30 days only in experiments with the former 
group. This is an important observation in the context of chronic infection experiments, 
as it highlights differences in behaviour between phylogroups. 
All strains initiated an acute immune response, evaluated using qPCR, with the 
magnitude of upregulation being higher in phylotypes IA1 and IB. The prostate-derived 
type III strain showed the highest number of downregulated inflammatory genes, 
highlighting the phylotype-specific response observed. Dysregulation of the epithelial-
mesenchymal transition (EMT) genes studied is not consistent between time points, 
however, a trend is seen with significant increase in more EMT-related genes by 
phylotypes IA1 and IB and more decreases in expression induced by types II, III and P. 
granulosum. A similar pattern is observed when the gene dysregulation of chronic 
infection models was studied. The dysregulation patterns, however, are not consistent 
with what would be expected if cells were undergoing EMT. 
Anchorage-independent growth is seen in only one of the chronic infection models, and 
a trend towards increased migration was seen in cells infected with NCTC737 (24 hours 
post-wound creation), CFU2 and P. granulosum (48 hours post-wound creation). 
 Strain 00035 (type IA1) as a cancer inducing agent? 
Cells infected with the type IA1 strain were the only infection model to shown 
anchorage-independent growth in soft agar assays. This infection was also the only one 
to show downregulation of E-cadherin/CDH1, which is a marker of “cadherin switch” 
and EMT. The initial decrease seen at day 15 of a chronic infection was not observed in 
the qPCR experiment (Chapter 4, Section 4.3.2.3), however, a trend towards a decrease 
was seen in the qPCR array (-1.59-fold downregulation, p = 0.0156, Chapter 5, Section 
5.3.2). By the day 30 timepoint, a significant decrease of -2.1-fold was seen. The 
dysregulation in numerous pathways, including phosphoinositide 3-kinase/protein 
kinase B (PI3K/AKT), apoptosis, cell cycle, Wnt/β-catenin and androgen-independent 
growth all point towards cancer-inducing dysregulation caused by this strain. 
 CFU2 (type III) and its potential cancer-protective role 
The CFU2-infection model demonstrated a dysregulation pattern consistent with 
cancer-protective behaviour, including increased apoptosis-inducing gene expression 




 Strain B3 (type IB) 
The type IB strain investigated caused a statistically significant change in the expression 
of only one gene in infected prostate RWPE-1 cells compared to non-infected controls. 
Previous work investigating the effect of P. acnes infection on primary prostate epithelial 
cells indicated that thiopeptide-producing P. acnes strains (phylogroup IB), have the 
ability to cause cell cycle arrest and thus prevent cancer-progression, likely by inhibiting 
FOXM1 (Sayanjali et al., 2016). The results in this thesis agree with these findings. In 
contrast, previous publications using the same type IB strain in an RWPE-1 immortalised 
cells line infection model have suggested that this phylogroup may induce cancer 
progression, however, the differences in incubation times for chronic infections and the 
multiplicity of infection (MOI) used could serve as an explanation for the discrepancies 
in observations (Mak et al., 2012; Fischer et al., 2013; Sayanjali et al., 2016). 
6.3. Study aims 
The aims of this study were outlined in Section 1.6 and were addressed over the course 
of this thesis. 
Aim 1 – Genotypic analysis of prostate cancer-associated phylogenetic types of P. 
acnes 
In Chapter 3, multilocus sequence typing (MLST) analysis, using a typing scheme 
developed by McDowell et al. (2013), was performed on a small group of available 
prostate isolates. The strains investigated belonged to different phylogenetic groups and 
to different STs, which are globally disseminated and highly prevalent in the human 
population, except for the two type IB strains which both belong to the same ST5. When 
the strains identified in this thesis are combined with the strains in the database 
available online, strains belonging to ST5 comprise 33% of all prostate isolates identified 
using the ‘Belfast’ MLST8 typing scheme, highlighting the potential importance of this 
sequence type (McDowell et al., 2013). This contrasts with previous findings where type 
II was the prevalent isolates from the prostate (at approximately 50%, followed by type 
IA1), however, the authors investigated multiple biopsies from a patient and each 
positive sample was counted as a separate isolate, thus inflating the number of samples 
investigated (Davidsson et al., 2016). The study included a total of 100 patients, with 




investigated; if a patient’s results were positive for P. acnes of the same type in multiple 
biopsy cores, it is likely that it is the same organisms isolated from all, rather than a 
separate infection (Davidsson et al., 2016). Thus, considering each isolated type from a 
patient rather that every individual sample, would have been more representative of 
the prevalence of the different phylogenetic types. Furthermore, as no washes of the 
sampled tissues are indicated in the methodology, the possibility for contamination 
cannot definitively excluded. 
With the large number of published whole genomes of P. acnes and general 
advancement in the field, the creation of a database uniting the different MLST schemes 
available and thus the work performed by different groups would offer easier access to 
information and could provide better insight into the significance of the prevalence of 
certain sequence types both on prostate cancer but also in a wider context. Developing 
an in silico PCR script to analyse available whole genome sequences based on the 
available MLST schemes, would make access to such information even easier. 
Aim 2 – Optimisation of in vitro infection model 
A number of extensive optimisation experiments were performed in Chapter 3. These 
initial experiments were extremely valuable and critical for further analysis, as previous 
published studies have not investigated in detail cellular and bacterial behaviour within 
this in vitro assay, and in general have not demonstrated clear validation of the infection 
models used. 
Investigating the optimal seeding density for the RWPE-1 prostate epithelial cells was 
necessary to limit any external factors, such as over-confluence, with potential to 
interfere in the study of the effects of P. acnes on the cells. If the cells were allowed to 
become over-confluent, increased death rate could occur, which may be interpreted to 
be as a direct consequence of infection. 
Additionally, at each passage, the cells were split to the optimal seeding density 
(100,000 cells/ml), rather than at a set ratio, which was to again ensure that only the 
infection’s effects upon the cells would be recorded while limiting the impact of 
additional extrinsic factors. Specifically, if infection with one strain induced the cells to 
proliferate faster, while another strain caused them to proliferate more slowly, and the 




confluence, while at the same time it could cause the slower-growing cells to have their 
growth delayed even further due to loss of contact-dependent signalling. These effects 
would be amplified at each passage. 
Another difference from the majority of publications is the MOI 15:1 selected for our 
experiments, compared to MOI 50:1 used in other key studies (Fassi Fehri et al., 2011; 
Mak et al., 2012; Sayanjali et al., 2016). While our results showed that there is no 
statistically significant difference in bacterial counts between cells infected with MOI 
15:1 and MOI 50:1 at days 10, 20 and 30 of a long-term infection models, the difference 
in the effect of the lower MOI would be seen in short-term infections. Additionally, the 
higher MOI could initiate changes in the cells during the first few days of infections (e.g. 
a stronger inflammatory response), before any media changes or passages. However, an 
MOI 15:1 is closer to the numbers observed in prostatectomy samples than MOI 50:1, 
and was thus selected for the experiments. MOI 15:1 is still an artificially high multiplicity 
of infection compared to in vivo scenarios. 
To perform accurate intracellular bacterial counts, eradication of extracellular bacteria 
is necessary. Previous published studies have not indicated whether bacteria remain 
viable following antibiotic treatment or whether negative controls were used to 
interrogate this possibility, thus the reported intracellular counts could have been 
overestimated (Mak et al., 2012; Fischer et al., 2013). Our results showed that regardless 
of the combinations of antibiotics and incubation times used, viable bacteria do indeed 
remain viable in the media, prior to lysing the eukaryotic cells to release intracellular 
bacteria. As a result, the number of bacteria present in the medium following treatment 
was taken into account, and subtracted from future counts, to allow more accurate 
intracellular counts to be reported. In addition to the possibility that the bacteria found 
in the media are released by dying eukaryotic cells during the treatment and thus the 
antibiotic has not had enough time to target them effectively, it is plausible that biofilm 
formation on the surface of the culture dishes interfered with the antibiotic activity 
(Holmberg et al., 2009b; Dessinioti and Katsambas, 2017). If biofilms are then disturbed 
during the removal of the medium for bacterial counts, this could lead to the presence 
of bacteria reported in the medium. Previous studies have shown that all phylogenetic 
types (excluding type III, as the study was conducted before the identification of this 




biofilm was formed they had higher resistance levels to commonly used antibiotics 
compared to planktonic cells (Coenye et al., 2007b; Holmberg et al., 2009b; Achermann 
et al., 2014). An investigation into the ability of the prostate isolates to form biofilm 
would be needed to confirm this possibility. 
Another set of experiments which required the addition of antibiotics was soft agar 
assays. Our results showed that, as expected, if no antibiotics are used in soft agar assays 
with infected cells, bacterial colonies form in the assay. On the other hand, when 
antibiotics were used (at a final concentration 20 μg/ml erythromycin), a significant 
decrease was seen in the number of colonies formed by the prostate cancer cell line 
22Rv1. As bacterial colonies cannot easily be distinguished from colonies formed by cells 
due to anchorage independent growth (difference in the edges of the colonies could be 
seen when observed under the microscope, with the bacterial colonies having smoother 
edges), antibiotics are critical for the successful and accurate representation of the 
results. However, the use of antibiotics may have decreased the number of observed 
colonies in the 00035 assay, and could have prevented the formation of colonies in the 
remainder of the soft agar assays performed. 
The selection of a stable housekeeping gene is necessary for the accurate relative 
quantification analysis of qPCR data. Our findings in Chapter 3 showed that HPRT1 is the 
most stable housekeeping gene in this cell culture model, and it also has a higher 
stability value than a combination of genes. This issue was highlighted once again in 
Chapter 5, when a selection of 5 housekeeping genes was interrogated as potential 
endogenous references for qPCR experiments. In agreement with the previous 
experiment, HPRT1 was once again shown to be the most stable housekeeping gene. 
However, the results also did show a significant dysregulation of two potential 
housekeeping genes (GAPDH, upregulated 10.85-fold, and B2M, downregulated -2.77-
fold, both in the 00035 infection model). Two previous studies exist examining the gene 
dysregulation as a result of P. acnes infection in a model using the RWPE-1 cell line. Mak 
et al. (2012) do not specify the housekeeping gene used for normalization to identify 
fold-change expression in a microarray, while a study conducted by Fassi Fehri et al. 
(2011) used GAPDH for microarray normalization. No information about housekeeping 




the calculated fold-change, especially as the GAPDH dysregulation we observed here is 
more than 10-fold. 
An extensive troubleshooting process led to the identification of an issue with the 
detection antibodies in the Peprotech ELISA kits. As a result of these findings, time and 
financial constraints, it was not possible to independently confirm the molecular results 
presented in the latter chapters. However, previous studies have demonstrated 
cytokine upregulation of IL-6 and IL-8 at the protein level in similar infection models, 
thus the data presented in this thesis is in line with previous findings (Fassi Fehri et al., 
2011; Davidsson et al., 2016). 
Overall, the experiments performed in Chapter 3 achieved the essential aim of 
optimising the methods to be used in future chapters. This work also highlighted 
potential weaknesses in previous studies and ensured robust data to address the 
overarching aims 
Aim 3 – Investigation of the potential of P. acnes phylogenetic types to drive 
oncogenesis 
Chapter 4 focused on an investigation of how infection affects the RWPE-1 cells, 
including viability counts, performed for the duration of the experiments, molecular 
dysregulation of inflammatory and EMT-related genes, anchorage-independent growth, 
migration and its ability to induce proliferation in endothelial cells. P. acnes bacterial 
counts in the infection models and the cytotoxicity of the different strains were also 
assessed, as well as intracellular counts for each strain used. 
For experiments, strains representing each phylogenetic type which have been linked to 
prostate cancer were used. Previous studies have reported that strains belonging to 
phylotype II are commonly isolated from the prostatectomy samples, however, our 
study did not discover any type II strains (Mak et al., 2013b; Davidsson et al., 2016). This 
is most likely a result of the small sample size available here. Due to the unavailability of 
a prostate isolate type II, the reference strain NCTC10390 was used as a proxy in 
experiments, assuming type II strains would behave in similar ways. However, as seen 
with the behaviour of the different type IA1 strains (most notably in the case of NCTC737 
and 00035 versus ST27), this is not always the case, and any conclusions would need to 




Strains from the IA2 and IC phylotypes were not investigated in this study, as they are 
not associated with prostate infections (Mak et al., 2013b). Strains NCTC737, ST27 and 
P. granulosum were used as controls: NCTC737 (type IA1, ST1) as the most widely studied 
representative of the P. acnes species; ST27 as a health-associated strain; P. granulosum, 
as a related member of the cutaneous Propionibacterium genus, which has also been 
isolated from the prostate (Mak et al., 2013b). P. avidum, another cutaneous P. acnes 
relative, was also trialled as a control, however, it led to the death of the RWPE-1 cells 
by the 72-hour time point of infection. 
The intracellular counts showed that most P. acnes strains (00035, NCTC737, ST27 and 
B3) have the ability to become intracellular in the prostate epithelial cells, with the 
number of bacteria which become intracellular differing between strains. The results 
were presented with extracellular bacteria subtracted, to ensure accurate 
representation. 
The ability of P. acnes to invade epithelial cells, and also to remain viable in 
macrophages, raises a number of questions about the importance of ‘intracellularity’ in 
this infection model and its involvement in cancer development. While in vitro studies 
have shown that P. acnes can remain viable in a range of cell lines, including 
macrophages, conflicting conclusions exist about whether the organism can reproduce 
intracellularly (Fischer et al., 2013; Nakamura et al., 2016). What is the significance of 
intracellularly infected cells in the context of this infection model? Does cancer originate 
in the cells which harbour intracellular infection or in surrounding cells, which become 
cancerous as a result of secretions produced by the infected cell? What is the effect or 
media changes and passages on the number of challenged cells? 
An experiment designed to address the first question could also identify infected cells 
and isolate them using flow cytometry. Similar experiments have been performed 
previously to investigate the ability of Mycobacterium tuberculosis (a distant P. acnes 
relative; both belong to the Actinomycetales order) to survive intracellularly in 
macrophages, using CD14 (co-receptor of TLR4 and MD2) and CD119 (interferon gamma 
receptor 1 or IFNGR1) as targets (Sharma et al., 2012). The infected cells could be 
selected out of the population and cultured independently to investigate the direct 
effect of infection on the RWPE-1 cells. If it is the case that only one of the subgroups is 




loss of significance of the results. Thus, studying the two subpopulations separately 
could give insight of dysregulation, which would otherwise be hidden in the mixture of 
cells. 
Another limitation of the infection model is the potential loss of cells and bacteria as a 
result of passages and media changes. As seen in strains NCTC10390 and CFU2, during 
the acute infections, both demonstrate steady numbers for the duration of the 
experiments. However, in the long-term infection the numbers of both decrease 
overtime. If conditioned medium containing any bacteria was collected, centrifuged to 
pellet the bacteria and bacteria resuspended in fresh medium and added to the newly 
split cells, it would answer the question whether the drop in numbers in the case of 
CFU2 and NCTC10390 is due to bacterial death, or as a result of them being washed off. 
This decrease in bacterial counts has not previously been investigated and it is unclear 
whether it is an in vitro artefact or it is something that is also applicable to an in vivo 
situation. 
Another potential issue is the loss of RWPE-1 cells during passages. Setting up the 
infection models in a small vessel, e.g. 6-well plate and then increasing the size of the 
vessel at each passage and keeping all the cells, rather than disposing of a large 
proportion of them, would limit the loss of any cells which could harbour mutations 
resulting from rare events induced by infection, and would allow them to continue 
proliferating until apoptosis occurs.  
The investigation of the cytotoxic properties of the different phylogenetic types of P. 
acnes and P. granulosum revealed that they did not appear to be cytotoxic to the RWPE-
1 cells. The highest cytotoxicity levels are observed in strains 00035 (highest value 8.7% 
at 24 hours) and B3 (highest value 10.2 at 72 hours). 
Dysregulation of the inflammatory genes investigated here is seen in all strains in the 
acute infections, and in most infection models during the long-term infections, showing 
chronic immune response. Some of the EMT genes are also dysregulated in the acute 
infection, but the most notable change is seen in cells infected with 00035 at day 30 
when a decrease in the expression levels of E-cadherin (CDH1) is seen, signalling a 
possible “cadherin switch”. This, together with 00035 being the only infection model to 




with the type IA1 strain 00035 are undergoing early cellular transformation and are 
beginning to acquire cancer hallmarks. These findings are in line with the observations 
from Chapter 5, which also support a potential role of 00035 in driving oncogenesis by 
promoting proliferation and survival, inhibiting apoptosis, and inducing androgen-
independent growth, characteristics of advanced treatment-resistance tumours. 
Two studies have been published analysing the transcript levels of a range of genes in 
long term infection models of prostate epithelial cells with P. acnes. The experimental 
design in those studies differed from the methodology used here, however, comparison 
can still be made, focusing on the trends seen. 
The studies performed by Mak et al. (2012) and Fassi Fehri et al. (2011) used a type IB 
strain (P6, ST119) for their analysis, and selected an MOI 50:1, which differs from the 
MOI optimised in Chapter 3 of this thesis. Both studies used microarrays to assess gene 
dysregulation in a 24-hour infection of RWPE-1 cells There are four genes in common 
between the microarray used by Mak et al. (2012) and the genes investigated in Chapter 
4 – IL1B, IL6, IL8 and TNF. P6 caused an upregulation of 4.5-fold, and an increase in this 
study was seen when the cells were infected with strains 00035, ST27, B3, NCTC10390 
and P. granulosum, with varying levels of increase (ranging between 130-fold for 00035 
and 2.1-fold for NCTC10390; 40-fold for B3). A milder increase was seen in IL1B, with 
cells infected with P6 showing upregulation of 2.8-fold, which is close to the levels 
observed here with 2.5-fold increase for cells infected with ST27, and 2.4-fold for B3. IL6 
levels were upregulated in all infections. Finally, while P6 caused an insignificant change 
in TNF levels, it was upregulated in all infection models tested in Chapter 4. The study 
conducted by Fassi Fehri et al. (2011) also showed significant upregulation of IL1B, IL6 
and IL8 expression 24 hours post-infection, with values of 3.1-fold, 5.8-fold and 8.6-fold, 
respectively. 
Interestingly, despite the higher MOI used by Mak et al. (2012) and Fassi Fehri et al. 
(2011), the upregulation in inflammatory genes observed in both studies is significantly 
lower than what was seen in Chapter 4. A possible explanation is the different 
methodologies employed to assess differences in expression levels (microarrays vs 
qPCR). Additionally, as mentioned above, the selection of GAPDH as a housekeeping 




Fassi Fehri et al. (2011) also investigated gene dysregulation in a long-term infection 
model, defined as 21-days. They observed a mild upregulation in IL1B, IL6 and IL8 of 2.1-
fold, 2.9-fold and 4.6-fold, respectively. These values demonstrate similar trends to what 
was observed in the infection models with types IA1 and II in Chapter 4 at day 15. 
Immunofluorescence was used here to quantify protein expression of E-cadherin and 
vimentin. However, this method can be used to identify bacterial presence, for example 
by using P. acnes specific antibodies such as QUBPa1 (specific for phylogenetic type I) , 
and could help localise the infection; alternatively, the method could also be used to 
identify infected cells utilising the antibodies used in flow cytometry experiments 
described above (targets CD14 and CD119) (McDowell et al., 2005; Sharma et al., 2012). 
MTT assays were employed to assess the ability of conditioned medium from chronic 
infection models to initiate angiogenesis in endothelial cells. 
The MTT assay used is not a proliferation assay but rather measures cell metabolic 
activity, thus increased or decreased MTT production, does not necessarily mean 
increased proliferation. The MTT assay was used as it was cost effective for an initial 
pilot study investigation into the angiogenic potential of chronic infection models. 
The results from the MTT assay experiments showed no overall difference between 
proliferation in cells treated with conditioned medium from infected versus non-
infected prostate epithelial cells. The results can be confirmed using a dedicated 
proliferation assay such as Ki67 or Bromodeoxyuridine (BrdU). The Ki67 assay uses an 
antibody to target the Ki67 protein which is only expressed in proliferating cells (and 
absent in cells in the G0 phase) (Kim and Sederstrom, 2015). BrdU is a nucleotide 
analogue which replaces thymidine during DNA replication; BrdU can then be targeted 
by antibodies, leading to the detection of all actively proliferating cells (Messele et al., 
2000). Additionally, an apoptosis assay, such as terminal deoxynucleotidyl transferase 
(Tdt) dUTP nick end labelling (TUNEL, which binds fragmenting DNA during apoptosis 
and can be tagged with a fluorochrome and measured) or annexin 5 (which binds dead 
cells and can be quantified using flow cytometry) could be used to investigate whether 
any apoptosis is present which is not detected by the MTT assay (Kyrylkova et al., 2012; 




In addition to confirming whether the endothelial cells have increased proliferation or 
increased apoptosis, further investigation could focus on how treatment with 
conditioned medium affects the ability of endothelial cells to form tubules in an 
appropriate extracellular matrix (DeCicco-Skinner et al., 2014). A scratch assay can also 
be used to assess migration of endothelial cells following treatment with conditioned 
medium (Guo et al., 2014). 
The experiments in Chapter 4 addressed the aim and provided a detailed comparison of 
the effects of different strains on the RWPE-1 cells and highlighted strain 00035 as a 
potential pro-oncogenic strain. The data from Chapter 4 was also used as a basis of the 
selection of strains 00035 (type IA1), B3 (type IB), and CFU2 (type III) to be interrogated 
at the molecular level by qPCR array in Chapter 5. 
Aim 4 – Analysis of prostate cancer-related genes following infection 
In Chapter 5, a commercially available qPCR array was used to investigate the 
dysregulation of prostate-cancer related genes induced by infection with the three 
strains selected in Chapter 4 in comparison to uninfected controls. 
While the qPCR array used here provides information about the expression of 84 
prostate cancer-related genes, the number of genes and the restricted gene selection 
are an obvious limitation of the array. While some genes are of interest, including those 
involved in apoptosis, cell cycle control and in fatty acid synthesis, others do not carry 
valuable information, e.g. gonadotropin-releasing hormone (GNRH1, involved in 
hormone secretion in the brain). 
An alternative approach to analysing the transcriptome and comparing changes in 
expression between infection models and to untreated controls would be RNA 
sequencing (RNAseq). This method provides unbiased detection of expressed transcripts 
and it is not limited by template availability. It is highly specific and it offers the capability 
to detect novel transcripts and novel sequence variants (Marioni et al., 2008). While the 
data analysis is more complex, requiring the use of multiple bioinformatics tools and 
sophisticated programming skills, the resulting data gives a complete analysis of all 
transcripts in the cell and would allow the detection of differentially expressed genes. It 
could also permit a more thorough investigation of gene expression within pathways – 




pathway, RNAseq could provide transcript information about all genes involved in the 
process. 
The study performed by Fassi Fehri et al. (2011) mentioned above, also contains three 
gene which are common between the microarray they used, and the qPCR used here to 
analysed gene dysregulation. The three genes the studies have in common are IL6, 
prostaglandin-endoperoxide synthase (PTGS2) and vascular endothelial growth factor a 
(VEGFA). The dysregulation seen in IL6 and PTGS2 is only significant in cells infected with 
the type IA1 00035 (1811.96-fold and 14.62-fold, respectively) which is significantly 
higher than the upregulation seen in the previous study at 2.9-fold and 2-fold for IL6 and 
PTGS2, respectively (Fassi Fehri et al., 2011). The findings of increased levels of PTGS2 
(encoding cyclooxygenase-2, COX-2) is line with expectations, as COX-2 has previously 
been shown to be upregulated in prostate adenocarcinomas (Gupta et al., 2000; Uotila 
et al., 2001). Production of COX-2 is known to be upregulated if inflammation is present, 
and in the case of H. pylori infection, the bacterium has been shown to induce its 
production (McCarthy et al., 1999; Badary et al., 2017). A similar observation is made 
here, with COX-2 being upregulated as a result of infection; this suggests the possibility 
for P. acnes infection to drive oncogenesis via upregulation of COX-2. 
In the study by Fassi Fehri et al. (2011) VEGFA levels at 21-days were not significantly 
different, compared to untreated controls (i.e. less than 2-fold change). In contrast, in 
our study the levels of VEGFA are 3.77-fold upregulated for the 00035 infection and 
2.23-fold for the CFU2, it is possible that 6 days later that increase in expression would 
be lost, however, it is worth noting once again that different phylotypes and MOIs are 
being compared. While upregulation of VEGFA, a known inducer of angiogenesis is seen 
in two of the infection models (type IA1 00035 and type III CFU2), when the potential of 
infected cells to induce proliferation of endothelial cells was investigated in Chapter 4, 
no such induction was seen. The most likely explanation is the fact that the qPCR assays 
were performed at 15 days post-infection, while the endothelial cells were treated with 
medium from RWPE-1 cells infected for 30 days, and thus the transcript information is 
not reflective of the processed in the cell at the later timepoint. 
The data from experiments in Chapter 5 address the aim and led to findings, suggesting 
that the type IA1 strain causes dysregulation related to cancer progression, while CFU2 




6.4. The role of the immune system 
The prostate, similarly to the intestine, is an immunocompetent organ, meaning that a 
range of immune cells are present within it (including CD4+ T cell, CD20+ B cells, 
macrophages) (Hussein et al., 2009). Another thing that distinguishes prostate cells from 
other cell types is that due to the accumulation of high levels of zinc ions they have a 
truncated Krebs cycle. As a result, prostate cells do not produce energy using cellular 
respiration and unlike other cells in the body, they are not exposed to reactive oxygen 
species (ROS), a by-product of respiration. This makes prostate more sensitive to ROS-
induced DNA damage, compared to other cell types. 
If the infection model included inflammatory cells, they would be affected by the 
secreted inflammatory genes, and as a result, ROS may be released, exposing the 
prostate cells to high levels of a carcinogen they have not encountered before. 
Additionally, the immune cells would attempt to eradicate the infection with P. acnes, 
with macrophages engulfing the bacteria and the bacteria remaining viable 
intracellularly, as previously reported (Fischer et al., 2013). All in all, if macrophages 
were involved, the infection model would behave differently, and it would be more likely 
that a cancer-inducing event would occur, such as the excretion of matrix 
metalloproteases (MMPs) by the immune cells and ROS damage to the cells as a result 
of the attempt to eradicate infection. 
While small changes in response of the endothelial cells are seen when treated with 
medium from infected prostate cells, the macrophage is a key player in angiogenesis 
whose involvement is not investigated in this study. Monocytes are recruited to the 
cancer site by hypoxic cells (which release macrophage chemoattractant protein-1 
(MCP-1)); there the monocytes would differentiate into tumour associated 
macrophages; the macrophages also release pro-apoptotic signals, just like the cancer 
cells, and also induce the production of IL-6 and MCP-1, both of which lead to the 
summoning of monocytes, initiating an activation loop (Roca et al., 2009). Additionally, 
the macrophages also secrete MMP2, MMP7, MMP9, MMP12, and cathepsin proteases 
(Lewis and Pollard, 2006; Gocheva et al., 2010; Mason and Joyce, 2011; Small et al., 
2013). The MMPs play a role in extracellular matrix remodelling and also stimulate the 
proliferation rate and migration of endothelial cells (Lu et al., 2012; Guo et al., 2013). 




causes arrest in the development of cancer-associated blood vessels; cathepsin has also 
been shown to induce tumour proliferation, invasiveness and metastasis (Small et al., 
2013; Olson and Joyce, 2015). 
Taken together, these observations highlight the important role of the inflammatory 
response in infection-induced cancer. 
6.5. Future work 
 Are epigenetic modifications involved? 
Studies of the mechanism H. pylori utilises to cause gastric carcinoma have discovered 
that the infection has the ability to cause DNA methylation, thus silencing genes 
necessary for the function of healthy cells (Nardone et al., 2007). An example observed 
was methylation (resulting in silencing) of the CDH1 gene when H. pylori infection was 
present and loss of the methylation if the infection was eradicated (Chan et al., 2003; 
Leung et al., 2006). Such a methylation-induced loss of E-cadherin would allow cells to 
undergo a “cadherin switch” and become motile, initiating cellular transformation. 
To investigate whether any epigenetic changes are present following infection and initial 
screen of global methylation levels would present a snapshot of the epigenome. 
However, it is theoretically possible that the results of a global methylation analysis 
could be the same between treatments while the genes affected differ. Thus, a bisulfide 
treatment approach, followed by whole genome sequencing would provide information 
about the methylation status of all genes in the cells which could easily be compared 
between infections and to untreated controls. 
 Can infection speed up cancer progression? 
Investigation of the effects of P. acnes infection on cancer cell lines could provide insight 
in whether the bacterium could speed up cancer progression once the disease has 
developed. Infecting prostate cancer cell lines, for example the androgen-sensitive cell 
line LNCaP and investigating whether P. acnes infection could lead to androgen-
independent growth. 
To investigate any dysregulation of the androgen receptor in the RWPE-1 cell line 
treatment with synthetic androgen is necessary, as it is currently unknown whether P. 
acnes infection has an effect on the androgen receptor function. As the RWPE-1 cells 




uninfected controls in complete keratinocyte serum-free medium supplemented with 
synthetic androgen (e.g. mibolerone) would allow the investigation of androgen 
receptor dysregulation. 
 Development of a superior infection model 
The culture of a single cell type in a monolayer and the addition of bacteria is a simple 
way to investigate the direct response in the epithelial cells, however, it is not 
representative of an in vivo situation. Using primary cells, rather than an immortalised 
cell line, would allow the investigation of dysregulation caused by infection in an 
environment representative of in vivo situation. Improving the currently used infection 
model would provide new ways to study interaction between bacteria and between 
different cell types. 
A further limitation of the currently established infection models is that by focusing on 
a single cell line it does not address the tumour heterogeneity seen in vivo. Using primary 
cells for infection models could help investigate the effect on infection on a heterogenic 
population of cells. Clonal selection of chronically cells could lead to the generation of 
distinct cell lines demonstrating differential expression as a result of infection. 
Furthermore, single cell could be used to better study the heterogeneity within the cell 
population in infection models. 
A simple approach would be to create variations of the experiments in Chapter 4 (where 
endothelial cells were treated with medium from infection models), using different cell 
lines. For example, what effect would be observed if the monocytic cell line THP-1 was 
treated with medium from P. acnes-infected RWPE-1 prostate epithelial cells? 
Alternatively, what would the effect be on the HDMEC cells if they were treated with 
conditioned medium from infected THP-1 cells? And what if conditioned medium from 
the RPWE-1 cells was exposed to the THP-1 cell line, and then conditioned medium from 
this experiment was used on the HDMEC cells? 
A more complex approach would be to set up co-culture experiments, for example with 
RWPE-1 prostate epithelial cells and THP-1 monocytes and then initiate a P. acnes 
infection. While optimising the co-culture infection model would be a challenge, the 




In the body, multiple cell types work together; cells are not in monolayers but form 
structures. The development of flow-cytometry technology has allowed for FACS-sorted 
cells to be cultured to form 3D prostate organoid cultures (Chua et al., 2014; Gao et al., 
2014; Karthaus et al., 2014; Drost et al., 2016). These organoids can then be used for the 
generation of complex co-culture experiments with stromal or inflammatory cells. 
Optimising an in vitro infection model of P. acnes infection of a 3D prostate organoid, 
co-cultured with inflammatory cells would offer an environment closer to that observed 
in vivo compared to the currently used monolayer monoculture (Fatehullah et al., 2016). 
As murine prostates greatly differ from the human prostate gland, the usage of complex 
organoid cultures may be the only way to accurately study the effect of infection on the 
gland and the role it plays in oncogenesis (Grabowska et al., 2014). 
6.6. Conclusion 
The results from this study clearly demonstrate that there is a strain-specific response 
when prostate epithelial cells are challenged with different P. acnes isolates. The results 
of infection models with strain 00035 in particular, support a potential role of P. acnes 
in prostate oncogenesis. 
Opponents of the role of P. acnes in the development of prostate cancer have suggested 
that the presence of the bacterium in prostatectomy samples and biopsies could be a 
result of contamination which has occurred during the procedure. However, as the 
phylogenetic types of P. acnes isolated from the prostate (predominantly types IB and 
II) differ from those commonly isolated from the skin (IA1), it is unlikely that 
contamination is the source of the bacterium. Additionally, with improved culturing 
techniques, care is taken to wash the tissue sample thoroughly and only to culture 
bacteria present within the tissue itself. 
Stratified medicine aims to identify the most appropriate treatment for each individual 
based on pre-disposing factors. Being able to prescribe the correct treatment to a 
patient, guaranteeing that they would respond to the selected treatment is not only cost 
effective, but it also prevents the physical and emotional suffering of the patient. As 
prostate cancer is a complex multifactorial disease, infection as a potential modifiable 




identification of a subgroup of men harbouring an infection which could potentially lead 
to cancer. 
There is currently no simple way to diagnose prostate cancer. While the PSA test used 
highlights possible cases of the disease, its low specificity and sensitivity mean 
uncertainty for the patients, and a high risk of unnecessary biopsy based on the test 
result. The only way for a prostate cancer to be diagnosed currently is through a prostate 
biopsy. 
With P. acnes infection being a potential cause of prostate oncogenesis, there is a need 
for the development of a test which could identify men harbouring an asymptomatic 
infection of the prostate. At present, the only way to identify the presence of infection 
is via a biopsy. Developing a blood or urine test which can distinguish between carrier 
of the bacterium from the general population, and which can also identify the 
phylogenetic type of the bacterium present, would allow the stratification of the 
subgroup of men who are at risk of developing prostate cancer as a result of P. acnes 
infection. As seen here, the phylotype specific response to infection in prostate cells, 
confirms the existence of prostate cancer-inducing and suggest the possibility for 
cancer-protective strains. The ability to identify these cancer-causing strains, such as 
00035, via a test, would allow patients to be stratified into groups and those at risk could 
receive preventative antibiotic treatment eradicating the bacterium prior to 
oncogenesis; in contrast, in patients who have a cancer-protective strain (similar to 
CFU2), then no action would be needed. This separation based on specific pathogen 
characteristics would be similar to what is observed in the case of HPV-related 
oncogenesis, where only some viral types (e.g. HPV-16, HPV-18, etc.) have been lined to 
malignancy (Woodman et al., 2007). 
In addition to a screening test, the development of a vaccine would protect men from 
the harmful effects of being colonised with a potentially cancerous strain of P. acnes. 
Recently, a vaccine targeting the P. acnes Christie–Atkins–Munch-Petersen (CAMP) 
factor was developed and used successfully to treat in vivo P. acnes skin infections in 
animal models (Liu et al., 2011). Similar vaccine could be optimised to target the harmful 





This study is the basis necessary for the development of such screening tests and 
vaccines as it demonstrates that the specific phylogenetic types of P. acnes have the 
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Appendix B: Gene dysregulation in short-term infection models 
Figures of the fold-change in expression of inflammatory and epithelial-mesenchymal transition (EMT) genes used in short-term infection models. 
Inflammatory genes 
     
EMT genes 




Appendix B Figure 1. Dysregulation in 00035 short-term infection model. 
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 2. Dysregulation in NCTC737 short-term infection model. 
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 3. Dysregulation in ST27 short-term infection model. 
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 4. Dysregulation in B3 short-term infection model. 
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 5. Dysregulation in NCTC10390 short-term infection model. 
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 6. Dysregulation in CFU2 short-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix B Figure 7. Dysregulation in P. granulosum short-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
































































































Appendix C: Gene dysregulation in long-term infection models 
Figures of the fold-change in expression of inflammatory and epithelial-mesenchymal transition (EMT) genes used in short-term infection models. 
Inflammatory genes 
     
EMT genes 




Appendix C Figure 1. Dysregulation in 00035 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
HPRT as a housekeeping gene. Data is presented as presented as mean fold change of three biological replicates, +/- standard error. 
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Appendix C Figure 2. Dysregulation in NCTC737 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix C Figure 3. Dysregulation in ST27 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix C Figure 4. Dysregulation in B3 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix C Figure 5. Dysregulation in NCTC10390 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix C Figure 6. Dysregulation in CFU2 long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 
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Appendix C Figure 7. Dysregulation in P. granulosum long-term infection model.  
Ratio difference in the expression of each gene in infected RWPE-1 prostate epithelial cells, calculated by normalising to uninfected controls, with 





























































































Appendix D: Pathways analysis for qPCR array experiments 
Pathway analysis and gene ontology analysis performed using STRING (Szklarczyk et al., 
2017). 
 
Appendix D Figure 1. STRING analysis of 00035 qPCR array results 
STRING analysis performed using medium confidence (0.400) and all active interaction 
sources with lines representing “confidence”. Total number of nodes: 66. 
Biological Process (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0051726 regulation of cell cycle 22 1.59e-10 
GO:0070887 cellular response to chemical stimulus 31 1.59e-10 
GO:0048511 rhythmic process 14 8.68e-10 
GO:0070482 response to oxygen levels 14 8.68e-10 
GO:0009628 response to abiotic stimulus 22 1.25e-09 
Molecular Function (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0005515 protein binding 41 1.78e-09 
GO:0019899 enzyme binding 20 2.72e-06 
GO:0031625 ubiquitin protein ligase binding 8 0.000383 
GO:0004693 cyclin-dep. protein S/T kinase activity 4 0.00228 









Appendix D Figure 2. STRING analysis of B3 qPCR array results 
STRING analysis performed using medium confidence (0.400) and all active interaction 
sources with lines representing “confidence”. Total number of nodes: 11. 
Biological Process (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0030162 regulation of proteolysis 7 7.54e-05 
GO:0052548 regulation of endopeptidase activity 6 7.54e-05 
GO:0010951 -ve regulation of endopeptidase activity 5 0.000226 
GO:0022617 extracellular matrix disassembly 4 0.000627 
GO:0051919 positive regulation of fibrinolysis 2 0.00242 
Molecular Function (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0004252 serine-type endopeptidase activity 4 0.000816 
GO:0004175 endopeptidase activity 
 
5 0.00123 








Appendix D Figure 3. STRING analysis of CFU2 qPCR array results 
STRING analysis performed using medium confidence (0.400) and all active interaction 
sources with lines representing “confidence”. Total number of nodes: 53. 
Biological Process (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0007169 transmembrane receptor protein tyrosine kinase signalling pathway 22 1.47e-15 
GO:0010033 response to organic substance cellular 33 1.47e-15 
GO:0071310 response to organic substance 30 1.47e-15 
GO:0048010 VEGFR signalling pathway 13 3.24e-15 
GO:0009719 response to endogenous stimulus 26 2.28e-14 
Molecular Function (GO) 
Pathway ID Pathway description No. genes 
False discovery 
rate 
GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity 4 8.26e-08 
GO:0035005 1-phosphatidylinositol-4-phosphate 3-kinase activity 4 1.92e-06 
GO:0016303 1-phosphatidylinositol-3-kinase activity 4 6.86e-06 
GO:0043168 anion binding 23 1.08e-05 
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